Molecular characterisation of metacaspase 5 and the production of oligopeptidase b-specific single chain variable fragment antibodies for potential animal African trypanosomosis chemotherapies and diagnostics. by Eyssen, Lauren Elizabeth-Ann.
  
 
 
 
MOLECULAR CHARACTERISATION OF METACASPASE 5 AND THE 
PRODUCTION OF OLIGOPEPTIDASE B-SPECIFIC SINGLE CHAIN VARIABLE 
FRAGMENT ANTIBODIES FOR POTENTIAL ANIMAL AFRICAN 
TRYPANOSOMOSIS CHEMOTHERAPIES AND DIAGNOSTICS 
 
by 
 
Lauren Elizabeth-Ann Eyssen 
 
M.Sc 
 
 
 
Submitted in the fulfilment of the 
academic requirements for the 
PhD degree 
in 
Biochemistry 
School of Life Sciences 
University of KwaZulu-Natal 
Pietermaritzburg 
 
 
2018
ii 
 
PREFACE 
 
The experimental work described in this dissertation was carried out in the School of 
Life Science, University of KwaZulu-Natal, Pietermaritzburg, from July 2014 to March 
2017, under the supervision of Professor THT Coetzer. The studies represent original 
work by the author and have not otherwise been submitted in any other form to another 
University. Where use has been made of the work of others, it has been duly 
acknowledged in the text. 
 
 
Lauren Eyssen 
January 2018 
 
 
As the candidate’s Supervisor I agree to the submission of this dissertation. 
 
 
Prof. Theresa H. T. Coetzer  
iii 
 
DECLARATION – PLAGIARISM 
 
I, Lauren Elizabeth-Ann Eyssen, declare that 
 
1. The research reported in this dissertation, except where otherwise indicated, is 
my original research. 
 
2. This dissertation has not been submitted for any degree or examination at any 
other university. 
 
3. This dissertation does not contain other persons’ data, pictures, graphs or other 
information, unless specifically acknowledged as being sourced from other 
persons. 
 
4. This dissertation does not contain other persons' writing, unless specifically 
acknowledged as being sourced from other researchers. Where other written 
sources have been quoted, then: 
 
a. Their words have been re-written, but the general information attributed to them 
has been referenced 
b. Where their exact words have been used, then their writing has been placed in 
italics and inside quotation marks, and referenced. 
 
5. This dissertation does not contain text, graphics or tables copied and pasted from 
the Internet, unless specifically acknowledged, and the source being detailed in 
the dissertation and in the Reference section. 
 
Lauren Eyssen 
January 2018  
iv 
 
DEDICATION 
 
This thesis is dedicated to my grampa,  
Edward Henry Middleborough (1939 - 2016). 
  
v 
 
AKNOWLEDGEMENTS 
 
I would like to express my heartfelt thanks and appreciation to the following persons:  
Firstly, to Prof Coetzer for the opportunity to complete this degree under your guidance, 
and your belief in my scientific ability.  
To the lecturers in our department, Prof Goldring, Dr Hewer, and Prof Niesler for your 
time, your advice and encouragement.  
To Charmaine Ahrens, Tanya Karalic, Natalie Jones for their tireless administration 
work which makes our lives as post graduate students much easier. To Pat Joubert for 
all the ordering of our desperately needed lab reagents and all the other small, but very 
necessary things you do. To Celeste Clarke, for your constant fixing and organising of 
all the necessary things. Along with Megan Brunkhorst, thank you all for your time and 
friendship.  
To my fellow post graduates both past and current: each of you have, in some way or 
other, shaped me into the researcher that I am today with your advice, encouragement 
and even your presence. Thank you.  
To the National Research Foundation (NRF) for their financial assistance.  
Finally, to my families here, there and everywhere, a huge thank you for your never 
ending love and support during my many years at UKZN. 
.   
vi 
 
ABSTRACT 
 
African trypanosomosis (AT) is a major obstacle in the establishment of agriculture and 
economic sustainability in Africa. Animal AT is responsible for large numbers of 
livestock succumbing to the tsetse transmitted kinetoplastid parasites, Trypanosoma 
congolense and T. vivax, and as a result, losses in further downstream sectors are 
experienced. Due to the ability of the trypanosomal parasites to undergo antigenic 
variation, vaccine candidates are highly unlikely. Peptidases have been identified as 
virulence factors and are the focus of the development of novel chemotherapies and 
diagnostics. The metacaspases (MCAs) are a prime example of a chemotherapeutic 
target and oligopeptidase B (OPB), that of a diagnostic target. Towards the validation 
of a chemotherapeutic target, recombinant expression was used to obtain an active 
peptidase which could be enzymatically characterised. Various inhibitors were 
investigated and their effect on the parasite, analysed. Current diagnostics are based 
on antibody detection, but an antigen detection format would be preferable as it could 
differentiate between active and cured infections as anti-trypanosomal antibodies can 
persist for years. Given the rural, resource-poor locations in the areas of AT incidence, 
an ideal rapid diagnostic test (RDT) would be robust, affordable, sensitive and specific 
and requiring minimal training, such as a dipstick test. The MCAs are cysteine 
peptidases which are found in all kingdoms other than the metazoa, and share a 
secondary structure fold and catalytic dyad with the metazoan caspases. Since the 
caspases play a role in apoptosis, it is thought that the MCAs may function in a similar 
manner. The single copy MCAs of Trypanosoma spp. and Leishmania spp. differ from 
the multicopy MCAs in that they possess a Pro-, Gln-, Tyr-rich C-terminal domain which 
is thought to mediate protein-protein interactions. The activity of the single copy MCAs 
from T. cruzi and L. major has been implicated in the cell cycle of the kinetoplastid 
parasite. 
The aim of the project was to express, purify and enzymatically characterise the 
recombinant and native MCA5 from T. congolense and T. vivax. Using the 3D 
structures, solved by X-ray diffraction, of MCA2 from T. b. brucei, molecular docking 
studies were used to validate the inhibition potential of a published library of inhibitors, 
designed based on the, then, hypothetical structure of TbbMCA2. Since the elucidation 
of the 3D structure of TbbMCA2 by X-ray diffraction, the inhibitory power of the library 
of inhibitors against TbbMCA2 and the MCA5s was investigated. The serine peptidase, 
OPB, has been shown to be released into the host bloodstream by dead and dying 
vii 
 
parasites. The use of phage displayed scFv (single chain fragment variable) antibodies 
for the detection of OPB in serum from infected cattle is reported, towards the 
development of a RDT. 
Recombinantly expressed TcoMCA5 was shown to autoprocess and over autoprocess 
when purified using nickel affinity chromatography. Mutagenesis of the catalytic dyad 
residues reduced the over autoprocessing and the mutated form was enzymatically 
active at a pH between 6 and 9. This active mutant and purified TcoMCA5 showed a 
prefence for Arg over Lys at the P1 substrate position and were able to hydrolyse gelatin. 
Possible novel inhibitors of TbbMCA2 and the MCA5s of T. congolense and T. vivax 
were identified using a library of ligands (Berg library) based on the P1 specificity of 
TbbMCA2 and molecular docking. Commercial fluorogenic peptide substrates and 
inhibitors reported in literature for the characterisation of various MCAs, revealed 
interactions with the MCAs which should be taken into consideration when modifying 
the Berg ligands to achieve higher affinity for the MCAs.  
The application of scFv antibodies, derived from the Nkuku® phagemid library, for the 
diagnosis of current AAT infections by the detection of OPB, released in the 
bloodstream of the infected mammalian host, was investigated. After the successful 
isolation and production of OPB-specific scFv, MCA-specific scFv antibodies can be 
pursued using the Nkuku® phagemid library. The resulting OPB-specific scFv identified 
a conserved peptide between T. congolense and T. vivax and was able to detect native 
OPB in a western blot format. It was predicted that the scFv interacted with OPB in such 
a way that it would restrict the hinge motion between the C-terminal catalytic and 
N-terminal regulatory domains of the enzyme and limit access to the active site pocket. 
The ability of scFv and rabbit-anti-OPB polyclonal antibody in an antigen detection 
ELISA with sera from T. congolense infected cattle indicated that detection of OPB 
fluctuated with parasitaemia.  
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CHAPTER 1 
LITERATURE REVIEW 
1.1 African trypanosomosis 
The trypanosomal parasites which cause human and animal African trypanosomosis 
(HAT and AAT respectively), otherwise known as sleeping sickness in humans and 
nagana in cattle, are transmitted by the bite of an infected tsetse fly (Glossina spp.). In 
2004, HAT cost the African continent 1.6 million disability-adjusted life years (DALYs) 
(Févre et al., 2008). Together with serological screening, reservoir control and 
appropriate treatment, the disability-adjusted life-years (DALYs) has been lowered to 
202 438 (GBD et al., 2017). African trypanosomosis affects human health and has 
economic consequences due to its impact on agriculture resulting from the reduction 
in animal numbers and productivity (Hotez et al., 2009; Jackson et al., 2015). Since 
both HAT and AAT occur in rural areas, affect poor smallholders, and pose no 
immediate threat to wealthy nations, the disease is often considered neglected (Diall 
et al., 2017). 
Trypanosoma brucei gambiense is responsible for HAT in eastern and southern 
African, while T. b. rhodesiense causes HAT in western and central Africa (Welburn et 
al., 2001a). The T. b. gambiense parasite causes chronic infections which can persist 
for years, whilst T. b. rhodesiense infections result in death within 6 to 8 months if 
untreated (Checchi et al., 2008). It is estimated that 55 million people in an area of 
1.08 million km2 are at risk of T. b  gambiense infections, whilst 6 million in 
100 000 km2 are at risk of T. b. rhodesiense infections (Franco et al., 2017). The areas 
in which HAT infections are likely have halved in less than a decade, with fewer than 
4 000 reported cases in 2014 (Franco et al., 2017) (Fig. 1.1, panel A). However, due 
to the remote locations and poor coverage by surveillance systems of these areas, the 
number of reported cases may be higher.  
Both T. b. gambiense and T. b. rhodesiense parasites are harboured in wild and 
domestic animals, which act as reservoirs (Anderson et al., 2011). Domestic cattle are 
the major reservoir of T. b. rhodesiense in Uganda (Welburn et al., 2001b) and the 
introduction of infected cattle from districts with established human T. b. rhodesiense 
infections, caused outbreaks in previously unaffected districts (Picozzi et al., 2005).  
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A third subspecies of T. brucei, which is non-pathogenic in humans, is T. b. brucei and 
causes AAT. This parasite is distributed across sub-Saharan Africa and is restricted to 
non-human vertebrates. In addition to T. b. brucei, several other trypanosomal species 
cause infections in animals and are transmitted by insect vectors other than the tsetse 
fly. Trypanosoma b. brucei, T. congolense and T. vivax, cause Nagana in Africa, 
T. evansi cause Surra in northern Africa and Asia, infect a wide range of domestic 
animals as well as wild animals which act as reservoirs, whilst T. simiae and T. suis 
infect pigs (Uilenberg and Boyt, 1998; Lucius et al., 2017). In addition, since the 
development of the trypanosome is restricted to the tsetse proboscis in T. vivax, the 
direct mechanical transmission by other haematophagous flies, such as tabanids and 
Stomoxys, occurs frequently (Rotureau and Van Den Abbeele, 2013). Consequently, 
T. vivax infections has spread beyond the borders of the sub-Saharan tsetse belt into 
northern Africa and south America (Jones and Dávila, 2001; Osório et al., 2008; 
Gonzatti et al., 2014). The threat of AAT has restricted the development of agriculture 
due to the ineffective use of available land in tsetse-infested areas (Matthews, 2005; 
Jackson et al., 2015; Diall et al., 2017).  
 
Figure 1.1: Distribution of HAT and AAT. (A) Number of T. b. gambiense (red) and 
T. b. rhodesiense (blue) HAT cases reported between 2010 and 2014. Areas where no cases 
were reported are indicated in green (Franco et al., 2017). (B) Distribution of important animal 
infective trypanosomal species in Africa. The real geographical distribution of T. congolense 
and T. vivax in South Africa and Namibia is limited (Giordani et al., 2016). 
 
Multiple species and sub-species of animal infective trypanosomes circulate in cattle 
within HAT areas (Fyfe et al., 2017) (Fig. 1.1, panel B). The animal infective 
T. congolense, is considered to be the most pathogenic trypanosome species in cattle 
(Giordani et al., 2016), followed by T. vivax (Osório et al., 2008), both of which are able 
to infect multiple animal species. Whilst T. congolense and T. vivax impact on both 
animal health and productivity across much of Uganda (Okello et al., 2015); 
T. b. brucei and T. b. rhodesiense cause only mild illness in indigenous breeds with 
infection often going undetected (Fyfe et al., 2017). It is estimated that 20% production 
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losses are experienced due to mortality and the reduction of calving rate, draft power 
and the production of meat and milk due to AAT infections (Swallow, 2000). 
1.2 Trypanosome classification 
Trypanosomes are protozoan parasites and belong to the order Kinetoplastida and 
genus Trypanosoma. The genus comprise the Stecoraria and Salivaria groups (Haag 
et al., 1998). Trypanosomes belonging to the Stecoraria group, migrate to the hind gut 
of the vector and are transmitted through faeces to the mammalian host, whilst those 
in the Salivaria group, migrate from the gut to the mouth parts of the vector and are 
transmitted through the vector’s saliva (Lucius et al., 2017). The salivarian parasite, 
T. equiperdum, is an exception as it is transmitted during copulation (Brun et al., 1998). 
Nine trypanosomal clades have been identified based on the heat shock protein (HSP) 
60 molecular marker (Fraga et al., 2016); namely, T. cruzi, T. rangeli, T. lewisi, 
T. theileri, T. grayi, T. carassi, Trypanozoon T. congolense and T. vivax as outlined in 
Table 1.1. The Trypanozoon clade includes T. b. gambiense, T. b. rhodesiense, 
T. b. brucei, T. evansi and T. equiperdum. 
Table 1.1: Taxonomy of the trypanosomatidae 
Group Subgenus Species Subspecies Cladea 
Stecoria 
Schizotrypanum# T. cruzi  T. cruzi 
Herpetosoma 
T. rangeli  T. rangeli 
T. lewisi  T. lewisi 
T. musculi   
Megatrypanum# 
T. theileri  T. theileri 
T. grayi  T. grayi 
T. carassi  T. carassi 
T. avium  Avianb 
Salivaria 
Trypanozoon 
T. brucei 
T. b. gambiense 
Trypanozoon 
T. b. rhodesiense 
T. evansi  
T. equiperdum  
Nannomas 
T. congolense  T. congolense 
T. simiae   
T. godfreyi   
Dutonella 
T. vivax  T. vivax 
T. uniforme   
Pycnomonas T. suis   
Adapted from Baral (2010), Fraga et al. (2016)a and Simpson et al. (2006)b.  
#Only a few species belonging to the Schizotrypanum and Megatrypanum subgenus are given. 
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1.3 Parasite structure and genomic organisation  
The elongated shape of the trypanosomal trypomastigotes and epimastigotes is 
defined by a polarised microtubule cytoskeleton, which remains intact throughout the 
cell cycle (Matthews, 2005). The trypanosomal parasites possess a number of single 
copy organelles which are precisely positioned within the cytoskeleton; namely, the 
nucleus, flagellar pocket, basal body, kinetoplast, mitochondrion, nucleus, Golgi 
apparatus and the flagellum (Matthews, 2005), which is attached to the body of 
trypomastigotes and epimastigotes (Fig. 1.2).  
 
Figure 1.2: The cellular structure of T. b. brucei. The cellular structures found within 
the T. b. brucei trypomastigote are shown and numbered as follows: 1, nucleus; 2, kinetoplast; 
3, flagellar pocket; 4, basal body and probasal body; 5, axoneme and paraflagellar rod; 6, Golgi 
apparatus; 7, lysosome; 8, endosomes; 9, mitochondrion; 10, microtubule cytoskeleton and 
11, glycosomes (Matthews, 2005). 
 
The single kinetoplast comprises the mitochondrial genome and consists of 
approximately 50 copies of maxicircles and 10,000 copies of minicircles (Klingbeil and 
Englund, 2004). Mitochondrial proteins are encoded by the maxicircles, whilst short 
guide RNAs are encoded by the minicircles (Klingbeil and Englund, 2004). The 
maxicircle transcripts are post-transcriptionally edited by the incorporation or deletion 
of uridines using the minicircles as templates (Klingbeil and Englund, 2004). The 
replication of the kinetoplast is coordinated with that of the nucleus (Matthews, 2005). 
The nuclear genome of T. brucei contains 11 megabase chromosomes and more than 
100 minichromosomes which are approximately 50 kb in size (Wickstead et al., 2004; 
Cross et al., 2014). The minichromosomes function to provide a large repertoire of 
telomeric variable surface glycoproteins, VSGs (Pays, 2006; Hovel-Miner et al., 2016). 
The genes are arranged in polycistronic arrays, which are not organised into operons, 
but are rather differentially expressed through the life cycle (Matthews, 2005).  
1.4 VSG and antigenic variation 
A dense ∼15 nm-thick coat of VSGs is present on the surface of the parasite and 
protects against complement-mediated lysis and hides invariant proteins from 
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recognition by the host’s immune system (Engstler et al., 2004; Field and Carrington, 
2009; Schwede et al., 2011). Bloodstream trypomastigote parasites possess about 107 
copies of the VSG, which constitutes approximately 5% of the total cellular protein 
(Turner, 1985).  
The VSG molecule is composed of a large, alpha-helical N-terminal domain which 
interacts with the host immune system (Blum et al., 1993), and a small C-terminal 
domain which links the VSG dimer to the plasma membrane via a 
glycosylphosphatidylinositol (GPI) anchor (Jones et al., 2008). The VSG repertoire of 
T. b. brucei bloodstream trypomastigotes, comprising more than 1 000 VSGs 
(Berriman et al., 2005), is significantly larger than the 12 VSGs found in procyclic 
trypomastigotes (Lenardo et al., 1984). 
As VSGs are highly immunogenic, an immune response is generated by the host to 
eliminate the parasite. However, the periodic switching of the expressed VSGs, with 
distinct antigen variants, allows for immune evasion, resulting in an undulating 
parasitaemia profile, characteristic of trypanosome infections (MacGregor et al., 2012). 
The process of antigenic variation is the result of either transcriptional switching 
between VSG expression sites (ESs), or homologous recombination between the 
active VSG gene and another VSG gene from the repertoire (Pays et al., 2006). The 
genome of T. b. brucei encodes as many as 1 700 VSGs, most of which are 
pseudogenes which require assembly into functional mosaics (Marcello and Barry, 
2007). This implies that the VSG repertoire is essentially infinite (Taylor and Rudenko, 
2006).  
A single VSG is expressed at any one given time as only a single VSG allele and can 
be transcribed from the VSG repertoire (Pays et al., 2006). The transcription of VSG 
occurs at one of several VSG ESs (Pays et al., 2006). Each VSG ES has polycistronic 
transcription units which contain expression-site-associated genes (ESAGs) together 
with the VSG gene (Pays et al., 2001). The T. b. brucei genome codes for a set of 15 
to 20 similar, but not identical ESs (Pays et al., 2006).  
The serum resistance associated (SRA) gene encodes a truncated VSG where the 
region encoding the surface-exposed epitopes is missing (Vanhamme et al., 2001). 
The R-ES is the ES which contains the SRA gene (De Greef et al., 1989) and is not 
active when the parasite is present in the serum of non-human vertebrates 
(Vanhamme et al., 2000). Only when T. b. rhodesiense is exposed to human serum, is 
the R-ES selected and the transcription of SRA triggered (Pays et al., 2006). Animal 
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infective trypanosome parasites do not possess the SRA gene and are unable to infect 
humans as they are lysed in human serum.  
1.5 Life cycle of the trypanosomal parasite  
The complex life cycle of the trypanosome requires various adaptations to survive in 
the mammalian bloodstream and in the different compartments within the tsetse fly 
(Matthews, 2005). Stage-specific changes to basic cell biological processes are 
required for differentiation (Matthews, 2005). The life cycle of T. b. brucei is detailed in 
Fig. 1.3. 
 
Figure 1.3: Life cycle of T. b. brucei in the mammalian host and insect vector. 
The circular arrows indicate that the form is proliferative. CNS, central nervous system 
(Langousis and Hill, 2014). 
 
The mammalian host is infected through the bite of a tsetse fly which harbours growth-
arrested T. b. brucei metacyclic trypomastigotes. Thereafter, the metacyclic 
trypomastigotes differentiate into proliferative slender forms which are able to establish 
and maintain infection in the host circulation as bloodstream trypomastigotes 
(Matthews, 2005) through evasion of the host antibody responses using antigenic 
variation (Pays et al., 2004). Once in the bloodstream, the long slender forms 
differentiate into short stumpy forms, which are cell-cycle arrested and pre-adapted for 
survival in the tsetse fly, facilitated by a quorum sensing-like mechanism (MacGregor 
et al., 2011). This transition between slender and stumpy forms, together with the 
process of antigenic variation, prolongs the infection and increases the potential for 
further parasite transmission (MacGregor et al., 2012). In the second stage of T. brucei 
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infection, parasites penetrate the blood brain barrier and enter the central nervous 
system (Langousis and Hill, 2014).  
A blood meal, from an infected mammalian host, allows for the parasites to establish 
in the tsetse midgut, through the differentiation of short stumpy forms into proliferative 
procyclic trypomastigotes. The differentiation of bloodstream trypomastigotes to 
procyclic trypomastigotes is characterised by morphological changes, switching from 
glycolysis to oxidative phosphorylation, and the replacement of the VSGs with 
procyclins (Maudlin and Welburn, 1994), which are also GPI anchored (Roditi and 
Liniger, 2002). Procyclic trypomastigotes migrate from the midgut to the salivary gland, 
and en route, undergo extensive restructuring and asymmetric division to generate 
both long and short epimastigotes which are covered in brucei alanine-rich protein 
(BARP) (Urwyler et al., 2007). The short epimastigotes attach to the epithelial cells in 
the salivary gland and are able to replicate via asymmetric division to generate 
metacyclic trypomastigotes (Matthews, 2005). The metacyclic trypomastigotes regain 
a coat of VSGs and are released into the salivary gland lumen where they can be 
transferred to the mammalian host; thereby, completing the life cycle (Rotureau et al., 
2012). 
Similar, but non-identical in vivo life cycles are shared between T. congolense and the 
T. brucei subspecies. The bloodstream trypomastigotes of T. brucei occur as 
proliferative long slender forms as well as a non-proliferative short stumpy forms, 
whereas those from T. congolense have the corresponding proliferative forms but the 
stumpy forms are less obvious (Vickerman, 1985). The epimastigotes of T. congolense 
are directed to the tsetse fly’s proboscis and mouth parts, but not to the salivary glands 
as for T. brucei epimastigotes, where they differentiate into non-proliferative, infective 
metacyclic trypomastigotes (Roditi and Lehane, 2008). In the case of T. vivax, the 
procyclic trypomastigote form is skipped as the parasite does not enter the insect gut 
(Rotureau and Van Den Abbeele, 2013). Instead, the bloodstream trypomastigotes 
differentiate directly into epimastigotes within the tsetse proboscis (Rotureau and Van 
Den Abbeele, 2013). 
1.6 Immune response 
African trypanosomes are extracellular parasites, and as such, encounter both the 
innate and the adaptive immune responses of the host. The VSG molecules provide a 
defence barrier against both innate and specific immune effectors (Vickerman and 
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Luckins, 1969). Polyclonal B-cell activation is a characteristic of both bovine and 
murine trypanosomosis, whereby increased numbers of B-cells and plasma 
immunoglobulin levels is evident (Luckins and Mehlitz, 1976).  
Proliferation of B-cells, producing a lytic antibody response, is caused by the 
immunogenic VSGs as illustrated in Fig. 1.4 (Pays et al., 2001). During the early stage 
of infection, trypanosome-specific antibodies can mediate clearance of parasites and 
are able to neutralise parasite products (Dempsey and Mansfield, 1983). However, a 
significant proportion of these antibodies are either polyspecific or auto-reactive 
(Kobayakawa et al., 1979). The suppression of B cell memory results in the total 
absence of IgG responses and a strongly reduced IgM response in the later stages of 
infection (Hudson and Terry, 1979; Radwanska et al., 2008).  
The VSG-antibody complexes facilitate opsonisation and lysis via the complement 
system of the parasites expressing the VSG against which the response was triggered. 
Thus, by the process of antigenic variation, trypanosomes avoid detection by host 
antibodies (Horn and McCulloch, 2010). Through the reduction of parasite numbers, 
prolonged infection is ensured. 
 
Figure 1.4: Lytic antibody response to the immunogenic VSGs. The hypothetical 
interaction between the IgM (turquoise) and the N-terminus of the immunogenic VSG (dark 
blue) molecules (Mugnier et al., 2016). 
 
The initial immune response to trypanosome infection is the initiation of an acute 
inflammatory response via the innate system, which affects B- and T-cell responses to 
parasite antigens, whereby cytokines and chemokines are secreted to prompt 
clearance of the infecting parasite (Mansfield and Paulnock, 2005). Natural killer cells 
may also participate in the initiation of the inflammatory response through the synthesis 
of cytokines and chemokines such as interferon (IFN)-Ɣ and tumor necrosis factor 
(TNF)-α (Vincendeau and Bouteille, 2006). However, the parasite can interfere with 
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the cytokine network, using the cytokines as growth factors, and modifying the effector 
functions of the immune system (Hide et al., 1989).  
The first response of the host immune system consists of classically activated 
macrophages secreting pro-inflammatory molecules such as TNF, IL-1, IL-6 and nitric 
oxide (NO) (Duxbury et al., 1972; Mosser and Roberts, 1982; Pan et al., 2006). The 
classically activated macrophages phagocytose antibody-opsonised parasites (Shi et 
al., 2004) as well as secrete trypanotoxic molecules such as TNF and NO (Mabbott et 
al., 1994; Sternberg and Mabbott, 1996; Kaushik et al., 2000) which are involved in the 
control of the first peak of parasitaemia.  
Despite the benefit of the initial inflammatory response, sustained inflammation can 
cause further damage to the mammalian host. Thus, a reduction in inflammation is 
required by the down regulation of the classically activated macrophages and their 
pro-inflammatory cytokines. The production of type II cytokines such as IL-4, IL-10 and 
IL-13 are able to modulate the macrophages to become alternatively activated 
macrophages, which are anti-inflammatory (Baral, 2010). 
1.7 Control, diagnosis and chemotherapy for 
trypanosomosis 
Despite an increase in health facilities throughout endemic countries that offer 
diagnosis and treatment for HAT, access to these facilities is limited due to the remote 
locations of the areas of incidence, which are often also in war zones (Franco et al., 
2017). In order to maintain and further reduce the numbers of HAT and AAT cases, 
innovative and cost-effective strategies are required. This includes the development of 
new tools for diagnosis, vector and reservoir control as well as effective trypanocides 
(Franco et al., 2017).  
1.7.1 Control 
The control of AT can be accomplished by reduction of parasite transmission through 
the control of the insect vector, as well as case detection and treatment (Büscher et 
al., 2017). Due to the existence of a wildlife reservoir, the elimination of HAT is unlikely, 
if the insect vector is not removed. However, the removal of tsetse populations has 
been achieved in less than 2% of the 10 million km2 estimated to be infested (Bouyer 
et al., 2013), and AAT integrated management has rarely been sustained (Vreysen et 
al., 2013; Shaw et al., 2015).  
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A number of trypanosomosis and tsetse control methods have been developed and 
implemented with varied levels of success in a number of endemic regions (Muhanguzi 
et al., 2015). Methods for the control of the insect vector include both stationary and 
mobile baits in the form of fly traps (Vale and Torr, 2004) and insecticide-treated cattle 
(Allsopp and Hursey, 2004), aerial spraying (Kgori et al., 2006), sterile insect technique 
(Vreysen et al., 2000) and the administration of trypanocides to cattle (Holmes et al., 
2004).  
The 86% reduction in T. b. gambiense infections, between 2000 and 2014, can be 
attributed to consistent active and passive surveillance, screening approximately 
2 million people per year (Franco et al., 2017). Vector control has been initiated in 
some T. b. gambiense endemic regions and is believed to have contributed to the 
reduction of reported cases in countries such as Guinea (Courtin et al., 2015) and 
Chad (Franco et al., 2017). Infections with T. b. rhodesiense represent an average of 
2.7% of the total number of reported HAT cases between 2000 and 2014 (Franco et 
al., 2017). The wildlife reservoir, which is difficult to manage, is the cause of the 
scattered but constant T. b. rhodesiense cases reported (Simarro et al., 2010). Due to 
the faster disease progression and poor effectiveness of active screening of 
T. b. rhodesiense infections, the rate of under-detection is, in all likelihood, higher than 
that of T. b. gambiense infections (Franco et al., 2017). 
The most widely used AAT control method is trypanocides (Grant, 2001; Holmes et al., 
2004; Torr et al., 2007), as livestock keepers in the tsetse infested areas of Africa, 
consider this to be a rapid and inexpensive means of control compared to that of tsetse 
control methods (Torr et al., 2007). This method requires multiple trypanocide 
administrations as the currently used trypanocides afford only a short period of 
protection (Bourn et al., 2005). However, there is a high risk of the development of 
drug resistance through the extensive use of trypanocides (Geerts et al., 2001; Holmes 
et al., 2004). 
In an attempt to control T. b. rhodesiense infections in livestock, mass administration 
of isometamidium chloride followed up by routine application of insecticides to protect 
cattle from tsetse flies (Welburn et al., 2006a; Kajunguri et al., 2014), has been 
implemented across large endemic focus areas in Uganda (Fyfe et al., 2017). This 
intervention allowed for the protection of the human population from HAT infections as 
well as the improvement of the health and productivity of livestock (Okello et al., 2015). 
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1.7.2 Diagnosis 
Ideal diagnostics in resource-limited settings should meet the WHO quality-ASSURED 
criteria (Peeling et al., 2006). This includes affordability, sensitivity, specificity, user 
friendly with minimal training, rapid and robust, equipment free and deliverable to end 
users.  
Diagnosis of trypanosomal infections require serological screening, followed by 
microscopic confirmation, and finally in the case of HAT, disease staging (Chappuis et 
al., 2005). Diagnosis of T. b. gambiense infections can be performed in 882 fixed health 
facilities, of which, 639 can perform serological testing, 326 are equipped to perform 
parasitological diagnosis and only 262 can perform disease staging (Franco et al., 
2017). Diagnosis of T. b. gambiense infections in the six endemic countries, i.e. Kenya, 
Malawi, Uganda, United Republic of Tanzania, Zambia and Zimbabwe, are offered by 
111 health facilities, all of which are able to perform clinical diagnosis (Franco et al., 
2017). Parasitological diagnosis is only offered by 49 and disease staging by 34 of the 
111 facilities (Franco et al., 2017). 
As the direct result of the highly immunogenic VSG molecules, high concentrations of 
VSG-specific IgG and IgM antibodies are produced (Crowe et al., 1984). Serological 
screening using the card agglutination test, CATT, detecting host antibodies against 
the LiTat 1.3 variant VSG of T. b. gambiense (Magnus et al., 1978) is the first step in 
diagnosis (Chappuis et al., 2005) and characterised by a 69-100% sensitivity and 
84-99% specificity (Mitashi et al., 2012). The immune trypanolysis test is based on 
complement-mediated lysis of trypanosomes (Chappuis et al., 2005). Despite being 
the gold standard in HAT and AAT diagnostics (Van Meirvenne et al., 1995) with a 
97.2-100% sensitivity and 100% specificity, the test is expensive and associated with 
a high infection risk to personnel (OIE, 2013). 
Microscopic examination of lymph node aspirates, blood or cerebrospinal fluid (CSF) 
from sero-positive patients provides direct evidence for trypanosome infection 
(Chappuis et al., 2005). Parasite detection can be labour intensive and failure to detect 
parasites does not rule out infection. With the aid of centrifugation techniques to 
concentrate parasites in the buffy coat fraction, prior to microscopic analysis, sensitivity 
can be improved (Woo, 1970). In the absence of a centrifuge, wet and thin blood films 
are the methods of choice for the confirmation of AT infection. However, parasitological 
tools are often not sensitive enough to detect parasites which may be present in bodily 
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fluids in low numbers (Field et al., 2009), and is estimated to fail to detect between 20 
and 30% of trypanosome infections (Robays et al., 2004). 
Following parasite visualisation, HAT disease staging is performed by the examination 
of CSF samples. The presence of parasites in CSF is indicative of second stage 
infection (Chappuis et al., 2005). However, the number of circulating parasites in the 
CSF may be very low, which may cause false negatives. Thus, sensitive diagnostic 
tools are required for the detection of low levels of parasites at various points during 
the infection period.  
Population screening using rapid diagnostic tests (RDTs) are able to detect antibodies 
in human finger-prick blood samples (Posthuma-Trumpie et al., 2009). These tests 
meet the ASSURED criteria as they are cost effective, simple to use and stable for 
distribution into remote areas of disease incidence. The SD BIOLINE HAT (Standard 
Diagnostics, Fig. 1.5, panel A) and the Sero-K-SeT (Coris Bioconcept) have been 
developed for the diagnosis of T. b. gambiense infections based on the detection of 
anti-trypanosome antibodies against the native T. b. gambiense LiTat 1.3 and LiTat 1.5 
antigens (Büscher et al., 2013). However, no RDT for T. b. rhodesiense has been 
developed (Büscher et al., 2017). Comparison of the diagnostic capabilities of the 
BIOLINE and Sero-K together with the CATT and trypanolysis methods, using sera 
from endemic regions: Angola, Democratic Republic of the Congo, and Central African 
Republic, have been reported by a number of research groups for T. b. gambiense 
infections (Büscher et al., 2013; Büscher et al., 2014; Jamonneau et al., 2015; Bisser 
et al., 2016; Lumbala et al., 2017). The general consensus is that these RDTs are as 
sensitive and specific as the CATT and trypanolysis methods, and can, thus, be used 
for active screening in remote areas more easily than the CATT which requires a cold 
chain and electricity. 
As with the immune trypanolysis test, the use of native antigens in BIOLINE and Sero-
K RDTs poses a risk to personnel due to the culture of human infective trypanosomes. 
As such, the application of recombinant antigens in an RDT format is being 
investigated. A study using dual-antigen lateral flow test prototypes with sera from the 
Democratic Republic of the Congo and WHO HAT Specimen Biobank (as a virtual field 
trial) showed promising results (Sullivan et al., 2014). Several prototypes have been 
developed using recombinant as well as native antigens. The prototype developed by 
Sullivan et al. (2014) was characterised by a sensitivity of 97% and specificity of 83% 
when using recombinant soluble VSG117/MiTat 1.4 and invariant surface glycoprotein 
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(ISG)-65. A sensitivity 82% and specificity 95% was obtained with the prototype 
reported by Sternberg et al. (2014) using recombinant LiTat 1.3 and -1.5, and an 88% 
sensitivity and 94% specificity for that developed by BBI Solutions (Cardiff, Wales), 
using recombinant ISG65 and native MiTat 1.4 (Sternberg et al., 2014). These 
prototypes have comparable sensitivity and specificity to that of the BIOLINE (89-99% 
and 88-98%) and CATT (69-95% and 95-98%) as measured in endemic areas 
(Büscher et al., 2013; Büscher et al., 2014; Bisser et al., 2016; Lumbala et al., 2017). 
The application of LiTat 1.3 and -1.5, recombinantly expressed in L.  tarentolae, in a 
diagnostic ELISA demonstrated that these antigens had a comparable sensitivity and 
specificity to that of the native LiTat 1.3 and -1.5 (Rooney et al., 2015). These results 
highlight the applicability of recombinantly expressed antigens in the generation of 
accurate HAT RDTs.  
  
Figure 1.5: Human and animal RDTs for the diagnosis of African 
trypanosomosis. (A) Positive test for T. b. gambiense using the SD BIOLINE HAT RDT 
where S, sample well; 1, LiTat1.3; 2, LiTat1.5 and C, control (Bisser et al., 2016). Positive AAT 
prototype for (B1) T. congolense infection, (B2) T. vivax infection and (B3) mixed T. congolense 
and T. vivax infection, where C, control; Tv, TviGM6 antigen and Tc, TcoCATB antigen 
(Boulangé et al., 2017). 
 
Serological diagnostic tools, such as the CATT, are limited to detection only and are 
not suitable for follow-up evaluations due to the persistence of anti-trypanosome 
antibodies after cure (Lejon et al., 2010). To distinguish between active and cured AT, 
a serological diagnostic test would have to be able to detect the antigens produced by 
the parasite rather than the IgM antibodies produced against the parasite (Tiberti et 
al., 2013). Trypanosomal antigens, which are circulating during active infections, are, 
thus, potential targets for diagnostics and even chemotherapy. Pathogeno-proteomics 
is considered a promising method for the identification of new diagnostic markers and 
new therapeutic targets (Hölzmuller et al., 2008). Using this method, diagnostic 
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antigens in T. b. gambiense (Sullivan et al., 2013) and T. vivax have been identified 
for use in diagnostics (Fleming et al., 2016). 
The GM6 antigen has been identified as a suitable diagnostic antigen for AAT 
diagnosis. The tandem repeat antigen is conserved amongst the salivarian 
trypanosomal parasites and the recombinantly produced antigen was applied in an 
indirect ELISA for T. vivax diagnosis (Pillay et al., 2013) and an RDT format for 
T. evansi diagnosis (Nguyen et al., 2015). However, this T. evansi RDT has not been 
commercialised. The use of the TcoCATB (Mendoza-Palomares et al., 2008) and 
TviGM6 (Pillay et al., 2013) antigens in a dual-antigen RDT prototype, was 
characterised by a sensitivity of 96% and a 92% specificity for the detection of both 
T. congolense and T. vivax infections (Fig 1.5, panel B) (Boulangé et al., 2017). 
Two related members of the T. vivax ISG family were shown to have good diagnostic 
applicability and the RDT prototype was characterised with a 92% sensitivity and 
89.9% specificity using sera from experimental infections (Fleming et al., 2016). Taken 
together with the success of the ISG65 in the HAT RDT prototypes (Sternberg et al., 
2014; Sullivan et al., 2014), these ISGs have great diagnostic potential for animal 
infections.  
Diagnostic methods, which do not meet the ASSURED criteria, include PCR and 
various modifications thereof. Despite being highly sensitive (70-100%) and specific 
(91.4-100%), DNA-based methods are not commonly used for active case finding in 
rural HAT endemic regions, due to the expense and requirement for sophisticated 
equipment and trained personnel (Mitashi et al., 2012). Instead, DNA-based methods 
are useful for population screening, with amplification of the 177 bp satellite DNA 
(Wickstead et al., 2004) and SRA gene (Welburn et al., 2001b) for HAT, 18S ribosomal 
sub-unit (Geysen et al., 2003) and the internal transcribed spacer (ITS1) of ribosomal 
DNA (Desquesnes et al., 2001) for AAT. The ITS1 PCR method is able to successfully 
distinguish between T. brucei spp., T. congolense, T. simiae, T. godfreyi and T. vivax 
infections in cattle and camels (Njiru et al., 2005). The finding that the ITS PCR method 
is suitable for large-scale epidemiological studies (Thumbi et al., 2008), and was used 
for the evaluation of trypanosome prevalence in cattle (Ahmed et al., 2013) and in 
tsetse flies (Isaac et al., 2016) in endemic areas. This data can serve as an indicator 
of where parasite control needs to be implemented. This was the case where the 
screening of goats and cattle in Zambia indicated that prevention and control strategies 
had reduced the number of infections (Musinguzi et al., 2016). 
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1.7.3 Chemotherapies 
The available chemotherapies used for the treatment of HAT are highly toxic, require 
trained healthcare providers and drug resistance has been reported (Garcia-Salcedo 
et al., 2014). The ideal trypanocide should be affordable, safe, effective and require 
simple administration (Kuzoe, 1993). In addition, the identity of the infecting parasite 
and disease stage needs to be considered prior to treatment. The currently used 
disease confirmation and staging are complex and painful to the patient, which results 
in under-reporting of cases (Odiit et al., 2005; Acup et al., 2017).  
First and second stage T. b. gambiense infections are treated with pentamidine and 
eflornithine, respectively (Kennedy, 2013). More recently, the use of nifurtimox-
eflornithine combination therapy (NECT) was recommended due to increased efficacy, 
decreased dosing and a reduction in emergence of drug resistance, despite the higher 
cost (Priotto et al., 2009; Lutje et al., 2010). Suramin and the organo-arsenical, 
melarsoprol, are administered for first and second stage T. b. rhodesiense infections, 
respectively (Kennedy, 2013). Each trypanocide causes adverse side effects, the 
worst of which is caused by melarsoprol, with 5 to 10% of treated patients succumbing 
to reactive encephalopathy (Burri, 2010).  
Target-based and phenotypic screening have been employed to identify both attractive 
molecular targets and cell permeable inhibitors which are toxic to the parasite but not 
to the mammalian host (Matthews, 2015). The identification and development of the 
orally effective drugs fexinidazole and benzoxaborole SCYX-7158 have been the direct 
result of phenotypic screening (Maser et al., 2012). Fexinidazole has almost completed 
phase 2/3 clinical trials (Tarral et al., 2014), whilst SCYX-7158 has just entered phase 
2/3 trials (Jacobs et al., 2011). 
Due to the decrease in the number of reported HAT cases (Franco et al., 2017), the 
human impact of AT is largely indirect, through the effects on livestock (Matthews, 
2015). However, research into the biochemistry and drug susceptibility of the causative 
agents of AAT is limited, and their importance is often overlooked. 
The currently used chemotherapies for AAT are diminazene aceturate (Berenil®), 
isometamidium chloride (Samorin®) and homidium chloride (Novidium®) (Geerts et al., 
2001). The indiscriminate use of trypanocides have resulted in reduced effectiveness 
and the emergence of drug resistance (Van den Bossche et al., 2000; Geerts et al., 
2001; Delespaux et al., 2002). Since the introduction of isometamidium chloride in 
1961 (Berg et al., 1961), no new AAT treatment has been introduced (Giordani et al., 
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2016). As such, it is not surprising that drug resistance is on the increase (Van den 
Bossche and Delespaux, 2011) and has been reported in 21 African countries 
(Delespaux and de Koning, 2007; Chitanga et al., 2011). A strategy to prevent the 
development of drug resistance is the use of isometamidium chloride or homidium 
chloride, together with diminazene aceturate as a sanative pair (Geerts et al., 2001; 
Holmes et al., 2004; Chitanga et al., 2011). 
It has been suggested that to prevent reinfection, trypanocides together with veterinary 
insecticides are required (Kajunguri et al., 2014; Muhanguzi et al., 2014), which is an 
economical option for HAT control as well as the control of tick-borne diseases and 
AAT (Muhanguzi et al., 2014). 
1.8 Peptidase virulence factors 
Due to the ability of trypanosomes to undergo antigenic variation and elimination of 
host B-cell memory (Radwanska et al., 2008), the development of a vaccine is highly 
unlikely (La Greca and Magez, 2011). Thus, prevention, through vector control, 
accurate diagnosis and timely treatment are the only options for the control of AT. In 
the absence of a vaccine, an anti-disease strategy was proposed for the neutralisation 
of the pathogenic effects of the trypanosomal parasite (Antoine-Moussiaux et al., 
2009). 
Pathogeno-proteomics entails an analysis of the interactions between the parasite, 
mammalian host and insect vector, towards characterisation of the mechanisms by 
which the disease progresses (Hölzmuller et al., 2008). This analysis identifies 
molecular targets which are essential for pathogenesis, and are termed virulence 
factors (Antoine-Moussiaux et al., 2009). Parasite peptidases are thought to play direct 
roles in disease pathogenesis as they are involved in host invasion, migration, 
metabolism and immune evasion (McKerrow et al., 2006). The cathepsin-L-like 
peptidases (Steverding et al., 2012), metacaspases (Helms et al., 2006), 
oligopeptidases (Morty et al., 2001) and the aurora kinases (Tu et al., 2006) are some 
of the trypanosome virulence factors identified to date. 
In addition to being potential diagnostic antigens, the virulence factors are attractive 
targets for the development of novel chemotherapies (Drag and Salvesen, 2010). 
Recently, the kinetoplastid proteasome was genetically and chemically validated as a 
promising target for the development of novel chemotherapies for the treatment of 
trypanosomosis, Chagas disease and leishmaniasis (Khare et al., 2016).  
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1.8.1 Metacaspases 
Caspases (cysteine-dependent aspartate specific proteases) are found only in the 
metazoan kingdom, whilst the other kingdoms possess the structurally related 
metacaspases, MCAs (Uren et al., 2000). Due to their structural similarity to the 
caspases, specifically the catalytic dyad and classic caspase-haemoglobinase fold 
(Aravind and Koonin, 2002) the MCAs have been assigned to clan CD, and the C14B 
subfamily of cysteine peptidases (Rawlings et al., 2016). The MCAs differ from 
caspases in their preference for basic Arg and Lys residues over acidic Asp residues 
at the P1 substrate position, together with a low shared sequence homology and their 
inability to form dimers (McLuskey et al., 2012). 
A highly selective S1 pocket ensures the strict substrate specificity of clan CD 
peptidases. This feature permits their involvement in specific processing events, with 
little chance of random peptidolytic degradation. An example of this specificity is 
evident in the signalling pathways involving caspases during their participation in 
apoptosis and inflammation (Pop and Salvesen, 2009). 
1.8.1.1 Structure of metacaspases 
The MCAs are divided into type I, to which the ancestral form found in unicellular 
organisms belongs, and type II, which have evolved for larger, more complex 
organisms (Lam and Zhang, 2012). More recently, type III metacaspases, found only 
in algae which have undergone secondary endosymbiosis, have been discovered 
(Choi and Berges, 2013). Type I MCAs are typically found in plants, yeasts and 
protozoa whilst type II MCAs are found only in plants. The most studied MCAs are from 
Arabidopsis thaliana, which possess both type I MCAs 1 to 3 and type II MCAs 4 to 9. 
Similar to the caspases, the MCAs possess a large catalytic domain (p20), within which 
the catalytic dyad is found, and a smaller N-terminal domain (p10) (Fig. 1.6). The type 
II MCA is an exception, where the p10 domain is found at the C-terminus. Unlike 
caspases, type I MCAs possess a short linker region and type II MCAs a long linker 
region between the p20 and p10 domains. An N-terminal domain, which is present in 
initiator caspases, is found in type I MCAs, which in plants contains a zinc finger motif 
(Vercammen et al., 2004; Tsiatsiani et al., 2011). Conversely, type II MCAs lack the 
N-terminal domain and are similar to execution caspases, by way of their dependency 
on autoprocessing for activation (Vercammen et al., 2004; Tsiatsiani et al., 2011).  
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The MCAs are a functionally diverse family of peptidases, and may harbour a capacity 
for multifunctionality within organisms which possess only a single MCA copy. The 
single copy MCA from Leishmania spp. and the trypanosomal MCA5s possess a Pro-, 
Gln- and Tyr-rich C-terminal extension, unlike the short C-terminal extension of the 
multicopy genes, TbbMCA 1 to 4 (Mottram et al., 2003) and the 16 copies of TcrMCA3 
(Kosec et al., 2006). The C-terminal domain of LmjMCA interacts with proteins involved 
in stress regulation (Casanova et al., 2015). This demonstrates that the Pro-rich 
C-terminal domain of the MCAs could be responsible for protein-protein interactions 
as suggested by Kay et al. (2000).  
 
Figure 1.6: Domain organisation of the caspases and metacaspases. The catalytic 
domain (p20), in which the catalytic dyad is found, is highlighted in green, whereas the smaller, 
p10 domain, is highlighted in pink. The domains are not drawn to scale and the additional 
domains are not shown in this instance. 
 
1.8.1.2 Functions of metacaspases 
The study by Madeo (2002) identified the Saccharomyces cerevisiae MCA (YCA1) as 
a positive regulator of programmed cell death (PCD). YCA1 has been implicated in 
both cell cycle regulation (Lee et al., 2008) and the clearance of insoluble protein 
aggregates (Lee et al., 2010). It has been demonstrated that the single copy LmjMCA 
has a role in PCD induced by oxidative stress (Zalila et al., 2011) and is also required 
for cell cycle progression (Ambit et al., 2008). In addition, an antagonistic relationship 
exists between two of the A. thaliana MCAs in the hypersensitive response cell death 
pathway, whereby AtMCA1 promotes cell death and AtMCA2 functions as a negative 
regulator. Together, this highlights the potential of the action of MCAs in key regulatory 
processes (Coll et al., 2010).  
An RNAi study revealed that the pseudopeptidase, TbbMCA4, functioned in both cell 
cycle progression and parasite virulence during mammalian infection (Proto et al., 
2011). It was demonstrated that TbbMCA4 was processed by TbbMCA3, both of which 
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are palmitoylated (Emmer et al., 2009), and may comprise a MCA peptidolytic 
cascade. (Proto et al., 2011).  
Irrespective of the elucidation of the role of MCA, the lack of a mammalian homologue 
and the MCAs’ involvement in the parasite cell cycle and in cell death pathways, make 
the MCAs attractive targets for the development of novel chemotherapies for 
trypanosomosis, Chagas disease and leishmaniasis (Ambit et al., 2008; McKerrow et 
al., 2008; Alvarez et al., 2011). In addition, the presence of MCAs in the plant and fungi 
kingdoms, make them attractive targets for the development of pesticides and 
fungicides (Lam and Zhang, 2012).  
1.8.2. Oligopeptidase B 
The serine peptidase, oligopeptidase B (OPB), is present in the cytosol of 
trypanosomes and bacteria (Burleigh et al., 1997; Morty et al., 2005a; Rea and Fülöp, 
2006), and has been identified as an important virulence factor in AAT caused by 
T. b. brucei, T. congolense and T. evansi (Troeberg et al., 1996; Morty et al., 1999; 
Morty et al., 2001; Morty et al., 2005a). The trypanocidal drugs suramin (Morty et al., 
1998), pentamidine (Ashall, 1990; Morty et al., 1998) and diminazene (Morty et al., 
1998), were shown to inhibit TbbOPB. In addition, irreversible inhibitors of TbbOPB 
exhibited anti-trypanosomal activity in vitro and in vivo (Morty et al., 2000), and OPB 
can therefore be regarded as a potential target for the development of novel 
trypanocides (Coetzer et al., 2008; Canning et al., 2013). However, despite a 60% 
protein sequence similarity between the OPB from T. b. brucei and L. major, a gene 
deletion study suggested that OPB is not an essential virulence factor in L. major 
(Munday et al., 2011). This was further confirmed in a study by Moss et al. (2015) 
where it was demonstrated that the activity of TbbOPB was not required for infection. 
The OPB peptidase is dimeric, and is comprised of a C-terminal catalytic domain with 
an α/β hydrolase fold, and a N-terminal regulatory domain with a seven-bladed 
β-propeller (Fig. 1.7) (Canning et al., 2013). The peptidolytic activity of monomeric 
OPB is limited to peptide substrates which are smaller than 30 amino acid residues, 
and has a P1 site specificity for Arg and Lys (Kanatani et al., 1991).  
Peptide hormones, which are rich in basic residues, are favoured substrates of OPB, 
with cleavage of atrial natriuretic factor (Ndung’u et al., 1992; Troeberg et al., 1996; 
Morty et al., 2005a), adrenocorticotropic hormone (de Andrade et al., 1998; Tsuji et al., 
2004), angiotensins I and II (Nishikata, 1984; Kanatani et al., 1991; Bagarozzi et al., 
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1998), bradykinin potentiator B (Nishikata, 1984), vasoactive intestinal peptide and 
substance P (Bagarozzi et al., 1998), neurotensin (Kanatani et al., 1991; Troeberg et 
al., 1996), reduced (Arg8)/ (Lys8)vasopressin (Troeberg et al., 1996), serum thymic 
factor (Nishikata, 1984), somatostatin-28, glucagons and dynorphin A (Tsuji et al., 
2004) being reported in literature. It has been demonstrated that synthetic substrates, 
up to 17 residues in length, based on the structure of bradykinin, were hydrolysed by 
recombinant TbbOPB and TcrOPB (Hemerly et al., 2003).  
 
Figure: 1.7: Monomeric 3D structure of TbbOPB. The C-terminal catalytic domain of 
TbbOPB (PDB: 4BP9) is highlighted in purple, whilst the N-terminal regulatory domain is 
highlighted in turquoise (Canning et al., 2013). 
 
1.8.2.1 Functions of oligopeptidase B 
Invasion of non-phagocytic mammalian cells is mediated by T. cruzi metacyclics and 
trypomastigotes through the action of OPB whereby the free intracellular calcium 
concentration in host cells is increased (Burleigh and Andrews, 1995). It is thought that 
OPB acts as a processing enzyme which generates active calcium from a cytosolic 
precursor molecule (Caler et al., 1998). 
It was shown that TbbOPB (Morty et al., 2005b), TcoOPB (Pinto Dias, 2006) and 
TevOPB (Morty et al., 2005a) is released from the respective lysed, dead and dying 
parasites into the bloodstream (Morty et al., 2005a; Munday et al., 2011), and is, thus, 
an attractive diagnostic antigen. The OPB from T. b. brucei is not inhibited by plasma 
serpins nor α-2 macroglobulin, and is able to hydrolyse regulatory peptides in the host 
serum (Troeberg et al., 1996; Morty et al., 2001; Morty et al., 2005a). The action of 
OPB has been implicated in the disruption of the hormone levels of the infected host 
(Morty et al., 1999; Morty et al., 2001; Morty et al., 2005a) through the cleavage of 
peptide hormones, such as atrial natriuretic factor in the blood of T. b. brucei infected 
rats (Tetaert et al., 1993). The disruption of host hormone signalling pathways, through 
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the action of OPB, is thought to contribute to disease progression (Morty et al., 2005a; 
Munday et al., 2011).  
1.9 Structure-based drug design 
The elucidation of the roles that virulence factors play in trypanosomal pathogenesis, 
together with biochemical characterisation, including structural details, form the basis 
for the development of specific inhibitors using computational-assisted drug design 
(Frearson et al., 2007). The availability of large libraries of inhibitor compounds which 
can be accessed, allows for the testing of novel trypanocides (McKerrow et al., 2008). 
Approaches for the discovery of novel chemotherapies include target-based, 
phenotypic screening and compound repurposing (Field et al., 2017). The most 
promising methodologies to identify suitable ligands for target proteins are 
structure-based drug design (SBDD) and virtual ligand screening (VLS) (Bleicher et 
al., 2003; Foloppe et al., 2006; Klebe, 2006). The use of SBDD provides insight into 
the interactions between the protein ‘receptor’ and the ligand, inhibitor or substrate, 
which highlights chemical modifications required to improve the binding affinity of the 
ligand to the protein ‘receptor’.  
A peptidomimetic library based on the substrate P1 specificity site of TbbMCA2 was 
synthesised and showed promising results in vitro against the recombinant enzyme as 
well as T. b. brucei, T. cruzi, L. infantum and Plasmodium falciparum (Berg et al., 
2012). When tested in vitro, it was suggested that the inhibitors may be acting on 
multiple targets. Analysis and molecular docking, in an SBDD methodology, is required 
for the validation of ligand binding to the TbbMCA2 molecular target for the 
development of possible new ligands targeting the MCAs. 
1.10 Antibody production using phage display 
Target-specific antibodies, generated using phage display, have applications in 
proteomics, drug delivery studies and the analysis of intracellular antigens 
(Hoogenboom, 2005). Phage display is independent from the immune system, 
whereby in vitro selection from combinatorial libraries of immunoglobulin VH and VL 
genes, is used to generate antibodies, which are displayed on phage particles (Smith, 
1985; Pini and Bracci, 2000; Schirrmann et al., 2011). The advantage of in vitro 
technologies over animal immunisation is the unlimited and defined source of antigen 
binders where the DNA is known (Schirrmann et al., 2011).  
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The process of phage display is based on the linkage of foreign antibody gene 
fragments to the minor phage coat protein (pIII) of the M13 bacteriophage (Smith, 
1985). As a result, the genes encoding the antibody (genotype) is directly linked to the 
displayed antibody on the phage particle (phenotype). This feature allows the coding 
sequence of the antibody to be exactly known and exactly reproduced. The 
antibody::pIII fusion protein are assembled in E. coli and secreted into the periplasmic 
space and are often soluble, stable and folded in their native form (Marston, 1986). 
The process of phage display is illustrated in Fig. 1.8 which starts with the construction 
of a phagemid library whereby the immunoglobulin VH and VL genes are amplified and 
ligated into a phagemid plasmid (Step A). After the propagation of E. coli transfected 
with the phagemid cells (Step B), the scFv::pIII fusion proteins are displayed on the 
bacterial cell surface (Step C). The phagemids are then rescued by the M13KO7 helper 
phage which provides the essential proteins (dark grey outline) for the packaging of 
the recombinant phage DNA within the phage and the display of the fusion proteins on 
the bacterial cell surface (Webster, 1996) (Step D). As a result, a mosaic population 
where E. coli containing either phagemid or the helper phage exists whereby the WT 
pIII (dark gray) competes with the scFv::pIII fusion proteins for incorporation into the 
phage particle (Step E). In Step F, the mosaic population is panned against the 
immobilised antigen to isolate antigen specific scFv (light blue), whilst non-specific 
scFvs are discarded (pale yellow). The bound phagemids are eluted from the E. coli 
host, and under antibiotic selection, only the phagemids are transfected back into 
E. coli (Step G). It is at this step, that the WT phagemid is lost. The resulting phagemid 
population is rescued once again (Step H) and used to pan against the immobilised 
antigen once again. This process is repeated numerous times to select for scFv with a 
high affinity for the immobilised antigen. 
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Figure 1. 8: Schematic representation of the genotype:phenotype linkage of scFv and the process of phage display. The resultant 
myc-tagged scFv antibody fragment::pIII fusion is displayed by the bacterial host (light pink). The genes coding for the immunoglobulin VH and VL genes 
are coloured in light green and turquoise, respectively, and are joined by a linker region (GGGGS)3 which prevents dissociation. A myc sequence, 
coloured in bright pink, is included to facilitate affinity purification. The pIII phage coat protein is coloured in light grey and the WT pIII in dark grey. The 
essential packaging proteins, supplied by the helper phage, is shown as the grey outline of the E. coli. The process by which the scFv antibodies are 
selected from the phagemid library is detailed in steps A to H. The stepwise explanation of the process is given in the text. Adapted from McCafferty et 
al. (1990).
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1.10.1 Antibody formats produced by phage display 
The most common antibody fragments produced by phage display (Fig. 1.9) are the 
single chain variable fragment (scFv) and the antigen binding fragment (Fab) of all 
mammalian species as well as the variable heavy domain (VHH) of camel antibodies 
(Holt et al., 2003; Hoet et al., 2005; Hust and Dübel, 2005). The monovalent scFv (VL 
and VH), Fab (VL, CL, VH, CH) and nanobody (VHH) fragments retain their respective 
specific antigen binding affinity compared to that of the VH1 and CH1, since the antigen 
binding surface is not altered (Bird et al., 1988; Huston et al., 1988).  
 
Figure 1.9: Commonly produced antibody fragments using phage display. 
(Hammarström and Marcotte, 2015). 
 
The evolution of high affinity single V-like domains (VHH) is an integral part of the 
camelid immune system (Fig. 1.9, panel B) (De Genst et al., 2005). The VHH domain 
possesses extended surface loops which are able to penetrate the narrow cavities on 
various pathogens’ surfaces (Nuttall et al., 2004; Streltsov et al., 2004). In order to 
escape immunodetection, many pathogens have evolved narrow cavities in their 
surface antigens in order to make them inaccessible by host antibodies (Janeway Jnr 
and Medzhitov, 2002). A prime example is evident in the close packing of the VSG 
dimers on the parasite surface. A VHH antibody fragment was able to penetrate further 
between the VSGs on the surface of T. b. brucei compared to the Fab antibody 
fragment (Fig. 1.10) and the anti-VSG IgM antibody (Fig. 1.4) (Stijlemans et al., 2004). 
The development of combinatorial libraries for human or mouse V genes is complex 
due to the requirement for multiple primer sets. In birds, the genes for the heavy (H) 
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and light (L) chains are subjected to VDJ and VJ rearrangement, respectively. As a 
result of the incorporation of pseudo V region genes, variability arises by resultant gene 
conversion (Reynaud et al., 1985; Reynaud et al., 1987; Thompson and Neiman, 1987; 
Reynaud et al., 1989). This results in the V regions of the chicken immunoglobulins, 
having identical amino acid residues at both termini. This simplifies the development 
of a combinatorial library of the naïve chicken antibody repertoire as only one set of 
primers is required: one for the H and another for the L chain. This characteristic of the 
genes coding for chicken antibodies was first exploited by Davies et al. (1995) using 
chicken bursal lymphocyte RNA to produce a naïve scFv library, from which scFv 
antibodies were produced against three proteins. Since chickens are able to produce 
antibodies against a wide range of antigens (Conroy et al., 2012; Shih et al., 2012), 
together with the their phylogenetic distance from mammalian species, a combinatorial 
library using chicken antibody coding genes for the development of diagnostic 
antibodies would be advantageous (Conroy et al., 2014). In 2004, one such phage 
display library, using chicken immunoglobulin genes, was developed and named the 
Nkuku® library (van Wyngaardt et al., 2004). The Nkuku® phagemid library will be used 
in the present study. 
 
Figure 1.10: Comparison of the penetration of VHH and Fab antibody fragments 
in between VSG dimers on trypanosome surfaces. The VSG dimer is coloured green 
and blue, the VH, and VL, CH and CL of the Fab fragment are coloured red and black, 
respectively. The structure of VHH is coloured in light blue and the complementary determining 
loops in yellow. (Stijlemans et al., 2004). 
 
1.10.2  Applications of phage display 
A study of protein-protein interactions (Hertveldt et al., 2009), identification of 
immunogenic proteins from pathogens (Stijlemans et al., 2004) and of agonists and 
antagonists to probe receptor site function (Koolpe et al., 2005) can all be achieved 
using phage display technology.  
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In addition, phage display is a cost effective and efficient method to map the epitopes 
of various antigens which are involved in antibody interaction, thus, providing vital 
information for the development of diagnostics, immunotherapies and vaccines 
(Böttger and Böttger, 2009; Wang and Yu, 2009). The Nkuku® phage display library 
was used to map the epitopes of the SAT2 foot-and-mouth disease virus in an attempt 
to neutralise the virus (Opperman et al., 2012). 
Antibodies are used directly in diagnostics for pathogen antigen detection (Dussart et 
al., 2008) and for competition with serum antibodies for binding to the pathogen antigen 
(Dong et al., 2007). Single chain variable fragment antibodies can be used in many 
standard immunodiagnostic tests (Thompson and Neiman, 1987; Nissim et al., 1994; 
van Wyngaardt and Du Plessis, 1998).  
The Nkuku® phage display library has been used to generate antibody fragments for 
the use in ELISA immunodiagnostic tests against bluetongue virus (Fehrsen et al., 
2005; Rakabe et al., 2011), African horse sickness virus (van Wyngaardt et al., 2004; 
van Wyngaardt et al., 2013), a 16 kDa antigen of Mycobacterium tuberculosis (Sixholo 
et al., 2011), and the 65 kDa HSP of Mycobacterium bovis (Wemmer et al., 2010). In 
addition, the HSP65 antibody fragments were engineered to form bivalent constructs, 
“gallibodies”, which were conjugated to gold particles and used in a sandwich RDT 
(Wemmer et al., 2010). 
1.11 Objectives of current study 
Objective 1: Determination of the applicability of the MCA5s from T. congolense and 
T. vivax as a chemotherapeutic target. 
1. To recombinantly express and purify MCA2 and -5 in order to raise antibodies 
for further research. 
2. To identify the amino acid residues required for autoprocessing of MCA5. 
3. To isolate native MCA5 enzyme. 
4. To enzymatically characterise both the recombinant and native MCA5. 
5. To perform molecular docking studies of Berg ligands and commercial inhibitors 
and substrates into the active site of TbbMCA2, for which the library was 
designed, as well as TcoMCA5 and TviMCA5. 
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Objective 2: Application of OPB-specific scFv antibody fragments in an antigen 
detection ELISA format. 
1. To pan the Nkuku® phagemid library against OPB as a model antigen to select 
for OPB-specific scFvs. 
2. To determine the most likely site at which the selected scFv interacts with OPB. 
3. To demonstrate that the isolated scFv detects both recombinant and native 
OPB in different cellular compartments as well as OPB released into the 
parasite culture medium. 
4. To detect OPB in the sera of experimentally infected cattle using OPB-specific 
scFv and polyclonal anti-OPB antibodies in an antigen detection sandwich 
detection ELISA. 
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CHAPTER 2 
CLONING AND EXPRESSION OF THE METACASPASES FROM 
TRYPANOSOMA BRUCEI BRUCEI, MCA2, AND 
TRYPANOSOMA VIVAX, MCA5 
2.1 Introduction 
African trypanosomosis affects both humans (HAT) and animals (AAT) in rural central 
Africa. The human infective parasites use wild and domestic animals as a reservoir 
(Njiokou et al., 2006; Cordon-Obras et al., 2009; Anderson et al., 2011). Thus, the 
control of AAT is critical for the elimination of HAT, as control of the insect vector is an 
ineffective strategy (Rotureau and Van Den Abbeele, 2013). The indiscriminate use of 
trypanocides and the lack of new chemotherapies, resulted in the emergence of drug 
resistance, and there is consequently a need for new drugs (Field et al., 2017). 
Molecular targets for the development of novel chemotherapies are those which are 
essential for the parasite’s survival in the host (Hölzmuller et al., 2008). These targets, 
also known as virulence factors, are used in an anti-disease strategy rather than an 
anti-parasite strategy (Antoine-Moussiaux et al., 2009) as the development of a 
vaccine is unlikely due to antigenic variation (La Greca and Magez, 2011). The 
anti-disease strategy focusses on targeting of factors which are essential to the growth 
and survival of the parasite (Stuart et al., 2008). 
Homologues of the metazoan caspases are the metacaspases (MCA) which are found 
in all kingdoms except that of the metazoan (Uren et al., 2000). Apoptosis is a 
controversial process in unicellular organisms; however, evidence in its favour is 
mounting (Deponte, 2008; Kaczanowski et al., 2011). Morphological and biochemical 
features, which are similar to those seen during apoptosis, have been described in 
T. brucei (Welburn et al., 2006b), T. cruzi (Ameisen et al., 1995), Leishmania spp. 
(Gannavaram and Debranbant, 2012), Giardia lamblia and Plasmodium falciparum 
(Bruchhaus et al., 2007). Due to the roles played by caspases in apoptosis and 
non-apoptotic events, it is thought that the MCAs may function in a manner similar to 
that of the caspases. As such, the MCAs are considered to be virulence factors as well 
as attractive drug targets due to their absence in their mammalian hosts. 
Despite the conserved caspase-haemoglobinase fold (Aravind and Koonin, 2002), the 
caspases and MCA are distinctly different in their substrate specificity, activation 
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mechanisms, calcium dependency and control of peptidolytic activity. In order to 
determine the role and processes they are involved in, the MCAs need to be identified, 
functionally characterised and their roles in parasite homeostasis determined.  
A number of kinetoplastid MCAs have been studied to date, including the multicopy 
MCAs, MCA1 (Szallies et al., 2002), MCA2 (Helms et al., 2006; Moss et al., 2007; 
McLuskey et al., 2012; Machado et al., 2013), MCA3 (Helms et al., 2006), MCA4 
(Szallies et al., 2002; Proto et al., 2011) and MCA5 (Helms et al., 2006) from 
T. b. brucei, the MCA3 and -5 from T. cruzi (Kosec et al., 2006; Laverrière et al., 2012), 
and the single copy MCAs from L. major (Gonzáles et al., 2007; Zalila et al., 2011; 
Castanys-Muῆoz et al., 2012; Casanova et al., 2015), L. donovani (Lee et al., 2007; 
Raina and Kaur, 2012) and L. mexicana (Castanys-Muῆoz et al., 2012). Most studies 
focused on the native MCA function in vitro when cell death has been induced in the 
parasites. Very few studies focus on the characterisation of the recombinant and native 
enzymes themselves. 
Analysis of the phylogenetic relatedness of the multi- and single copy MCA peptidases 
in Trypanosoma spp. T. cruzi, Leishmania spp. and the single MCA from 
Saccharomyces cerevisiae (YCA1), shows a clear division between the multi- and 
single copy groups, shown in yellow and blue, respectively, in Fig. 2.1. Within the 
multicopy group, a high sequence identity exists between the MCA2 and -3 of 
T. b. brucei, T. b. gambiense and T. evansi. The MCA2 and -3 of the animal infective 
T. congolense and T. vivax species, are not as related to their human infective 
counterparts. The MCA1, -4 and -5 of T. b. brucei, T. b. gambiense and T. evansi share 
a 100% sequence identity, and therefore, reference will only be made to those from 
T. b. brucei. 
Pseudopeptidases have substitutions for the catalytic residues and have been shown 
to be inactive (Reynolds and Fischer, 2015). The MCA1s (Fig. 2.1, shown in red) have 
both the catalytic His and Cys substituted with Tyr and Ser, respectively, whilst the 
MCA4s (Fig. 2.1, shown in purple) all possess the catalytic His, but have a Ser 
substitution for the catalytic Cys. The substitution of catalytic residues are common 
with some pseudopeptidases being shown to play key regulatory roles (Pils and 
Schultz, 2004; Reynolds and Fischer, 2015). It has been reported that TbbMCA3 
processes TbbMCA4, releasing TbbMCA4 which plays a role in cell cycle and parasite 
virulence (Proto et al., 2011). 
The focus of the current study is the MCA5 from the animal infective T. congolense 
and T. vivax (Uilenberg and Boyt, 1998). These MCAs differ from the multicopy gene 
30 
 
products, as they possess a long Pro-, Gln-, Tyr-rich C-terminal domain. This extended 
domain is present in each of the single copy MCAs in both Trypanosoma spp. and 
Leishmania spp. (Appendix A3) and is thought to play an important role in 
protein-protein interactions (Kay et al., 2000). One such example is the apoptotic-like 
response in T. cruzi parasites, in which the TcrMCA5 lacking the C-terminal domain, 
was overexpressed (Laverrière et al., 2012).  
 
Figure 2.1: Molecular phylogenetic analysis of the kinetoplastid MCAs and the 
single MCA from S. cerevisiae. The bootstrap consensus tree from 500 replicates 
(Felsenstein, 1985) utilising the maximum likelihood method, was used to deduce the 
evolutionary history of 26 MCA protein sequences (Jones et al., 1992) with MEGA7 (Kumar et 
al., 2016). The protein sequences were obtained from TriTrypDB (Aslett et al., 2010); TbbMCA 
from T. b. brucei (927), TbgMCA from T. b. gambiense (DAL972), TviMCA from T. vivax (Y486), 
TevMCA from T. evansi (STIB 805), TcoMCA from T. congolense (IL3000), TcrMCA from 
T. cruzi (Sylvio X10/1), LmjMCA from L. major (Friedlin), LmxMCA from L. mexicana 
(MHOM/GT/2001/U1103), LdnMCA from L. donovani (BPK282A1) and were compared to the 
YCA1 from S. cerevisiae (UniProt Q08601). The single copy MCAs are grouped in yellow and 
the multicopy MCAs in blue. The multicopy MCAs with mutations of the catalytic Cys (purple) 
and both catalytic His and Cys (red) were blocked in their respective colours. The tree is drawn 
to scale, with branch lengths measured in the number of substitutions per site. 
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In the work described in this chapter, the MCA2 gene from T. b. brucei and MCA5 gene 
from T. congolense were cloned, to include a N-terminal 6xHis tag, and were 
expressed in the soluble and insoluble fractions using Escherichia coli. After 
solubilisation, on column refolding and purification using nickel affinity 
chromatography, purified recombinant TviMCA5 was used to produce antibodies in 
chickens. The chicken antibodies produced against both TcoMCA5 and TviMCA5 were 
separately coupled to hydrazide resin to purify the respective MCAs present in the 
soluble expression fractions. 
2.2 Materials and methods 
 Materials 
Molecular biology: The oligonucleotide primers were synthesised at the department 
of Molecular and Cellular Biology at the University of Cape Town, South Africa. BamHI, 
EcoRI, NdeI, XhoI [for nomenclature see Roberts et al. (2003)], T4 DNA ligase, 10 mM 
dNTPs, High-fidelity PCR enzyme mix, GeneJet™ Plasmid Miniprep Kit, 
TransformAid™ Bacterial Transformation Kit, pTZ57R/T cloning plasmid, 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (IPTG), isopropyl-β-D-thiogalactopyranoside 
(X-gal) and dithiothreitol (DTT) were obtained from Fermentas (Vilnius, Lithuania). The 
pGEM-T® cloning plasmid and T4 DNA ligase were purchased from Promega 
(Madison, WI, USA) and the pET-28a and pET-32a expression plasmids from Novagen 
(Darmstadt, Germany). FIREpol® Taq polymerase, 10xPCR reaction buffer and 25 mM 
MgCl2 were from Solis Biodyne (Tartu, Estonia). The ZymoResearch Clean and 
Concentrator™ kit and Zymoclean™ Gel DNA Recovery Kit were purchased from 
Zymo Research (Orange, CA, USA). Seakem®LE agarose was purchased from Lonza 
(Rockland, ME, USA), ampicillin sodium salt from USB Corporation (Cleveland, OH, 
USA) and kanamycin from Gibco, (Paisley, UK). Bacteriological agar, tryptone and 
yeast extract were purchased from Merck Biolab (Darmstadt, Germany). Crystal violet 
and ethidium bromide were purchased from Sigma (St. Louis, MO, USA). Buffer salts 
and other common chemicals were purchased from Merck (Germany) and Sigma (St. 
Louis, MO, USA) and were of the highest purity available. The O’GeneRuler™ 1 kb 
DNA Ladder from Fermentas (Vilnius, Lithuania) was used in all agarose gels unless 
otherwise stated. 
E. coli cells: Escherichia coli cells, JM 109 and BL21 (DE3) strains, were purchased 
from New England Biolabs (Ipswitch, MA, USA). The JM 109 strain allowed for 
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blue/white screening for transformants in the presence of IPTG and X-gal. The 
BL21 (DE3) strain is deficient in both Lon and OmpT peptidase expression (Graslund 
et al., 2008). 
Purification and quantification of recombinant proteins: His-select® nickel affinity 
resin, 4-chloro-1-naphthol, phosphorylase B (97.4 kDa), bovine serum albumin (BSA, 
68 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa), soyabean trypsin inhibitor 
(SBTI, 21.5 kDa), lysozyme (14 kDa) and the semi dry blotter were purchased from 
Sigma (St. Louis, MO, USA). Equal volumes of 5 mg/ml solutions of phosphorylase B, 
bovine serum albumin, ovalbumin, carbonic anhydrase, soyabean trypsin inhibitor and 
lysozyme, made in reducing treatment buffer, were combined to produce the molecular 
weight marker used in all the SDS-PAGE gels. The BCA™ Protein Assay Kit was 
purchased from Pierce (Rockford, IL, USA), BioTrace™ nitrocellulose from PALL Corp 
(Ann Arbor, USA), 4-chloro-1-naphthol and UltraLink® hydrazide resin from 
ThermoScientific (Waltham, MA USA) and non-fat powdered milk from Amresco 
(Solon, OH, USA). 
Chicken IgY preparation and ELISA: Freund’s complete and incomplete adjuvants 
and bovine serum albumin (BSA, catalogue no.: A7906) were purchased from Sigma 
(St. Louis, MO. USA). Polyethylene glycol (PEG) Mr 6 000 was purchased from Merck 
(Darmstadt, Germany), Nunc-Immuno™ Maxisorp 96-well plates from Nunc Intermed 
(Roskilde, Denmark), 2, 2’-azinobis [3-ethyl-3, dihydrobenzithiazole-6-sulfonate] 
(ABTS) from Roche (Mannheim, Germany). The BIOTEK® ELx50™ Microplate washer 
was purchased from BioTek Instruments Inc. (USA) and the FLUORStar Optima 
Spectrophotometer from BMG Labtech (Offenburg, Germany). 
Antibodies: The chicken anti-6xHis antibody was purchased from Merck (Germany) 
and the rabbit anti-chicken IgY HRPO conjugate from Sigma (St. Louis, MO. USA). 
Approval was obtained for antibody production using chickens, with protocols approved 
by the University of KwaZulu-Natal animal research ethics committee (Reference 
053/15/Animal). 
 Cloning of TbbMCA2 and TviMCA5 into the pGEM-T® 
cloning plasmid 
The genomic DNA of purified bloodstream trypomastigotes of T. b. brucei (strain 927) 
and T. vivax (strain Y486) parasites was isolated utilising the method developed by 
Medina-Acosta and Cross (1993). Briefly, parasites were washed with PBS [100 mM 
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Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl and 137 mM NaCl, pH 7.2, 1 ml], centrifuged 
(2 000 g, 10 min, RT), resuspended in TELT buffer [50 mM Tris-HCl buffer, pH 8.0, 
62.5 mM Na2EDTA, pH 9.0, 2.5 M LiCl, 4% (v/v) Triton X-100, 150 μl] and incubated 
at RT for 5 min. A phenol-chloroform [1:1 (v/v)] extraction with end-over-end mixing, at 
RT for 5 min was subsequently performed. To the resulting top phase, 100% (v/v) 
ethanol (300 μl) was added and mixed using an end-over-end rotator at RT for 5 min 
to facilitate the precipitation of genomic DNA. Following centrifugation (10 000 g, 
10 min, RT), the pellet was washed with 100% (v/v) ethanol (1 ml) and any residual 
ethanol allowed to evaporate at 37 °C for 30 min. The pellet was resuspended in TE 
buffer [100 mM Tris-HCl buffer, pH 7.5, 10 mM Na2EDTA, 20 μg/ml RNAse, 30 μl] and 
incubated at 37 °C for 45 min. A sample of the isolated DNA (2 μl) was electrophoresed 
on a 1% (w/v) agarose gel, containing ethidium bromide (0.5 µg/ml), in 1xTris-Acetate-
EDTA (TAE) buffer (40 mM Tris-HCl buffer, 100 mM acetic acid, 1 mM Na2EDTA, 
pH 8.0). 
Using Primer 3 (Rozen and Skaletsky, 2000), primers were designed to amplify the 
1044 bp and 1 569 bp genes which encodes the MCA2 protein from T. b. brucei (strain 
927) [GenBank® accession: AAX80349.1] and the MCA5 protein from T. vivax (strain 
Y486) [GenBank® accession: CCC50891.1], respectively. To facilitate subcloning into 
expression plasmids, restriction sites were included in the designed primers. In Table 
2.1, the primers used for PCR amplification of the TbbMCA2 and the TviMCA5 genes 
as well as those required for colony PCR of the recombinant cloning and expression 
plasmids, are listed. In addition, the cloning and expression plasmids, into which the 
genes were ligated, are specified (Appendix A4). 
The isolated DNA was used as the PCR template. Briefly, the final concentrations of 
the PCR master mix were: 0.25 μM of each gene primer, 1 x High-fidelity PCR enzyme 
mix buffer, 2.5 mM MgCl2, 1 U High-fidelity PCR enzyme mix and 0.25 mM dNTPs in 
a total reaction volume of 50 μl. The PCR amplification of the TbbMCA2 and TviMCA5 
genes was performed with incubation at 95 °C for 2 min as the initial DNA denaturation 
step, followed by 30 cycles of 95 °C for 10 s, 55 °C for 15 s and 72 °C for 1 min. A final 
elongation step was carried out at 72 °C for 7 min. A sample of the amplified gene 
products (2 μl) was electrophoresed on a 1% (w/v) agarose gel, containing ethidium 
bromide (0.5 µg/ml), in 1xTAE buffer. The remaining reaction mixture was purified 
using the Zymo Research Clean and Concentrator™ kit, as per the manufacturer’s 
instructions. A sample of the amplified TbbMCA2 and TviMCA5 genes were sequenced 
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at the Central DNA Facilities, Stellenbosch University, South Africa, using the specific 
gene primers. 
Table 2.1: Primer sequences to be used throughout the TbbMCA2 and TviMCA5 
cloning process. 
Primer 5' - 3' 
Cloning 
plasmid 
Expression 
plasmid 
TbbMCA2 
forward (NdeI) 
GCC ATA TGT GCT CCT TAA TTA 
CAC AAC TCT GTG 
pTZ57R/T pET-28a 
TbbMCA2 
reverse (XhoI) 
CTC GAG CTA TTG GAT AGA TCT 
GTC AAC AG 
TviMCA5 
forward (BamHI) 
AAG GAT CCA TGA ATA TTC TTA CC 
GA TCT CTT TTT G 
pGemT® pET-32a 
TviMCA5 
reverse (EcoRI) 
AAG AAT TCT GTG ATA CAT CAC 
TTG TGA CCA 
T7 promoter TAA TAC GAC TCA CTA TAG GG pGemT® 
pET-28a and 
pET-32a T7 terminator CTA GTT ATT GCT CAG CGG TG 
pTZ57R/T 
pGemT® 
SP6 promoter ATT TAG GTG ACA CTA TAG pGemT® - 
Underlined sequences correspond to the restriction sites. 
Sequences in bold correspond to the start and the stop codon in the forward and reverse primer, 
respectively. 
 
Ligation of the TbbMCA2 and TviMCA5 inserts into the pTZ57R/T and the pGEM®-T 
cloning plasmids, respectively, was performed using a 3:1 ratio of plasmid to purified 
PCR product and incubation with 1 U of T4 DNA ligase at 37 °C for 1 h, followed by a 
further incubation step at RT for 16 h. The ligation mixture was transformed into 
competent E. coli JM 109 cells using the TransformAid™ Bacterial Transformation Kit, 
as per the manufacturer’s instructions. The resulting E. coli JM 109 cells (50 μl) from 
the transformation reaction were plated onto pre-warmed 2xYT plates [1.6% (w/v) 
tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl, 1% (w/v) bacteriological agar, 
containing 50 μg/ml ampicillin, 20 μg/ml X-gal, 10 μg/ml IPTG] and incubated at 37 °C 
for 16 h. The incorporation of X-gal and IPTG onto the 2xYT plates facilitated blue/white 
screening in order to identify which clones contained the plasmid with the ligated gene 
insert. The white colonies, which contained the recombinant pTZ57R/T and pGEM®-T 
plasmid, were selected and grown in 2xYT medium (containing 50 μg/ml ampicillin, 
5 ml) at 37 °C for 16 h with agitation. The plasmid DNA of the recombinant colonies 
was isolated using the GeneJet™ Plasmid Miniprep Kit, as per the manufacturer’s 
instructions. The isolated plasmid DNA was used as the template for colony PCR using 
the previously described PCR amplification reaction conditions, with the exception that 
FIREpol® Taq polymerase was used instead of the High-fidelity taq polymerase. The 
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colony PCR products (5 µl) along with samples of the plasmid DNA (5 μl) were 
electrophoresed on a 1% (w/v) agarose gel, containing ethidium bromide (0.5 µg/ml), 
in 1xTAE buffer.  
The plasmid DNA of the positive clones of recombinant TbbMCA2-pTZ57R/T and 
TviMCA5-pGEMT was sequenced at the Central Analytical Facilities, Stellenbosch 
University, South Africa using both the gene and plasmid specific primers. 
 Subcloning of the TbbMCA2 and TviMCA5 gene 
constructs into the bacterial pET-28a and pET-32a expression 
plasmids 
The recombinant TbbMCA2-pTZ57R/T and TviMCA5-pGEMT plasmids were 
subjected to a restriction digestion (50 μl) with NdeI and XhoI, BamHI and EcoRI, 
respectively, in 2xTango buffer at 37 °C for 4 h with subsequent heat deactivation at 
80 °C for 15 min. The reaction mixture (50 µl) was electrophoresed on a 1% (w/v) 
agarose gel in 1xTAE buffer, containing crystal violet (10 μg/ml). Bands were visualised 
using crystal violet instead of ethidium bromide to avoid DNA damage by ultraviolet 
light which is required to excise ethidium bromide stained bands (Rand, 1996). The gel 
was viewed on a light box, the 1 044 bp and 1 569 bp TbbMCA2 and TviMCA5 
products were excised and subsequently purified using the Zymoclean™ Gel DNA 
Recovery Kit as per the manufacturer’s instructions. 
The restriction digestion of the pET-28a plasmid, with NdeI and XhoI, and the pET-32a 
plasmid, with BamHI and EcoRI, was done in 2xTango buffer at 37 °C for 4 h with 
subsequent heat deactivation at 80 °C for 15 min. A 3:1 ratio of plasmid to gene insert 
was incubated with 1 U of T4 DNA ligase at 37 °C for 1 h followed by a further 
incubation step at RT for 16 h.  
The ligation mixture was transformed into E. coli BL21 (DE3) cells by CalCl2 
transformation (Cohen et al., 1972; Sambrook et al., 2001). Briefly, 2xYT medium 
(10 ml) was inoculated with a single E. coli BL21 (DE3) colony and grown at 37 °C for 
16 h with agitation. The overnight culture was diluted 1:100 with fresh 2xYT medium 
and grown at 37 °C with agitation until an OD600 of 0.4 was obtained. The cultures were 
transferred into ice cold, sterile centrifuge tubes and incubated on ice for 10 min. The 
cells were pelleted (4 500 g, 10 min, 4 °C) and resuspended in ice cold, sterile CaCl2 
solution [60 mM CaCl2, 10 mM HEPES, pH 7.0, 40 ml]. The cell solution was pelleted 
again (4 500 g, 10 min, 4 °C) and resuspended in ice cold, sterile CaCl2 solution (2 ml). 
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Competent E. coli cells (20 μl) were incubated with the ligation mixture (1 μl) on ice for 
30 min. Thereafter, cells were heat shocked at 42 °C for 90 s and placed on ice 
immediately for 2 min. The cells were added to pre-warmed super optimal cataboliser 
with catabolite repression (SOC) medium [2% (w/v) tryptone, 0.5% (w/v) yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose, 80 μl] and 
incubated at 37 °C for 1 h with gentle agitation. The resulting cell mixture (100 μl) was 
plated onto pre-warmed 2xYT plates containing 34 µg/ml kanamycin for pET-28a and 
50 μg/ml ampicillin for pET-32a recombinant clones, and incubated at 37 °C for 16 h.  
Recombinant TbbMCA2-pET28a and TviMCA5-pET32a colonies were grown in 2xYT 
medium (5 ml), containing 34 µg/ml kanamycin for pET-28a and 50 μg/ml ampicillin for 
pET-32a, and grown at 37 °C for 16 h with agitation. The plasmid DNA was isolated 
using the GeneJet™ Plasmid Miniprep Kit, as per the manufacturer’s instructions and 
used as the template for the colony PCR. Using the previously described PCR 
amplification reaction conditions, with the exception that FIREpol® Taq polymerase was 
used instead of the High-fidelity Taq polymerase, a colony PCR was performed. The 
colony PCR products (5 µl) along with samples of the plasmid DNA (5 μl) were 
electrophoresed on a 1% (w/v) agarose gel, containing ethidium bromide (0.5 µg/ml), 
in 1xTAE buffer.  
 Recombinant expression of TbbMCA2 and TviMCA5 
Single colonies of positively identified recombinant TbbMCA2-pET28a and 
TviMCA5-pET32a BL21 (DE3) clones were used to inoculate terrific broth (TB) medium 
[1.2% (w/v) tryptone, 2.4% (w/v) yeast extract, 0.4% (v/v) glycerol, 0.17 M KH2PO4, 
0.72 M K2HPO4, 100 ml] which contained either 34 µg/ml kanamycin for pET-28a or 
50 µg/ml ampicillin for pET-32a. After incubation at 37 °C for 16 h in baffled flasks, the 
cells were pelleted by centrifugation (5 000 g, 10 min, 4 °C) and resuspended in 
1% (v/v) Triton-X-100-PBS (5 ml). A final concentration of 1 mg/ml lysozyme was 
added and incubated at 37 °C for 30 min. The cell suspension was frozen at -70 °C for 
1 h and subsequently thawed at RT. The cell suspensions were sonicated four times 
for 30 s each and the cellular debris along with the insoluble inclusion bodies were 
pelleted from the soluble protein lysate by centrifugation (5 000 g, 10 min, 4 °C). The 
insoluble pellet was resuspended in 1% (v/v) Triton-X-100-PBS (5 ml), was stored 
at -20 °C.  
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Samples of the supernatant and the pellet, containing the soluble and insoluble 
fractions, respectively, were electrophoresed on four 12.5% reducing SDS-PAGE gels 
(Laemmli, 1970) with one stained with Coomassie Blue R-250 and the others 
transferred onto nitrocellulose using the semi dry blotter from Sigma with the transfer 
of proteins confirmed by staining with Ponceau S [0.1% (w/v) Ponceau S, 15% (v/v) 
acetic acid]. The unoccupied sites on the nitrocellulose membrane were blocked with 
5% (w/v) non-fat milk powder in TBS (20 mM Tris-HCl buffer, 200 mM NaCl, pH 7.4) at 
RT for 1 h. The nitrocellulose was washed three times over 15 min with TBS. 
Thereafter, chicken anti-6xHis IgY [1:5 000 in 0.5% (w/v) BSA-PBS], chicken 
anti-TcoMCA5 IgY and chicken anti-TviMCA5 IgY [10 µg/ml in 0.5% (w/v) BSA-PBS] 
was added and incubated at 4 °C for 16 h. The nitrocellulose was washed and 
incubated with rabbit anti-chicken IgY HRPO conjugate [1:5 000 in 0.5% (w/v) 
BSA-PBS] at RT for 1 h. The nitrocellulose was washed before the addition of 4-chloro-
1-naphthol·H2O2 substrate [0.06% (w/v) 4-chloro-1-naphthol, 0.1% (v/v) methanol and 
0.0015% (v/v) H2O2 in PBS] and allowed to develop in the dark. 
 Solubilisation, refolding and purification of recombinant 
TbbMCA2 and TviMCA5 
Based on the success of the solubilisation and purification of recombinant TcoMCA5 
(Eyssen, 2013) using the method which was adapted Schlager et al. (2012), this 
method was employed for recombinant TbbMCA2 and TviMCA5. Sarkosyl 
solubilisation was performed on the inclusion bodies which were pelleted after 
expression in TB. The insoluble expression pellet was resuspended in lysis buffer 
[8 mM Na2HPO4, 286 mM NaCl, 1.4 mM KH2PO4, 2.6 mM KCl, 1% (w/v) SDS, pH 7.4, 
1 mM DTT, 10 ml for a 250 ml culture], sonicated twice over 4 min on ice, and incubated 
on ice for 30 min. The solubilised proteins were separated from the insoluble debris by 
centrifugation (13 000 g, 20 min, 4 °C).  
The refolding and purification of solubilised recombinant TbbMCA2 and TviMCA5 was 
performed by immobilised metal affinity chromatography. This purification method will 
be referred to as nickel affinity purification throughout this manuscript. Briefly, 
His-select® nickel affinity resin (1 ml) was placed in a 10 ml chromatography column, 
washed with dH2O (2 ml) and equilibrated with wash buffer [8 mM Na2HPO4, 286 mM 
NaCl, 1.4 mM KH2PO4, 2.6 mM KCl, 0.1 % (w/v) sarkosyl, pH 7.4, 5 ml]. The solubilised 
protein lysate (5 ml) was incubated with the resin at 4 °C for 3 h with agitation using an 
end-over-end rotator. The unbound proteins were collected, and the resin was washed 
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with PCW buffer (50 ml) until an absorbance value at 280 nm of 0.02 was reached. 
The bound proteins were eluted in 1 ml fractions with elution buffer [8 mM Na2HPO4, 
286 mM NaCl, 1.4 mM KH2PO4, 2.6 mM KCl, 0.1% (w/v) sarkosyl, 50 mM imidazole, 
pH 7.4, 10 ml]. The column was regenerated using dH2O (2 ml) followed by 6 M 
guanidine hydrochloride (5 ml), dH2O (3 ml) and wash buffer (3 ml) before storage in 
30% (v/v) ethanol at 4 °C. Samples of the unbound and the eluted fractions were 
electrophoresed on a 12.5% reducing SDS-PAGE gel (Laemmli, 1970) and stained 
with Coomassie Blue R-250. The western blot of TviMCA5 was performed as per 
Section 2.2.4 using chicken anti-TviMCA5 IgY. 
The protein concentration was determined using the BCA™ protein assay kit.  
 Antibody production and ELISA optimisation 
  Preparation of immunogen, the immunisation of 
chickens and IgY isolation 
Ethical clearance for animal procedures was obtained from the University of KwaZulu-
Natal animal research ethics committee (Approval number: 053/15/Animal). Chickens 
were used to raise antibodies against recombinant TviMCA5. Nickel affinity purified, 
full length, recombinant TviMCA5 (50 μg/ml, 1.5 ml) was added to an equal volume of 
Freund’s complete adjuvant and triturated to form a stable water-in-oil emulsion prior 
to immunisation. Two chickens were immunised intramuscularly on either side of the 
breast bone. Booster injections, using Freund’s incomplete adjuvant, were given at 
weeks 2, 4 and 6. Eggs collected prior to immunisation served as the pre-immune 
control.  
Chicken immunoglobulin (IgY) was isolated from the yolks of the eggs collected at each 
week as described by Goldring and Coetzer (2003). Briefly, the egg yolk was separated 
from the egg white and rinsed with water. The yolk sac was punctured, the yolk 
collected, and the volume was determined. The yolk was mixed with two yolk volumes 
of IgY buffer [100 mM NaH2PO4, pH 7.6, 0.02% (w/v) NaN3], 3.5% (w/v) PEG 6 000 
was added and dissolved with stirring. The resulting solution was centrifuged (4 420 g, 
30 min, RT), and the supernatant was filtered through absorbent cotton wool. The final 
PEG concentration was increased to 12% (w/v) by the addition of 8.5% (w/v) 
PEG 6 000 and was once again dissolved by stirring. The resulting solution was 
centrifuged (12 000 g, 10 min, RT), and the resulting pellet was dissolved in IgY buffer 
equal to the yolk volume. Finally, 12% (w/v) PEG 6 000 was added and dissolved with 
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stirring. The resulting solution was centrifuged (12 000 g, 10 min, RT), and the resulting 
pellet was dissolved in final IgY buffer [100 mM NaH2PO4, pH 7.6, 0.1% (w/v) NaN3], 
equal to a sixth of the yolk volume, and stored at 4 °C. The concentration of isolated 
IgY was determined spectrophotometrically at 280 nm using an extinction coefficient 
of E280 nm
1 mg/ml
 = 1.25 (Goldring et al., 2005). 
 ELISA evaluation of antibody production 
The progress of anti-TviMCA5 IgY antibody production during the immunisation period 
was monitored by using an enzyme-linked immunoadsorbent assay (ELISA). The wells 
of 96-well Nunc-Immuno™ Maxisorp ELISA plates were coated with recombinant 
TviMCA5 (1 µg/ml, 100 µl/well) in PBS for 16 h at 4 °C. The coating solution was 
discarded, and the plates were blocked with blocking buffer [0.5% (w/v) BSA-PBS, 
200 µl/well] to prevent non-specific binding of antibodies, and incubated at 37 °C for 
1 h. The wells were washed three times with 0.1% (v/v) Tween-20-PBS (PBS-T) using 
a BIOTEK® ELx50™ microplate washer and incubated with anti-TviMCA5 IgY primary 
antibody diluted in blocking buffer (100 µl/well) at 37 °C for 2 h. The wells were washed 
and rabbit anti-chicken IgY HRPO conjugate, diluted in blocking buffer (1:5 000, 
100 μl/well), was added and incubated at 37 °C for 1 h. The wells were washed and 
the ABTS substrate solution [0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in 0.15 M citrate-
phosphate buffer, pH 5.0, 100 μl/well] was added. The plate was incubated in the dark 
for 15 min prior to reading the absorbance at 405 nm using the FLUORStar Optima 
Spectrophotometer for a further three 15 min intervals until absorbance values above 
1.0 were reached. 
 Immunoaffinity purification of soluble, recombinant 
TbbMCA2, TcoMCA5 and TviMCA5  
 Antibody coupling to UltraLink® hydrazide resin 
Using the UltraLink® hydrazide resin, it is possible to form a hydrazone bond with an 
oxidised glycoprotein. Using this resin, chicken anti-MCA5 IgYs were immobilised to 
the UltraLink® hydrazide resin by the oxidation of the carbohydrates on the Fc region 
and the formation of a hydrazone bond (Fig. 2.2). As a direct consequence of 
immobilisation at the Fc region, the antibodies are in the correct orientation to bind the 
specified antigen.  
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Due to the cleavage of the N-terminal 6xHis tag upon overexpression of soluble 
recombinant MCAs, nickel affinity purification could not be employed. Thus, 
immunoaffinity purification was performed by the coupling of chicken anti-TcoMCA5 
IgY as well as anti-TviMCA5 IgY antibodies to Ultralink® hydrazide resin. This 
purification method will be referred to as immunoaffinity purification throughout this 
manuscript. Briefly, the chicken IgY antibodies (10 mg/ml, 1 ml), which had the highest 
signal in the ELISA (Appendix A5), was oxidised with 25 mM sodium meta periodate 
for 30 min at RT and desalted, using the Zebra desalting spin column as per the 
manufacturer’s instructions. The oxidised IgY antibody mixture was agitated with the 
hydrazide resin (1 ml), which had been previously equilibrated with coupling buffer 
(100 mM NaH2PO4, pH 7.0, 5 ml), using an end-over-end rotator for 2 h at RT followed 
by a further 16 h at 4 °C. The unbound fraction was collected, and the resin was washed 
with coupling buffer (10 ml) followed by 1 M NaCl (10 ml) and coupling buffer containing 
0.05% (w/v) NaN3 (10 ml). Coupling efficiency was determined using the BCA™ protein 
assay kit. 
 
Figure 2.2: Chemistry of the coupling of antibody glycoproteins to 
UltraLink® hydrazide resin. (ThermoFisher Scientific technical manual #53149). 
 
 Immunoaffinity purification 
The soluble fractions of recombinantly expressed TbbMCA2 and TcoMCA5 were 
purified using the anti-TcoMCA5 IgY-hydrazide resin and TviMCA5 with the 
anti-TviMCA5 IgY-hydrazide resin. The resin was incubated with the soluble 
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expression fraction (8 ml) with agitation using an end-over-end rotator for 3 h at 4 °C. 
The unbound fraction was collected, and the resin washed with coupling buffer (50 ml) 
until an absorbance value at 280 nm of 0.02 was obtained. The bound recombinant 
MCA was eluted with elution buffer (100 mM glycine-HCl, pH 2.8). Fractions (900 µl) 
were collected into microfuge tubes containing neutralisation buffer (1 M Tris-HCl 
buffer, pH 8.5, 100 µl) and each was immediately mixed by inversion. The resins were 
washed with coupling buffer (20 ml) and stored at 4 °C. Samples of the unbound and 
the eluted fractions were electrophoresed on a 12.5% reducing SDS-PAGE gel 
(Laemmli, 1970), transferred onto nitrocellulose and probed with chicken 
anti-TcoMCA5 IgY and anti-TviMCA5 IgY antibodies as described in Section 2.2.4.  
2.3 Results 
 Cloning of the TbbMCA2 and TviMCA5 genes into the 
pTZ57R/T and pGEM®-T cloning plasmids 
The single MCA2 gene from T. b. brucei (TbbMCA2, GenBank® accession: 
AAX80349.1), and the single putative full length MCA5 gene from T. vivax (TviMCA5, 
GenBank® accession: CCC5089.1), were identified. Genomic DNA was successfully 
isolated from T. b. brucei (strain 927) and T. vivax (strain Y486) bloodstream 
trypomastigotes (Fig. 2.3, panel A). The isolated genomic DNA of T. b. brucei and 
T. vivax were used as the templates for PCR amplification of the 1 044 bp TbbMCA2 
and 1 569 bpTviMCA5 genes using the specific primers designed for this purpose 
(Table 2.1). The high-fidelity PCR enzyme mix, comprising a combination of Taq DNA 
polymerase and a thermostable DNA polymerase with a proofreading ability 
(ThermoFisher Scientific technical manual K0191), was used for the amplification. 
These characteristics ensured that the exact sequence would be amplified from the 
genomic DNA as any transcription errors would result in inaccurate protein translation 
and, thus, incorrect protein folding in downstream experiments. 
The high-fidelity PCR amplification resulted in a single product at the expected sizes 
of 1 044 bp and 1 569 bp for TbbMCA2 and TviMCA5, respectively (Fig. 2.3, panels B 
and C). Sequencing of the TviMCA5 PCR product indicated a perfect match to the DNA 
sequence found at the GenBank® (TvY486.0907120). However, TbbMCA2 sequencing 
results indicated that there were four mismatches when compared to the sequence 
found at GenBank® (Tb927.6.940). Three of the four mismatches were degenerate. 
However, the final mutation resulted in the change of Gln71 to an Arg residue. In 
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relation to the gatekeeper residue (Tyr31) and the catalytic dyad (His158 and Cys213), 
this mutation is sufficiently distant in the predicted folded protein and should not 
interfere with any downstream results (Appendix A6).  
The PCR products were subsequently purified using the ZymoResearch Clean and 
Concentrator™ kit. The purified 1 044 bp TbbMCA2 and 1 569 bp TviMCA5 PCR 
products were successfully ligated into the pTZ57R/T and pGEM®-T cloning plasmids, 
respectively, and upon transformation, non-recombinant blue and recombinant white 
colonies were obtained after blue/white screening. Plasmid DNA isolation of the 
recombinant white colonies was performed and used as the template for colony PCR 
to determine which clones contained the TbbMCA2 and the TviMCA5 genes. 
Fifteen recombinant TbbMCA2-pTZ57R/T colonies were identified by the PCR 
amplification of the 1 044 bp product using the TbbMCA2 forward and reverse gene 
primers (Fig. 2.4, panel A). Using the TviMCA5 forward and reverse gene primers, the 
PCR amplification of the 1 569 bp product resulted in the identification of six 
recombinant TviMCA5-pGEMT colonies (Fig. 2.4, panel B).  
 
Figure 2.3: Analysis of the isolation of T. b. brucei (927) and T. vivax (Y486) BSF 
genomic DNA and PCR amplification of the TbbMCA2 and TviMCA5 genes. 
Samples from (A) DNA extraction and high-fidelity PCR amplification of (B) TbbMCA2 and (C) 
TviMCA5 were electrophoresed on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium 
bromide.  
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Figure 2.4: Screening for recombinant TbbMCA2 and TviMCA5 clones ligated 
into the pTZ57R/T and pGEM®-T cloning plasmids, respectively, by the PCR 
amplification of the isolated plasmid DNA. Following the transformation of 
TbbMCA2-pTZ57R/T and TviMCA5-pGEMT ligation mixture into competent E. coli JM 109 cells, 
and the subsequent selection of white colonies, the isolated plasmid DNA of (A) 
TbbMCA2-pTZ57R/T and (B) TviMCA5-pGEMT was subjected to PCR using their respective 
gene forward and reverse primers. Samples were electrophoresed on a 1% (w/v) agarose gel 
containing 0.5 µg/ml ethidium bromide. 
 
 Subcloning of the TbbMCA2 and TviMCA5 genes into the 
bacterial pET-28a and pET-32a expression plasmids 
A small scale restriction digestion was performed on the plasmid DNA of the PCR 
positive recombinant clones. Each of the digestion reactions resulted in the appropriate 
sized gene insert and plasmid for both TbbMCA2-pTZ57R/T and TviMCA5-pGEMT. 
Sequencing of a selection of clones resulted in the same result as obtained when the 
PCR amplified product was sequenced. The clones selected for sub-cloning were and 
will now be referred to as B6 from TbbMCA2-pTZ57R/T, V4 and V16 from 
TviMCA5-pGEMT, which corresponds to the extracted plasmid DNA. 
The isolated plasmid DNA from clones, B6, V4 and V16, were subjected to a large 
scale restriction digestion to obtain the insert for the subsequent ligation into the 
expression plasmids. As shown in Fig. 2.5, panel A, after the restriction digestion of B6 
and the pET-28a expression plasmid with NdeI and XhoI, two bands were produced at 
1 044 bp and 2 886 bp which corresponds to the TbbMCA2 insert and the pTZ57R/T 
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cloning plasmid, respectively. The pET-28a expression plasmid was effectively 
linearised at 5 369 bp. The restriction digestion of V4 and V16 along with the pET-32a 
expression plasmid, using BamHI and EcoRI, resulted in two bands at 1 569 bp and 
3 000 bp corresponding to the TviMCA5 insert and pGEM®-T cloning plasmid (Fig. 2.5, 
panel C). The band at 5 900 bp indicated that the pET-32a expression plasmid had 
been linearised. The restriction mixtures of the B6, V4 and V16 clones were 
electrophoresed on a 1% (w/v) agarose gel containing 10 µg/ml crystal violet, and the 
1 044 bp TbbMCA2 and the 1 569 bp TviMCA5 inserts were excised and purified 
(Fig. 2.5, panel B and D, respectively). The purity, size and approximate concentrations 
of the isolated TbbMCA2 and TviMCA5 inserts along with the linearised pET-28a and 
pET-32a expression plasmids were determined from Fig. 2.5 panels B and D using the 
SYNGENE GeneSys image acquisition software. 
 
Figure 2.5: Products of gel extraction of the TbbMCA2 and TviMCA5 inserts after 
restriction digestion of positive recombinant TbbMCA2-pTZ57R/T clone 6 and 
TviMCA5-pGEMT clones 4 and 16. Restriction digestion was performed on the (A) 
TbbMCA2-pTZ57R/T and pET28a plasmid DNA with NdeI and XhoI, (C) TviMCA5-pGEMT and 
pET32a plasmid DNA with BamHI and EcoRI for 4 h at 37 °C. The (B) TbMCA2 and (D) 
TvMCA5 inserts were visualised using 10 µg/ml crystal violet, excised from the 1% (w/v) 
agarose gel and purified using the E.Z.N.A® gel extraction kit. Samples were electrophoresed 
on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide.  
 
Ligation mixtures of the TbbMCA2 and TviMCA5 inserts along with the pET-28a and 
pET-32a expression plasmids, respectively, were prepared and transformed into E. coli 
BL21 (DE3) cells by CaCl2 transformation. Recombinant colonies were obtained for the 
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B6pET28a ligation, resulting in 4 colony forming units, as well as for the V4pET32a 
and V16pET32a ligations, with each yielding 2 and 6 colony forming units, respectively. 
The plasmid DNA of the resulting recombinant B6pET28a, V4pET32a and V16pET32a 
clones was isolated and used as the template for colony PCR to amplify the TbbMCA2 
and TviMCA5 genes using the respective forward and reverse gene primers (Fig. 2.6). 
In panel A, a band at approximately 1 044 bp was observed for each of the B6-pET28a 
clones and in panel B, a band at approximately 1 569 bp was observed for V4pET28a 
clones 1 and 2 and for V16pET32a clones 2, 3, 5 and 6.  
 
Figure 2.6: Screening for recombinant TbbMCA2 and TviMCA5 clones ligated 
into the pET-28a and pET-32a expression plasmids, from the isolated plasmid 
DNA by PCR amplification. Colonies were selected following transformation of the (A) 
TbbMCA2-pET28a and (B) TviMCA5-pET32a ligation mixtures into E. coli BL21 (DE3) cells. 
The isolated plasmid DNA from each clone was subjected to PCR amplification using the 
respective forward and reverse gene primers. Samples were electrophoresed on a 1% (w/v) 
agarose gel containing 0.5 µg/ml ethidium bromide. M: O’GeneRuler™. 
 
 Recombinant expression, solubilisation, refolding and 
purification of TbbMCA2 and TviMCA5 
The single full length TbbMCA2 gene (UniProtKB ID: Q585F4) codes for a protein of 
347 amino acids in length with an expected molecular size of 37.8 kDa and a pI of 5.81 
as predicted by the Compute pI/Mw tool on the ExPASy server (Gasteiger et al., 2005). 
The single putative full length TviMCA5 gene (UniProtKB ID: G0U3N4) codes for a 
protein of 522 amino acids in length with an expected molecular size of 58.4 kDa and 
a pI of 8.76 as predicted by the Compute pI/Mw tool on the ExPASy server (Gasteiger 
et al., 2005). 
 Expression of recombinant TbbMCA2 and TviMCA5 
The primary structure of a protein plays a pivotal role in its overall solubility (Smialowski 
et al., 2006). When overexpressed in E. coli, proteins containing stretches of 20 or 
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more hydrophobic residues and comprising of more than 16% aromatic residues 
(Bertone et al., 2001) were found to be more likely to be insoluble (Christendat et al., 
2000). The protein sequences of TbbMCA2 and TviMCA5 were analysed using the 
PROSO II sequence-based solubility prediction calculator. It was found that TbbMCA2 
had a 38.3% chance of being insoluble when overexpressed in E. coli, and TviMCA5, 
a 48% chance (Smialowski et al., 2006). The MCA-3 and -5 from T. cruzi (Kosec et al., 
2006) as well as TcoMCA5 (Eyssen, 2013) have PROSO II predictors between 47 and 
61% and were reported to be insoluble when overexpressed in E. coli. The MCA5s of 
T. congolense, T. cruzi and T. vivax share a high sequence identity, between 56 and 
67%. Given this, it is probable the TviMCA5 will be insoluble when overexpressed. The 
MCA2 differs from the MCAs by its lack of the Pro-, Gln- and Tyr-rich C-terminal 
extension. But given the fact that the single copy TcrMCA3 was insoluble, there is a 
chance that TbbMCA2 may also be insoluble when overexpressed.  
The MCAs have three domains; namely, the N-terminal domain, the catalytic domain 
and C-terminal domain. An additional domain was created by the incorporated 
sequence from the bacterial expression plasmids, comprising of the N-terminal 6xHis 
tag and sequence of the multiple cloning site up to the restriction site used. These are 
illustrated for recombinant TbbMCA2, TcoMCA5 and TviMCA5 in Fig. 2.7 where the 
estimated sizes of the domains are indicated. 
 
Figure 2.7: Schematic representation of the size and domain composition of the 
recombinantly expressed TbbMCA2, TcoMCA5 in pET-28a and TviMCA5 in 
pET-32a. The sizes and regions were annotated using NCBI Conserved Domains Database 
(Marchler-Bauer et al., 2017).  
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A 50 to 51% sequence identity is shared between TbbMCA2 and the MCA5s of 
T. congolense and T. vivax. As such, chicken anti-TcoMCA5 IgY was expected to 
detect the recombinantly expressed TbbMCA2. Autoprocessing of MCAs generally 
functions to remove the N- and C-terminal domains from the catalytic domain and is 
suggested to be required for optimal activity (Gonzáles et al., 2007). Autoprocessing 
was evident when both recombinant TbbMCA2 and TcoMCA5 were overexpressed in 
E. coli (Fig 2.8 and 2.9). Since the sites of autoprocessing are not conserved within the 
kinetoplastid MCAs (Appendix A3), the allocation of domains to autoprocessed protein 
fragments of TviMCA5 were predicted using literature (Vercammen et al., 2004; 
Gonzáles et al., 2007; Lee et al., 2007; Watanabe and Lam, 2011) as is shown in 
Fig. 2.9. The sizes of the anti-MCA IgY detected proteins correlate strongly to the 
estimated molecular weights in Fig 2.7. 
Using the chicken anti-TcoMCA5 IgY, multiple proteins in both the soluble and 
insoluble fractions of TbbMCA2 were detected (Fig. 2.8, panel B). The proteins at 82, 
72.3, and 68.5 kDa are of a higher molecular weight than the predicted 43 kDa 6xHis 
N-terminal tagged TbbMCA2. Due to the large size discrepancy between the predicted 
and actual, no domain allocations could be made with confidence. The 36 and 30 kDa 
proteins are similar to that of recombinant TcoMCA5, which were referred to as lower 
molecular weight products after autoprocessing (Eyssen, 2013). Given the sizes of the 
proteins and the estimations made in Fig. 2.7, the 30 kDa may be the catalytic domain 
and the 36 kDa the catalytic domain before the removal of the N-terminal domain. The 
21.5 kDa protein band may be as a result of the partial cleavage of the catalytic domain, 
once released from the full length protein. Despite numerous attempts, a blot using the 
anti-6xHis antibody was unsuccessful. Moss et al. (2007) showed that mutation of 
Lys55, interrupted the cleavage of the N-terminal 6xHis tag which facilitated purification 
of recombinant TbbMCA2 using the soluble expression fraction. However, the 
presence of TbbMCA2 in the inclusion bodies was not demonstrated in their study. 
Seen as each of the clones produced similar protein bands in the soluble and insoluble 
expression fraction, the B6pET28 clone 7 was selected for large scale expression.  
The predicted size of TviMCA5 is 58.4 kDa. However, when factoring in the N-terminal 
Trx and 6xHis tags incorporated by the expressed vector, recombinant TviMCA5 has 
a predicted size of 77.1 kDa (Fig. 2.7). The anti-6xHis antibody detected a single 
protein at 77 kDa in the insoluble fraction (Fig. 2.9, panel B). This protein was also 
detected using the chicken anti-TcoMCA5 IgY along with other lower molecular weight 
proteins at 66, 38, 29, and 21.5 kDa in the soluble and insoluble fractions (Fig. 2.9, 
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panel C). This result is in line with what was seen for recombinant TcoMCA5 (Eyssen, 
2013). The 77 kDa protein may be as the result of the cleavage of the N-terminal 6xHis 
tag, followed by the complete removal of the additional sequence from the expression 
plasmid, to produce the 66 kDa protein. Removal of the C-terminal domain (21.5 kDa 
band) from the 77 kDa full length protein would produce the 38 kDa protein. 
Subsequent cleavage of the N-terminal domain of the 38 kDa protein would result in 
the 29 kDa protein. Seen as each of the clones produced similar protein bands in the 
soluble and insoluble expression fraction, the V4pET32 clone 2 was selected for large 
scale expression. 
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Figure 2.8: Analysis of recombinantly expressed TbbMCA2 in pET-28a. Samples of the soluble (SN) and insoluble (P) fractions of the 
expression of recombinant TbbMCA2, from the B6pET28a clones 2, 3, 5 and 7 were electrophoresed on two 12.5% reducing SDS-PAGE gels with one 
(A) stained with Coomassie Blue R-250 and the other transferred onto nitrocellulose, blocked with 5% (w/v) milk-TBS and incubated with (B) chicken 
anti-TcoMCA5 IgY [10 µg/ml in 0.5% (w/v) BSA-PBS]. Rabbit anti-chicken IgY HRPO conjugate and [1:5 000 in 0.5% (w/v) BSA-PBS] and 4-chloro-1-
naphthol∙H2O2 were used as the detection system. 
 
Figure 2.9: Analysis of recombinantly expressed TviMCA5 in pET-32a. Samples of the soluble (SN) and insoluble (P) fractions of the 
expression of recombinant TviMCA5, from the V4pET32a clones 1 and 2, V16pET32a clones 2 and 3, were electrophoresed on three 12.5% reducing 
SDS-PAGE gels with one (A) stained with Coomassie Blue R-250 and the other two transferred onto nitrocellulose, blocked with 5% (w/v) milk-TBS 
and incubated with (B) chicken anti-His IgY [1:5 000 in 0.5% (w/v) BSA-PBS] and (C) chicken anti-TviMCA5 IgY [10 µg/ml in 0.5% (w/v) BSA-PBS]. 
Rabbit anti-chicken IgY HRPO conjugate and [1:5 000 in 0.5% (w/v) BSA-PBS] and 4-chloro-1-naphthol∙H2O2 were used as the detection system. 
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 Solubilisation, refolding and purification of 
recombinantly expressed TbbMCA2 and TviMCA5  
The structure of proteins which have been expressed within inclusion bodies can vary 
from being completely misfolded to mostly native protein (Bowden et al., 1991; Ventura 
and Villaverde, 2006). The presence of the N-terminal 6xHis tag in the insoluble fraction 
and absence in the soluble fraction, suggest that the expressed recombinant TbbMCA2 
and TviMCA5 may be in a partially native state and has retained some degree of 
activity. This cleavage which is observed in Fig. 2.8 and 2.9 can only be as a result of 
autoprocessing as peptidase deficient DE3 E. coli cells were used, and the addition of 
bacterial inhibitor cocktail resulted in the same cleavage pattern (results not shown). 
Solubilisation of the inclusion bodies from the insoluble fraction followed by on column 
refolding and purification were performed using the sarkosyl method together with 
nickel affinity purification.  
Due to the failure of the anti-6xHis antibody to detect TbbMCA2 in either the soluble or 
insoluble fraction, both fractions were subjected to nickel affinity purification. No 
proteins from the soluble fraction were bound to the resin (Fig. 2.10, panel A) when 
compared to those in panel B which had been solubilised and refolded. Prominent 
protein bands at 70.2, 32.6 and 29.2 kDa and a faint band at 51.9 kDa were eluted. 
This confirms that the recombinant TbbMCA2 autopeptidolytically cleaves the 
N-terminal 6xHis tag in the soluble expression fraction. 
When solubilised recombinant TviMCA5 was purified using nickel affinity resin 
(Fig. 2.11), numerous proteins, at various sizes, were eluted, which differs from the five 
proteins from recombinant expression detected by chicken anti-TviMCA5 IgY (Fig. 2.9, 
panel C). The approximate molecular weights of the prominent protein bands were 70, 
68, 38, 31, 25 and 23 kDa (Fig. 2.11, panel A) of which only 25 and 23 kDa proteins 
were not detected using the chicken anti-TviMCA5 IgY (panel B). Previous studies 
have shown that some MCAs require calcium for autoprocessing (Bozhkov, 2005; He 
et al., 2008; Ojha et al., 2010; Meslin et al., 2011; Proto et al., 2011; Laverrière et al., 
2012; Wen et al., 2013). A possible explanation for the multiple protein bands might 
that be the nickel ions are functioning in the same capacity as calcium, which assists 
in autoprocessing. This hypothesis will be referred to as nickel-induced over 
autoprocessing and will be discussed further in Chapter 3. 
51 
 
 
Figure 2.10: Nickel purified recombinant TbbMCA2 from expression supernatant and sarkosyl solubilised inclusion bodies. 
Samples of the TbbMCA2 nickel purified fractions from the (A) soluble expression fraction and (B) solubilised and refolded inclusion bodies using the 
sarkosyl method were electrophoresed a 12.5% reducing SDS-PAGE gel and stained with Coomassie Blue R-250. 
 
 
Figure 2.11: Solubilised, refolded and nickel purified recombinant TviMCA5. Samples of the eluted fractions from the purification of 
solubilised and refolded recombinant TviMCA5 from inclusion bodies were electrophoresed on two 12.5% reducing SDS-PAGE gels with one (A) stained 
with Coomassie Blue R-250 and the other transferred onto nitrocellulose, blocked with 5% (w/v) milk-TBS and incubated with (B) chicken anti-TviMCA5 
IgY [10 µg/ml in 0.5% (w/v) BSA-PBS]. Rabbit anti-chicken IgY HRPO conjugate [1:5 000 in 0.5% (w/v) BSA-PBS] and 4-chloro-1-naphthol∙H2O2 were 
used as the detection system.
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 Evaluation of anti-TviMCA5 IgY antibody production by 
ELISA 
The chicken anti-TviMCA5 IgY antibodies isolated during the immunisation period were 
used for an initial ELISA to determine when the production of chicken anti-TviMCA5 
IgY antibodies peaked (Appendix A5). The antibodies from chicken 1 at week 9 were 
used to couple to the UltraLink® hydrazide resin as well as for the determination of the 
optimal concentration for use in downstream applications.  
 Immunoaffinity purification of soluble TbbMCA2, 
TcoMCA5 and TviMCA5 
Since the recombinant MCAs are able to autoprocess thereby cleaving off their 
N-terminal 6xHis tag in the soluble fraction, an alternative purification strategy was 
employed. Chicken anti-MCA5 IgY coupled for the hydrazide resin were used in an 
immunoaffinity purification strategy. The soluble expression fraction of recombinant 
TbbMCA2 andTcoMCA5 was purified using the anti-TcoMCA5 IgY immunoaffinity 
resin, and recombinant TviMCA5 using anti-TviMCA5 IgY immunoaffinity resin. 
Purification of soluble recombinant TbbMCA2 using the immunoaffinity resin, resulted 
in the elution of 75.3 and 69.4 kDa proteins in fraction 1, 69.4 kDa in fraction 2, and 
56.6 kDa proteins in fractions 6 to10 (Fig. 2.12, panel A). Since there is a large 
molecular weight discrepancy between the predicted and actual molecular weight of 
TbbMCA2, as seen in Fig. 2.7 and 2.8, the assignment of most likely domains 
corresponding to each domain cannot be made with any degree of certainty. 
In panel B of Fig. 2.12 it is shown that the purification of soluble TcoMCA5 resulted in 
a 66.8 kDa protein eluted in fractions 1 to 7 together with a 59.1 kDa protein band in 
fractions 1 and 2. The 66.8 kDa protein may be the full length protein after the cleavage 
of the N-terminal 6xHis tag. The 59.1 kDa protein may be as a result of the cleavage 
of the entire N-terminal domain from the full length protein. Cleavage of the C-terminal 
domain from the full length protein may be the result of the 37.5 kDa protein which was 
eluted in fractions 3 and 4. 
Immunoaffinity purification of solubleTviMCA5 resulted in the elution of a 78.3 kDa 
protein band in fractions 1 to 6 which may be as a result of the cleavage of the 
N-terminal 6xHis tag (Fig. 2.12, panel C). In fractions 3 and 4, two proteins were eluted 
at 66.4 and 43.9 kDa. The 66.4 kDa protein may be as a result of the cleavage of the 
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additional sequence from the expression plasmid (Fig. 2.7). The cleavage of the 
N-terminal domain from the 66.4 kDa protein may result in the 43.9 kDa protein 
comprised of the catalytic domain and the C-terminal domain. 
 
Figure 2.12: Immunoaffinity purification of soluble recombinant TbbMCA2, 
TcoMCA5 and TviMCA5. Samples of the eluted fractions from the immunoaffinity purification 
using chicken anti-MCA5 IgY coupled to hydrazide resins of the soluble recombinantly 
expressed (A) TbbMCA2, (B) TcoMCA5 and (C) TviMCA5 were electrophoresed on 12.5% 
reducing SDS-PAGE gels. After transfer onto nitrocellulose and blocked with 5% (w/v) non-fat 
milk-TBS, the blots were incubated with (A and B) chicken anti-TcoMCA5 IgY [10 µg/ml in 0.5% 
(w/v) BSA-PBS] and (C) chicken anti-TviMCA5 IgY [10 µg/ml in 0.5% (w/v) BSA-PBS]. Rabbit 
anti-chicken IgY HRPO conjugate [1:5 000 in 0.5% (w/v) BSA-PBS] and 4-chloro-1-
naphthol∙H2O2 were used as the detection system. 
 
2.4 Discussion 
All active caspases, when overexpressed in heterologous expression systems, are 
able to undergo autoprocessing via cis activation (Roy et al., 2014). For the in vitro 
study of caspase autoprocessing, it has been shown that inducible bacterial expression 
systems are ideal. This is due to the fact that autoprocessing does not occur during the 
early stage of induction, but as the medium acidifies, rapid autoprocessing is observed 
(Roy et al., 2001).  
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Autoprocessing is required for the activation of caspases and type II MCAs, whereas 
type I MCAs do not depend on autoprocessing (Fuentes-Prior and Salvesen, 2004; 
McLuskey et al., 2012). Autoprocessing has been demonstrated in the MCAs of 
Leishmania spp. (Gonzáles et al., 2007; Ambit et al., 2008; Zalila et al., 2011; 
Castanys-Muῆoz et al., 2012), Plasmodium falciparum (Meslin et al., 2011), 
Toxoplasma gondii (Li et al., 2016), A. thaliana type II (Vercammen et al., 2004; 
Bozhkov, 2005; Watanabe and Lam, 2011; Wrzaczek et al., 2015), Lycopersicon 
esculentum (Wen et al., 2013) Triticum aestivum (Piszczek et al., 2012), T. cruzi 
(Laverrière et al., 2012), TbbMCA2 (Moss et al., 2007; McLuskey et al., 2012) and 
TbbMCA4 (Proto et al., 2011). 
The MCA2 from T. b. brucei (UniProtKB ID: Q585F4) and the MCA5 from T. vivax 
(UniProtKB ID: G0U3N4), were recombinantly expressed in E. coli. When taking in 
account the addition of the bacterial expression plasmid sequence, the expected 
molecular weights of TbbMCA2 increased from 37.5 to 42.6 kDa and TviMCA5 from 
58.4 to 77.1 kDa. Upon overexpression, autoprocessing was observed and detected 
with both chicken anti-TcoMCA5 IgY and chicken anti-TviMCA5 IgY. Protein bands 
corresponding to the estimated sizes of the full length TviMCA5 protein, after cleavage 
of the N-terminal 6xHis tag, the cleavage of the C-terminal domain (21.5 kDa) from the 
full length protein would produce the 38 kDa protein. Subsequent cleavage of the 
N-terminal domain of the 38 kDa protein would result in the 29 kDa protein. The 
expression of TbbMCA2 resulted in proteins which were of a higher molecular weight 
than what was expected. Thus, it was not possible to confidently assign protein 
domains to the cleaved products. This anomalous migration has not been reported by 
Moss et al. (2007), but has been observed in the MCA from Nicotiana tabacum 
(Acosta‑Maspons et al., 2014) and A. thaliana (Vercammen et al., 2004; Watanabe 
and Lam, 2005). 
Upon the addition of calcium, recombinant TbbMCA2 produced 30 and 6 kDa bands 
as a result of cleavage at Lys55 and Lys268 to release the catalytic domain from the 
full length protein (Moss et al., 2007). The Lys55 residue is only conserved in the 
TbbMCA2 and TbbMCA4, but cleavage at Lys64 was reported for TbbMCA4 (Proto et 
al., 2011). The Lys268 residue is conserved in TbbMCA2 and TbgMCA2, TbgMCA3 
and TevMCA3 (Appendix A3). 
Moss et al. (2007) were the first to recombinantly express and enzymatically 
characterise TbbMCA2. They reported that when overexpressed in E. coli, TbbMCA2, 
55 
 
with both K55G and K268G mutations, was detected in the soluble expression fraction. 
In our hands, recombinant TbbMCA2, without the mutation of the K55 and K268 
residues, was expressed within insoluble inclusion bodies. From the results of the 
PROSO II sequence-based solubility prediction calculator, TbbMCA2 had a 38.3% 
chance of being insoluble when overexpressed in E. coli (Smialowski et al., 2006). 
Given the predictor values for the single copy MCAs demonstrated to be insoluble, 
which varied between 31 and 61%, TbbMCA2 could be expressed either as a soluble 
or insoluble protein. It was demonstrated that the full length protein was expressed in 
the insoluble fraction but was also expressed in the soluble fraction after the removal 
of the N-terminal 6xHis tag. 
Western blot analysis of the expression of TbbMCA2 detected five bands at 82, 68.5, 
36, 30, 21.5 kDa and TviMCA5 at 77, 66, 38, 29, 21.5 kDa, using chicken anti-MCA5 
IgY. This cleavage pattern resulting from autoprocessing, was thought to be due to the 
separation of the various domains to release the catalytic domain. This is in line with 
what has been reported in the literature for LmjMCA, PfMCA, TbbMCA4 and LesMCA1, 
where autoprocessing occurs at both the N- and C-termini to produce lower molecular 
weight products containing the enzymatically active catalytic domain (Gonzáles et al., 
2007; Meslin et al., 2007; Proto et al., 2011; Wen et al., 2013).  
Affinity tags aid in the purification of recombinant peptidases and rarely affect their 
enzymatic activity (Uhlén et al., 1992). The most commonly used affinity tag is the 
6xHis which has a few advantages over other tags (Graslund et al., 2008). A 6xHis 
tagged protein allows for the simple purification using immobilised metal affinity 
chromatography (Block et al., 2009) and does not interfere with protein crystallography 
(Graslund et al., 2008). The protein’s structural and solubility characteristics are rarely 
affected by the presence of 6xHis tags when compared to that of larger affinity tags 
such as glutathione S-transferase and maltose-binding protein (Waugh, 2005; 
Nallamsetty and Waugh, 2007).  
Since difficulty was encountered with the detection of the 6xHis tag of TbbMCA2 in the 
expression fractions, both the soluble and insoluble fractions were subjected to nickel 
affinity purification. As expected, only the solubilised fraction bound to the nickel resin 
as demonstrated by the presence of proteins in the eluted fractions. Purification of 
recombinant TbbMCA2 resulted in three protein bands, at 70.2, 32.6 and 29.2 kDa. 
However, no over autoprocessing was evident for TbbMCA2 when compared to that 
seen for TviMCA5. 
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The nickel affinity purification of solubilised TviMCA5, resulted in multiple protein 
bands, predominantly at 70, 68, 38, 31, 25 and 23 kDa. These correlate with the full 
length protein and subsequent cleavage to release the catalytic domain from the 
N-terminal domain and the Pro-, Gln-, Tyr-rich C-terminal domain. The presence of 
numerous, less prominent protein bands, may point to secondary cleavage sites at 
which processing could occur after initial autoprocessing. This process was termed 
nickel-induced over autoprocessing and will be discussed in more detail in Chapter 3. 
Secondary cleavage has been demonstrated in LmjMCA where autoprocessing occurs 
at Arg268 followed by cleavage at Arg63, Arg79 and Arg135 (Zalila et al., 2011). 
Similarly, cleavage at Lys225 in AtMCA4 (Watanabe and Lam, 2005), AtMCA9 
(Vercammen et al., 2004; Watanabe and Lam, 2005) and MCA from Picea abies 
(Bozhkov, 2005; Watanabe and Lam, 2005) activates the peptidase, prior to cleavage 
at Arg190 (AtMCA4), Arg183 (AtMCA9) and Arg188 (PaMCA).  
Attempts to purify the separated domains resulting from autoprocessing were 
unsuccessful. This has been reported previously by Vercammen et al. (2004) and is 
thought that they had either formed complexes (Vercammen et al., 2004; Klemenčič et 
al., 2015). It was suggested by Moss et al. (2007) that the cleaved domains were still 
part of the mature protein structure and was confirmed by McLuskey et al. (2012) where 
they were shown to still be covalently linked to the main protein body. Analysis by a 
non-reducing SDS-PAGE by Moss et al. (2007) indicated that the fragments were not 
linked by disulphide bonds.  
Antibodies were raised in chickens against the purified full length recombinant 
TviMCA5. The antibodies were able to detect the autoprocessing products after 
expression and the eluted proteins after nickel affinity purification. Since the MCAs are 
virulence factors, and attractive drug targets, they may also be diagnostic antigens. 
The MCA4 was shown to be part of the T. b. gambiense secretome (Geiger et al., 
2010) and was secreted into the culture medium of T. b. brucei parasites (Proto et al., 
2011), similar to that of oligopeptidase B (Troeberg et al., 1996; Morty et al., 2001), a 
well-known virulence factor (Coetzer et al., 2008; Bastos et al., 2013). The chicken 
antibodies raised against another well-known trypanosomal virulence factor, 
congopain, which is the cathepsin-L-like peptidase from T. congolense (TcoCATL), 
was shown to successfully discriminate between serum from experimentally infected 
and non-infected cattle in an antibody detection ELISA using an inhibition format 
(Eyssen, 2013). Thus, the chicken antibodies raised against TcoMCA5 and TviMCA5 
may be used in the development of such an ELISA.  
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In the work described in the next chapter, the characterisation of the residues which 
may function in autoprocessing and peptidolytic activity of the MCA5s will be 
investigated by mutagenesis. Together with the kinetic analysis of both native and 
recombinant MCA5, insight can be gained into how the MCA5s function.  
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CHAPTER 3 
ENZYMATIC CHARACTERISATION OF NATIVE AND MUTATED 
RECOMBINANT METACASPASE 5 FROM T. CONGOLENSE 
AND T. VIVAX 
3  
3.1 Introduction 
African trypanosomosis affects both humans and livestock in rural, central Africa. 
There have been no new additions to the currently used chemotherapies in the last 60 
years (Giordani et al., 2016). As a result, drug resistance has emerged for 
chemotherapies used for animal treatment (Geerts et al., 2001; Van den Bossche and 
Delespaux, 2011; Giordani et al., 2016). Together with the toxicity of the currently used 
chemotherapies for the treatment of human infective T. b. gambiense and 
T. b. rhodesiense, novel chemotherapies are needed (Brun et al., 2010). Progress has 
been made towards human chemotherapies, with two compounds in clinical trials 
(Maser et al., 2012), but none regarding animal chemotherapies (Giordani et al., 2016). 
In an attempt to reduce drug resistance, the use of nifurtimox-eflornithine combination 
therapy (NECT) over eflornithine has been recommended for human infections and the 
use of a sanative pair for animal infections, consisting of isometamidium chloride or 
homidium chloride, together with diminazene aceturate (Geerts et al., 2001; Holmes et 
al., 2004; Chitanga et al., 2011). 
Due to the improbability of the development of a vaccine (La Greca and Magez, 2011), 
focus has shifted towards the molecular targets which are essential for pathogenesis 
(Antoine-Moussiaux et al., 2009). These molecules are known as virulence factors and 
are attractive targets for the development of chemotherapies (Drag and Salvesen, 
2010). Numerous peptidases have been identified as virulence factors as they play an 
essential role in the parasite and the host-parasite interactions (McKerrow et al., 2006). 
Due to the dual life cycle alternating between the mammalian host and insect vector, 
the molecular target should be as unrelated as possible to those of their mammalian 
hosts, to minimise any adverse side effects of the chemotherapies. Thus, in the pursuit 
of novel chemotherapies, the function and structure of the targeted virulence factors 
need to be elucidated to allow for the design of potent compounds. 
The MCAs are the homologue of the metazoan caspases, which are involved in 
apoptosis and also have non-apoptotic roles such as cytokine maturation, inflammation 
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and differentiation (Lamkanfi et al., 2007). Due to their presence in all kingdoms except 
for the metazoan kingdom, and their potential involvement in similar roles to those of 
the caspases, the MCAs have been identified as virulence factors. Thus, their 
implication in cell death, cellular processes and absence in the mammalian hosts, 
make the MCAs attractive targets for the development of novel chemotherapies.  
The single copy MCAs are different from the multicopy MCAs as they possess a Pro-, 
Gln-, Tyr-rich C-terminal domain which may be involved in protein-protein interactions 
(Kay et al., 2000). The single copy MCA5 from T. b. brucei, together with the multicopy 
MCA2 and -3 have been shown to be essential to bloodstream trypomastigotes (Helms 
et al., 2006). However, to date, there have been no reports of the molecular 
characterisation of any MCA5 from the animal infective T. b. brucei, T. congolense or 
T. vivax.  
The activation of initiator caspases involves the dimerisation of inactive caspase 
monomers, through their N-terminal prodomains, followed by interdomain cleavage, 
also known as autopeptidolytic cleavage and autoprocessing (Fig. 3.1). Dimeric 
executioner caspases are activated by cleavage mediated by the initiator caspases, 
which results in intramolecular rearrangements to form an active dimer (Tait and 
Green, 2010). 
 
Figure 3.1: Schematic of initiator and executioner caspase activation. Dimerisation 
and intramolecular autoprocessing results in an active initiator caspase. Once active, the 
initiator caspase activates the inactive executioner dimer by peptidolytic cleavage. The fas 
associated death domain, FADD, is an adapter protein which is recruited to the death-inducing 
signalling complex (DISC) during signalling via death receptors (Gupta et al., 2004). Adapted 
from Tait and Green (2010).  
 
Much research has been done on plant MCAs but very little on kinetoplastid MCAs, 
and even fewer reported the characterisation of both recombinant and native enzymes. 
The residues at which the MCA is autoprocessed and the mechanism by which it 
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occurs are crucial for the understanding of MCA activation. Metacaspases share the 
conserved catalytic dyad with the caspases, but due to conserved residues within close 
proximity to the dyad, the question is which residues are required for the subsequent 
peptidolysis after activation by autoprocessing. In addition, calcium has been shown to 
play an important role in the autoprocessing ability and/or peptidolytic activity of the 
MCAs. 
In the present study, the catalytic dyad residues, as well as an adjacent Cys to the 
catalytic Cys residue, were mutated to determine their role, if any, in autoprocessing 
and peptidolytic activity of the recombinant MCA5s from T. congolense and T. vivax. 
Using immunoaffinity purification, native TcoMCA5 was isolated and together with 
recombinant TcoMCA5, the substrate specificity, pH profile, inhibitor sensitivity and 
effect of various divalent cations was determined.  
3.2 Materials and methods 
 Materials 
Molecular biology: As per Section 2.2.1. The Q5® Site-Directed Mutagenesis Kit was 
purchased from New England Biolabs (Ipswich, MA). 
E. coli cells: NEB 5-alpha competent cells supplied with the Q5® Site-Directed 
Mutagenesis Kit. 
Purification and quantification of recombinant and native proteins: As per Section 
2.2.1. Digitonin was purchased from Merck (Darmstadt, Germany), the ECL western 
blotting substrate from Pierce (Rockford, IL, USA), and the peptidase inhibitor cocktail 
from Amresco (Solon, OH, USA). 
Antibodies: Chicken anti-TcoMCA5 IgY and chicken anti-TviMCA5 IgY were produced 
in Section 2.2.6. The chicken anti-6xHis IgY antibody was purchased Merck (Germany) 
and the rabbit anti-chicken IgG HRPO conjugate from Sigma (St. Louis, MO. USA). 
Parasite purification and culture: Eagle’s minimal essential medium (EMEM), Gln 
and Pro were purchased from Sigma (St. Louis, MO, USA), foetal bovine serum (FBS) 
was from Gibco (Paisley, UK), DE-52 from Whatman International Ltd (UK), filters 
(0.2 μm) from PALL Corp (Ann Arbor, USA) and sterile disposable cell culture 
plasticware from Corning (NY, USA). 
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Peptide substrates and inhibitors: The peptide substrates benzyloxycarbonyl (Z)-
Gly-Gly-Arg-7-amino-4-methylcoumarin (AMC), Z-Gly-Pro-Arg-AMC, H-Val-Gly-Arg-
AMC, Z-Pro-Arg-AMC, Z-Arg-AMC, Z-Arg-Arg-AMC, t-butyloxycarbonyl (Boc)-Val-
Leu-Lys-AMC, H-Ala-Phe-Lys-AMC, the inhibitors benzamidine, antipain, bestatin, N-
tosyl-L-lysyl chloromethylketone (TLCK), L-trans-epoxysuccinyl-leucylamido(4-
guanidino)butane (E-64), soyabean trypsin inhibitor (SBTI), 
ethylenediaminetetraacetic acid (EDTA), 4-(2-Aminoethyl)benzenesulfonyl fluoride 
(AEBSF), leupeptin, 1,10-phenanthroline, calpain I, iodoacetate; and porcine gelatin 
were purchased from Sigma (Munich, Germany). The Z-Phe-Ala-fluoromethylketone 
(FMK) and Z-Val-Ala-Asp-FMK inhibitors were purchased from BD Biosciences (San 
Jose, CA) and the black FluoroNunc™ 96-well plates from Nunc Intermed (Roskilde, 
Denmark). 
 Mutagenesis of the active site residues of TcoMCA5 and 
TviMCA5 
It was thought that the mutation of the catalytic dyad residues might impede the ability 
of MCAs to autoprocess. Other researchers who have generated catalytic dyad 
mutants of recombinant MCAs in Trypanosoma spp. and Leishmania spp., have 
generally used a His→Ala and a Cys→Gly mutation (Szallies et al., 2002; Gonzáles et 
al., 2007; Lee et al., 2007; McLuskey et al., 2012). Primers which would facilitate the 
generation of the point mutants of the catalytic dyad residues (His147 and Cys202) as 
well as the Cys adjacent to the catalytic Cys (Cys201) were designed using the Agilent 
QuikChange primer design software programme (http://www.genomics.agilent.com/ 
primerDesign Program.jsp) to achieve a Tm ≥78 °C, and compared to those designed 
by the above-mentioned authors. The mutagenic primers were first annealed to the 
gene in the pET expression plasmid, and then using the Pfu DNA polymerase, the 
primers were extended to copy the entire the plasmid. The plasmid DNA, which is 
isolated from dam+ E. coli cells, is methylated and can be digested with DpnI. Thus, 
only the synthetic plasmid, which contains the desired mutation, can be taken up into 
the competent E. coli cells following transformation (Fig. 3.2). 
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Figure 3.2: Overview of the site-directed mutagenesis process. (A) Annealing of 
mutagenic primers (purple and blue) encoding for site mutant to the parental plasmid template 
(orange and green), (B) followed by the amplification a new template plasmid from the parental 
expression plasmid (purple and blue). (C) DpnI digests the parental hemimethylated template, 
without the introduced mutation, (D) after which the plasmid with the mutation is transformed 
into competent E. coli. The image was obtained from the Agilent QuikChange Site-Directed 
Mutagenesis Kit manual. 
 
The plasmid DNA of previously cloned TcoMCA5 (M7pET28a) together with TviMCA5 
(V4pET32a) was used at the template for the PCR amplification with the primers 
outlined in Appendix B1. Briefly, the final concentrations of the PCR master mix were: 
0.5 µM of each mutagenic primer, 1x Q5 high-fidelity master mix in a total reaction 
volume of 20 μl. The amplification was performed with incubation at 98 °C for 30 s as 
the initial DNA denaturation step, followed by 25 cycles of 98 °C for 10 s, 55 °C for 30 
s and 72 °C for 4 min. A final elongation step at 72 °C for 2 min was subsequently 
carried out. A sample of the amplified plasmid which contained the gene with the 
introduced point mutation (2 μl) was electrophoresed on a 1% (w/v) agarose gel, 
containing ethidium bromide (0.5 µg/ml), in 1xTAE buffer. Thereafter, the plasmid with 
the point mutation (1 µl) was treated with Kinase, Ligase & DpnI enzyme mixture (KLD) 
for 5 min at RT. The de-methylated plasmid was transformed into competent NEB 5-
alpha E. coli cells as described in Section 2.2.3. The plasmid DNA of five resulting 
colonies, from each mutant, was isolated using the GeneJet™ Plasmid Miniprep Kit, 
as per the manufacturer’s instructions and sequenced at the Central Analytical 
Facilities, Stellenbosch University, South Africa, using the forward gene primer detailed 
in Table 2.1. 
63 
 
 Expression, nickel- and immuno-affinity purification of 
the TcoMCA5 and TviMCA5 WT and mutants 
Clones which were positive for the desired point mutation were expressed as outlined 
in Section 2.2.4 and analysed by 12.5% reducing SDS-PAGE (Laemmli, 1970) with 
Coomassie Blue R-250 staining and by western blot probed with chicken 
anti-TcoMCA5 IgY and chicken anti-TviMCA5 IgY (10 µg/ml). 
The soluble protein lysate was subjected to immunoaffinity purification as per 
Section 2.2.7.2. To facilitate the concentration of eluted proteins, instead of collecting 
10 sequential eluted fractions, elution buffer required for two fractions was added to 
the resin and agitated, prior to elution. Elution buffer, 0.1 M glycine, pH 2.8 (1.8 ml), 
was added to the resin followed by agitation using an end-over-end rotator for 5 min at 
RT. Thereafter, two 900 µl fractions were collected in microfuge tubes each containing 
1 M Tris-HCl buffer, pH 8.5 (100 µl). One final fraction was collected by the addition of 
elution buffer (900 μl) which was allowed to flow through the resin and collected in a 
microfuge tube containing 1 M Tris-HCl buffer, pH 8.5 (100 µl).  
The proteins from the insoluble inclusion bodies were solubilised and purified as per 
Section 2.2.5. Samples of each purification were electrophoresed on 12.5% reducing 
SDS-PAGE gels (Laemmli, 1970) and stained with Coomassie Blue R-250, with some 
requiring counter-staining with silver (Blum et al., 1987). 
 Trypanosoma congolense propagation, purification and 
cell culture 
Before the commencement of any animal procedures, ethical clearance was obtained 
from the University of KwaZulu-Natal animal research ethics committee 
(053/15/Animal). Six week old mice were kept in cages, along with enrichment material 
and access to food and water ad libitum, at the animal house at UKZN, 
Pietermaritzburg campus.  
Female Balb/c mice were injected intraperitoneally with approximately 5 000 
T. congolense IL3 000 bloodstream trypomastigotes with daily monitoring of 
parasitaemia by microscopic inspection of tail vein blood. Once parasitaemia reached 
70% of the field of view, mice were sacrificed by cervical dislocation and the blood 
collected, by cardiac puncture, into heparin containing tubes. An equal volume of 
20% (v/v) glycerol-phosphate saline glucose (PSG: 57 mM Na2HPO4, 3 mM NaH2PO4, 
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42 mM NaCl, 50 mM glucose, 1 mM hypoxanthine, pH 7.8) was added to the blood 
before storage at -80 °C or parasite purification by ion exchange chromatography. 
Sterile DE-52 resin (20 ml) was washed with PBS (40 ml) followed by PSG (40 ml), in 
a sterile syringe containing a piece of filter paper at the bottom. Parasites were added 
to the resin and allowed to settle for 30 min at RT. Parasites were eluted in five fractions 
of 10 ml each using PSG. The parasites were pelleted by centrifugation (3 500 rpm, 
15 min, 4 °C), resuspended to approximately 1x106 parasites/ml in 20% (v/v) 
glycerol-PSG and stored at -80 °C for 7 days before being transferred to liquid nitrogen 
for long-term storage. 
The in vitro culture of T. congolense bloodstream trypomastigotes as developed by 
Hirumi and Hirumi (1991) and reported by Eyford et al. (2011) was followed. Briefly, 
1x105 T. congolense bloodstream trypomastigotes per ml were seeded into Eagle’s 
minimum essential medium [EMEM base powder, 2 mM glutamine, 10 mM proline, 
20% (v/v) heat inactivated foetal bovine serum, 10 ml] and cultured at 37 °C and 
5% (v/v) CO2, with the medium being changed every two days. 
 Isolation of native TcoMCA5 
Parasite fractionation in the presence of digitonin was performed as per Zalila et al. 
(2011) with some modifications. Briefly, 2x108 parasites, from cell culture, were washed 
twice in PBS before washing in wash buffer (20 mM Tris-HCl buffer, pH 7.9, 20 mM 
glucose, 150 mM NaCl). The supernatant (SN) was retained, and the pelleted parasites 
resuspend in 100 µM digitonin/SoTe (600 mM sorbitol, 20 mM Tris-HCl buffer, pH 7.5, 
2 mM EDTA, containing 1x peptidase inhibitor cocktail, 750 µl). After incubation for 
5 min on ice, the total protein content from the parasite were present in the resulting 
SN. The total protein content was used for native immunoaffinity purification as per 
Section 3.2.5.1. 
To the total protein content (500 μl), 0.3 M sucrose (150 µl) was added to maintain the 
cellular structures during centrifugation (13 000 g, 5 min, 4 °C). The pellet was 
resuspended in 500 µM digitonin/SoTE (500 µl) to obtain the proteins from the 
mitochondrion which were present in the supernatant after centrifugation (13 000 g, 5 
min, 4 °C). The resulting pellet contained both the nuclear and insoluble proteins. 
The proteins secreted into the culture medium were precipitated using 1 volume of 
0.5 µg/ml trichloroacetic acid gently mixed with 4 volumes of medium, followed by 
centrifugation (18 000 g, 5 min, 4 °C). After washing the pellet twice with ice cold 
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acetone, and allowed to dry, the pellet was resuspended in reducing treatment buffer 
and boiled for 2 min. These samples were prepared for use in Section 5.2.13. 
 Immunoaffinity purification of native TcoMCA5 
Essentially, the same protocol as described in Section 2.2.7.2 was used with some 
adjustments. The total parasite protein sample was added in place of the recombinant 
lysate and incubated with agitation, using an end-over-end rotator, for 16 h at 4 °C. 
After collection of the unbound proteins, the resin was washed with wash buffer (50 ml) 
until the absorbance readings reached a baseline A280 reading of 0.2. To facilitate the 
concentration of eluted proteins, instead of collecting 10 sequential eluted fractions, 
elution buffer required for two fractions was added to the resin and agitated, prior to 
elution. Elution buffer, 0.1 M glycine, pH 2.8 (1.8 ml), was added to the resin followed 
by agitation using an end-over-end rotator for 5 min at RT. Thereafter, two fractions 
(900 µl) were collected in microfuge tubes each containing 1 M Tris-HCl buffer, pH 8.5 
(100 µl). A final fraction was collected by the addition of elution buffer (900 µl) which 
was allowed to flow through the resin and collected in a microfuge tube containing 1 M 
Tris-HCl, pH 8.5 (100 µl).  
 Enzymatic characterisation of recombinant and native 
TcoMCA5 
Initial activity of the purified enzyme in each eluted fraction was measured by 
combining 10 µl of each fraction with MCA assay buffer (50 mM Tris-HCl buffer, pH 7.2, 
150 mM NaCl, 10 mM CaCl2, 5 mM DTT, 90 µl) containing 10 mM Z-Gly-Gly-Arg-AMC, 
in a black FluoroNunc™ 96-well plate, in duplicate. After incubation at 37 °C for 10 min, 
the fluorescence (Ex360nm and Em460nm) was measured using a FLUORStar Optima 
Spectrophotometer from BMG Labtech (Offenburg, Germany). 
The protein concentrations of the fractions, which contained active enzyme, were 
determined using the BCA™ protein assay kit. The optimal enzyme concentration for 
the hydrolysis of the fluorogenic peptide substrate was determined by varying the 
concentration of the enzyme (0-5 μg/ml recombinant, 0-10 μg/ml native, in 10 µl) and 
incubation with MCA assay buffer containing 10 mM Z-Gly-Gly-Arg-AMC (90 µl), in 
triplicate, and fluorescence measured as described above. 
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 Peptide substrate specificity 
Fluorogenic peptide substrates used to determine the substrate specificity of 
recombinant MCA from various organisms varied from commercially available, Z-Gly-
Gly-Arg AMC, Z-Gly-Arg-Arg-AMC, Z-Val-Arg-Pro-Arg-AMC, Z-Arg-Arg-AMC, Z-Arg-
AMC, Boc-Val-Leu-Lys-AMC, H-Val-Leu-Arg-AMC, H-Ala-Phe-Lys-AMC, to libraries of 
specially designed pentapeptide fluorescence resonance energy transfer substrates 
derived from Abz-KARSSA-Q-EDDnp (Machado et al., 2013). However, the most 
commonly used fluorogenic peptide substrate used for kinetoplastid MCA 
characterisation is Z-Gly-Gly-Arg-AMC and was, hence, the substrate of choice for the 
present study. 
By varying the concentration of different fluorogenic peptide substrates, it is possible 
to determine the enzyme’s maximum velocity (Vmax) and its affinity for each substrate 
(Km). This is achieved by measuring initial reaction velocity (vo) for each of the substrate 
concentrations [S]. Using the Briggs and Haldane revised Michaelis-Menten equation 
(1925) [A], a direct plot of vo versus [S] allows for the determination of Vmax and Km.  
𝑣o =  
𝑉max[S]
[S]+ 𝐾m
                            [A] 
The active concentration of enzyme [E0] can be determined using a well-documented 
active site titrant. However, to date, there has been no report of an active site titrant 
specific for the kinetoplastid MCAs. Other workers assume that [E]t is equal to [E]0 
when determining the turnover number (kcat) from Vmax using equation [B] (Salvesen 
and Nagase, 1989): 
𝑘cat =  
𝑉max
[E]o
                            [B] 
Briefly, recombinant TcoMCA5H147AC202G (0.5 µg/ml) and native TcoMCA5 (7.5 µg/ml) 
were incubated with MCA assay buffer at 37 °C for 10 min. During that period, a dilution 
series of each fluorogenic peptide substrate made in MCA assay buffer, was added to 
the wells of a black FluoroNunc™ 96-well plate, in triplicate, for recombinant and in 
duplicate for the native enzyme. The fluorescence (Ex360nm and Em460nm) was measured 
every 30 s for 60 min, using a FLUORStar Optima Spectrophotometer from BMG 
Labtech (Offenburg, Germany). The AMC calibration curve (Appendix B2), was used 
to determine the velocity, and together with the substrate concentrations, the Vmax and 
Km was determined using the Hyper32© software (1991-2003, J. S. Easterby, University 
of Liverpool, UK). 
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 pH profile 
The pH optimum of the recombinant TcoMCA5H147AC202G (0.5 µg/ml) and native 
TcoMCA5 (7.5 µg/ml) was determined using the AMT constant ionic strength buffer 
(100 mM sodium acetate, 10 mM MES, 200 mM Tris-HCl, 5 mM EDTA, 5 mM DTT) at 
pH range of 4 to 9 (Ellis and Morrison, 1982). Enzyme (10 µl) was added to the wells 
of a black FluoroNunc™ 96-well plate, in triplicate for recombinant and in duplicate for 
native, followed by the addition of the AMT buffers, containing 10 mM Z-Gly-Gly-Arg-
AMC (90 µl). After incubation at 37 °C for 10 min, the fluorescence was measured 
every 30 s for 15 min for recombinant TcoMCA5H147AC202G and every 30 s for 60 min for 
native TcoMCA5. 
 Analysis of recombinant and native TcoMCA5 activity 
by zymography 
The peptidolytic activity of recombinant (0.5 μg/ml) and native (7.5 μg/ml) TcoMCA5 
was analysed on a 1% (w/v) porcine gelatin-containing SDS-PAGE gel (Heussen and 
Dowdle, 1980). The catalytic domain of congopain (TcoCATL, 0.5 μg/ml) was used as 
the positive control. An equal volume of non-reducing treatment buffer [125 mM 
Tris-HCl buffer, pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol] was added to samples 
without boiling. After electrophoresis, gels were washed twice over 1 h with 2.5% (v/v) 
Triton X-100 (50 ml) at RT, to remove the excess SDS. The gels were subsequently 
incubated at 37 °C for 16 h at 50 rpm, in AMT buffer, pH 7, 8 and 9. The gels were 
stained with amido black staining solution [0.1% (w/v) amido black, 30% (v/v) 
methanol, 10% (v/v) acetic acid] at RT for 1 h and destained with destain solution [30% 
(v/v) methanol, 10% (v/v) acetic acid]. 
 Inhibitor screening 
Taking into account that only a few inhibitors have been shown to effectively inhibit the 
MCAs from different organisms, recombinant TcoMCA5H147AC202G was incubated with a 
panel of serine (TLCK, antipain, leupeptin, AEBSF, SBTI, benzamidine), cysteine 
(antipain, leupeptin, E-64, iodoacetic acid, calpain I), aminopeptidase (bestatin), 
aspartic (pepstatin), metallo (1-10 phenanthroline, EDTA), and caspase specific (Z-
Phe-Ala-FMK, Z-Val-Ala-Asp-FMK) reversible and irreversible inhibitors at 1, 10 and 
100 µM.  
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Recombinant TcoMCA5H147AC202G (0.5 µg/ml) was incubated at 37 °C for 10 min with 
MCA assay buffer containing 10 mM Z-Gly-Gly-Arg-AMC. During that period, 1, 10 and 
100 µM of the panel of reversible and irreversible inhibitors, prepared in MCA assay 
buffer, were added, in triplicate, to the wells of a black FluoroNunc™ 96-well plate. 
Thereafter, the enzyme prepared in MCA assay buffer, was added to the wells and the 
fluorescence measured as before (every 30 s for 60 min). The AMC standard curve 
(Appendix B2) and the change in velocity were used to determine the resultant 
inhibition of the enzyme, which was reported as the percentage inhibition compared to 
that of the uninhibited enzyme. 
 Reversible inhibition of TcoMCA5 
Only the reversible inhibitors, antipain and leupeptin, were able to partially inhibit the 
activity of recombinant TcoMCA5H147AC202G. In order to determine the inhibition kinetic 
constant, Ki, the recombinant enzyme was incubated with inhibitors over a range of 
concentrations [I], which was in 20-fold molar excess over the enzyme concentration 
(0-100 μM). The change in steady state velocity without inhibitor (v0) and with the 
addition of inhibitor (vi) together with equation [C] (Salvesen and Nagase, 1989), a plot 
of vo / vi – 1 against [I], would result in the determination of Ki (app) from the gradient. 
𝑣o
𝑣i
= 1 +  
[I]
𝐾i (app)
                            [C] 
Substitution of Ki (app) into equation [D] (Salvesen and Nagase, 1989), allows for the 
determination of Ki. 
𝐾i =  
𝐾i (app)
1
+  
[S]
𝐾m
                            [D] 
To determine the extent of reversible inhibition by antipain and leupeptin on the 
peptidolytic activity of TcoMCA5, recombinant TcoMCA5H147AC202G (0.5 µg/ml) was pre-
incubated at 37 °C for 10 min with MCA assay buffer containing 10 mM Z-Gly-Gly-Arg-
AMC. During that period, a series of concentrations of antipain and leupeptin, made in 
MCA assay buffer, was added to the wells of a black FluoroNunc™ 96-well plate, in 
triplicate. Thereafter, the enzyme prepared in MCA assay buffer, was added to the 
wells and the fluorescence measured as before (every 30 s for 60 min). The AMC 
standard curve (Appendix B2) and the change in velocity were used to determine the 
resultant inhibition of the enzyme, which was reported as the percentage inhibition 
compared to that of the uninhibited enzyme. 
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 Effect of divalent cations 
The influence of metal ions on the activity of an enzyme can provide insight into its 
catalytic mechanism, as metals can serve as structural regulators, electron donors, 
electron acceptors or as Lewis acids (Riordan, 1977). Some MCAs have an absolute 
requirement for calcium for activation while others do not.  
To determine the effect of divalent cations on the activity of TcoMCA5, recombinant 
TcoMCA5H147AC202G (0.5 µg/ml) was pre-incubated at 37 °C for 10 min with MCA assay 
buffer without calcium, containing 10 mM Z-Gly-Gly-Arg-AMC. During that period, 
1, 10 and 100 µM of a variety of divalent cations, prepared in MCA assay buffer, was 
added to the wells of a black FluoroNunc™ 96-well plate, in triplicate. Thereafter, the 
enzyme prepared in MCA assay buffer, was added to the wells and the fluorescence 
measured as before (every 30 s for 60 min). The AMC standard curve (Appendix B2) 
and the change in velocity were used to determine the resultant inhibition of the 
enzyme, which was reported as the percentage inhibition compared to that of the 
uninhibited enzyme. 
3.3 Results 
 Mutagenesis of the active site residues of TcoMCA5 and 
TviMCA5 
The generation of the catalytic dyad residue mutations, H147A and C202G, along with 
the Cys adjacent to the catalytic Cys, C201G, was performed in order to determine if 
the active site residues played a role in autoprocessing as described in Chapter 2. In 
addition, the double mutant of the catalytic dyad residues, H147AC202G, was 
generated. The engineering of TcoMCA5 and TviMCA5 mutants was achieved using 
the Q5® Site-Directed Mutagenesis Kit. The high-fidelity PCR amplification of the 
desired mutations are given in Appendix B3. The sequences of the generated mutants 
are provided in Appendix B4.  
 Expression of recombinant WT and active site mutants 
A western blot of the expression of recombinant WT, using chicken anti-6xHis IgY 
antibodies, detected a His-tagged protein at 68 kDa for both TbbMCA2 and TcoMCA5, 
and at approximately 90 kDa for TviMCA5 (Fig. 3.3, panel A) in the insoluble 
expression fraction. Prominent protein bands at 68 and 60 kDa for TcoMCA5 and 
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TviMCA5, as well numerous lower molecular weight protein bands, were detected 
using their respective chicken IgY antibodies. From literature, autoprocessing results 
in the cleavage of the N- and C-terminal domains to release the catalytic domain from 
the full length protein. Thus, the 68 and 60 kDa bands, in the insoluble expression 
fraction, are suggested to be the full length protein with and without the N-terminal 
6xHis tag, respectively, corresponding to the proteins detected by the anti-6xHis IgY 
antibody. The 38 kDa protein is thought to be as a result of the removal of the 
C-terminal domain from the 60 kDa protein. After the removal of the C-terminal domain, 
23 kDa protein, from the 38 kDa protein, the 31 kDa catalytic domain is produced. 
A comparison of the soluble and insoluble expression fractions of the recombinant WT 
and mutants (panels B and C), revealed that apart from TcoMCA5C201G having the 
same full length, 70 kDa protein band in the insoluble expression fraction, similar to 
that of the WT, and lacking the protein bands at 31 and 38 kDa in the soluble fraction, 
the mutants all had a similar protein profile to that of the WT.  
No protein bands were detected after probing a western blot of the expression of 
BL21 (DE3) E. coli cells, with and without the pET-28a and pET-32a plasmids, using 
the chicken anti-6xHis IgY, chicken anti-TcoMCA5 IgY and chicken anti-TviMCA5 IgY 
antibodies (result not shown). 
 Affinity purification of recombinant WT and MCA5 
mutants from the soluble and insoluble expression fractions 
Following expression, and the detection of autoprocessed MCA in both the soluble and 
insoluble expression fractions, the purification strategy implemented as described in 
Chapter 2 was repeated. The soluble MCA was purified using immunoaffinity 
purification (Fig. 3.4), and the insoluble MCA was solubilised, refolded and purified 
using nickel affinity chromatography (Fig 3.5). 
The purification of soluble MCA resulted in two prominent lower molecular weight 
protein bands at approximately 41 and 35 kDa, which is thought to correspond to the 
release of the catalytic domain from the full length protein by the cleavage of the N- 
and C-terminal domain, was present for all clones. Due to the very faint Coomassie 
stained bands present after purification of TcoMCA5C202G, TviMCA5C201G and 
TviMCA5C202G, the SDS-PAGE gels were counter-stained with silver. The full length 
protein was only evident for TcoMCA5C202G at approximately 68 kDa, and faintly for 
TviMCA5C201G and TviMCA5C202G after silver staining.  
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Figure 3.3: Western blots of the expression of WT MCA5 and catalytic mutants. Samples from the soluble (SN) and insoluble (P) fractions 
of the expression of TbbMCA2, TcoMCA5, TviMCA5 WT along with the H147A, C201G, C202G and H147AC202G mutants of TcoMCA5 and TviMCA5 
were electrophoresed on reducing 12.5% SDS-PAGE gels. After transfer onto nitrocellulose, blocking with 5% (w/v) milk-TBS, incubation with (A1) 
chicken anti-6xHis IgY [1:5 000 in 0.5% (w/v) BSA-PBS], (A2 and B) chicken anti-TcoMCA5 IgY and (A3 and C) chicken anti-TviMCA5 IgY [10 µg/ml 
in 0.5% (w/v) BSA-PBS] was carried out. Rabbit anti-chicken IgY HRPO conjugate [1:5 000 in 0.5% (w/v) BSA-PBS] and 4-chloro-1-naphthol∙H2O2 were 
used as the detection system. 
72 
 
 
Figure 3.4: Immunoaffinity purification of the soluble WT and mutant MCA5s after 
recombinant expression. Samples of the three eluted fractions from the purification of 
soluble TbbMCA2, TcoMCA5 and TviMCA5 WT along with the TcoMCA5 and TviMCA5 
mutants, were electrophoresed on 12.5% reducing SDS-PAGE gels and stained with 
Coomassie Blue R-250. The TviMCA5C201G and TviMCA5C202G gels were subsequently 
counter-stained with silver. 
 
Similar to the observations described in Chapter 2, solubilisation, refolding and 
purification using nickel affinity chromatography, nickel-induced over autoprocessing 
was observed. That is, more protein bands were eluted than were detected in the 
western blot of expression samples (Fig. 3.3) and by the immunoaffinity purification 
(Fig. 3.4). In most clones, the 70, 68, 35, 25 and 20 kDa proteins were detected 
(Fig. 3.5), proteins which were visible in the western blot of expression samples. 
However, in the second eluted fraction, an increase in the number of eluted proteins 
was evident, as was shown in Chapter 2. In the case of TcoMCA5C201G and 
TcoMCA5H147AC202G and TviMCA5H147AC202G clones, very little over autoprocessing was 
evident in the second eluted fraction, with prominent protein bands at 68, 35 and 28 
kDa, corresponding to the full length and release of the catalytic domain. In fractions 4 
to 10, almost pure full length protein was eluted. The elution pattern of TcoMCA5H147A 
and TviMCA5 WT (panel C) differed from the other clones, with the elution of 30, 25, 
21 and 14 kDa proteins in fractions 3 to 10.  
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 Isolation of native TcoMCA5 
A search of the NCBI database indicates that the MCA5 from both T. congolense and 
T. vivax are putative peptidases. Detection of native TbbMCA5 and TviMCA5 in 
bloodstream trypomastigote lysate was achieved using both chicken anti-TcoMCA5 
IgY and chicken anti-TviMCA5 IgY. The existence of TcoMCA5 (Eyssen, 2013) and 
TbbMCA5 (Helms et al., 2006) were demonstrated previously. However, the 
characterisation of TbbMCA5 was not conducted. Native TviMCA5 was detected at 
approximately 50 kDa by chicken anti-TcoMCA5 IgY and at 68 and 30 kDa by chicken 
anti-TviMCA5 IgY, but more intensely by the latter (Fig. 3.6, panels A and B, 
respectively). However, native TbbMCA5, at approximately 70 kDa, was only detected 
by chicken anti-TcoMCA5 IgY. As we do not currently have access to viable T. vivax 
parasites, and since TbbMCA5 is not a priority enzyme in this study, only the isolation 
of native TcoMCA5 and its enzymatic characterisation was pursued.  
Following the application of the total parasite protein to the chicken anti-TcoMCA5 IgY 
immunoaffinity resin, 70 and 46 kDa proteins bound to the resin and were eluted by 
decreasing the pH (Fig. 3.7). There was a small amount of the 46 kDa protein in the 
eluted fractions when compared to the amount of protein loaded onto the resin. The 
sizes of these proteins correspond well with the western blot of T. congolense 
bloodstream trypomastigote lysate using chicken anti-TcoMCA5 IgY (Eyssen, 2013). 
However, not all of the full length protein bound the resin as some was detected in the 
unbound fraction.  
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Figure 3.5: Nickel affinity purification of solubilised recombinant TbbMCA2, TcoMCA5 and TviMCA5 WT, along with TcoMCA5 
and TviMCA5 catalytic mutants. Samples of the eluted fractions from the nickel affinity purification of recombinant MCA WT and catalytic dyad 
mutants were electrophoresed on 12.5% reducing SDS-PAGE gels and stained with Coomassie blue R-250. The eluted fractions of the TcoMCA5C202G 
and the TviMCA5 mutants were counted stained with silver. 
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Figure 3.6: Detection of native MCA5 in T. b. brucei and T. vivax bloodstream 
trypomastigote lysates. Parasite lysates (1x109 parasites/ml) were electrophoresed on a 
12.5% reducing SDS-PAGE gel and transferred onto nitrocellulose. After blocking with 5% (w/v) 
milk-TBS, the nitrocellulose was incubated with (A) chicken anti-TcoMCA5 IgY and (B) chicken 
anti-TviMCA5 IgY [10 µg/ml in 0.5% (w/v) BSA-PBS]. Rabbit anti-chicken IgY HRPO conjugate 
[1:5 000 in 0.5% (w/v) BSA-PBS] and 4-chloro-1-naphthol∙H2O2 were used as the detection 
system. 
 
 
Figure 3.7: Immunoaffinity purification of native TcoMCA5. Samples of the total 
protein content loaded onto the resin, unbound fraction, wash fractions as well as the eluted 
fractions were electrophoresed on a 12.5% reducing SDS-PAGE gel and transferred onto 
nitrocellulose. After blocking with 5% (w/v) milk-TBS, the nitrocellulose was incubated with 
chicken anti-TcoMCA5 IgY [10 µg/ml in 0.5% (w/v) BSA-PBS]. Rabbit anti-chicken IgY HRPO 
conjugate [1:5 000 in 0.5% (w/v) BSA-PBS] and ECL were used as the detection system. 
 
 Enzymatic characterisation 
Both the WT and mutants were enzymatically characterised based on their P1 site 
specificity, pH profile as well as which inhibitors they were sensitive to. 
Hydrolysis of the Z-Gly-Gly-Arg-AMC substrate was only detected in the second 
fraction of the double mutant TcoMCA5H147AC202G purified using nickel affinity 
chromatography. In addition, hydrolysis was detected with the immunoaffinity purified, 
native TcoMCA5. To prove that these two enzymes were indeed the only active MCAs, 
the second eluted fraction from each of the ‘inactive’ clones, were tested alongside 
those of the ‘active’ MCAs. It was found that 0.5 µg/ml TcoMCA5H147AC202G (pink) and 
7.5 µg/ml native TcoMCA5 (green) were active with a discernible increase in velocity 
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(Fig. 3.8, panels A and B, respectively), whilst the eluted fractions from the ‘inactive’ 
clones showed no activity. Despite the higher enzyme concentration, native TcoMCA5 
had a much slower velocity, 3.51 µM/s, compared to recombinant TcoMCA5H147AC202G, 
at 145 µM/s. 
The fact that the clone in which both the catalytic residues were mutated, was shown 
to be the most active, supports the suggestion of the existence of a secondary catalytic 
Cys (Vercammen et al., 2004; Proto et al., 2011; Piszczek et al., 2012). The Cys 
residue in question, Cys81 in TcoMCA5, is in close proximity to the catalytic Cys202 
and adjacent Cys201 (Appendix B5), and is conserved in the MCAs found in 
Trypanosoma spp. and Leishmania spp. (Appendix A3). Further support for this 
suggestion is that neither the catalytic His nor Cys were shown to be essential for the 
‘trypsin-like’ activity of native LdnMCA (Lee et al., 2007).  
 
Figure 3.8: Enzymatic activity of the purified recombinant WT, mutants and 
native TcoMCA5. From the purifications using nickel affinity chromatography of: recombinant 
WT and all mutants of both TcoMCA5 and TviMCA5, together with the immunoaffinity purified 
native TcoMCA5, the second eluted fraction (0.5 µg/ml and 7.5 µg/ml for recombinant and 
native, in triplicate and duplicate, respectively) was incubated with MCA assay buffer, containing 
10 µM Z-Gly-Gly-Arg-AMC and the resultant fluorescence measured (Ex360nm and Em460nm). 
The equation of the (A: pink) recombinant TcoMCA5H147AC202G trendline is given by y = 145.88x 
with a correlation coefficient of 0.9997 and for (B: green) native TcoMCA5, y = 3.5158x with a 
correlation coefficient of 0.9868.  
 
 Substrate specificity 
The preference of recombinant TcoMCA5H147AC202G and native TcoMCA5 for different 
amino acid residues at the P1, P2 and P3 sites was investigated. Due to the low activities 
obtained for Lys in the P1 site, only the activities with Arg in the P1 site are reported in 
Table 3.1. Despite the higher affinity for both Z-Pro-Arg-AMC and Z-Arg-Arg-AMC, by 
recombinant TcoMCA5H147AC202G, Z-Gly-Gly-Arg-AMC was characterised by a higher 
turnover number. However, recombinant TcoMCA5H147AC202G cleaved Z-Arg-Arg-AMC 
two times more efficiently than Z-Gly-Gly-Arg-AMC. The most commonly reported 
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fluorogenic peptide substrate used for kinetoplastid MCAs is Z-Gly-Gly-Arg-AMC, 
which was selected for the remaining enzymatic characterisations. 
Since a high concentration of native TcoMCA5 was required to observe any activity, it 
was only tested against Z-Gly-Gly-Arg-AMC, and in duplicate. As seen in the velocities 
reported in Fig. 3.8, native TcoMCA5 hydrolysed the fluorogenic peptide substrate very 
slowly (3.917 µM/s), with a low turnover of 0.52 s-1, as well as having a 14 times lower 
substrate affinity compared to that of the recombinant TcoMCA5H147AC202G. The catalytic 
efficiency constant, kcat/Km,
  is useful in comparing the relative rates of an enzyme 
acting on different substrates, but is not to be used to compare two different enzymes 
acting on the same substrate (Eisenthal et al., 2007). Thus, the low value for native 
TcoMCA5, compared to recombinant TcoMCA5H147AC202G, does not necessarily mean 
that Z-Gly-Gly-Arg-AMC is a poor choice of substrate. The Lineweaver-Burke plots are 
provided in Appendix B6. 
Table 3.1: Substrate specificity of recombinant TcoMCA5H147AC202G and purified 
native TcoMCA5. Recombinant TcoMCA5H147AC202G (0.5 µg/ml) and native TcoMCA5 
(7.5 µg/ml) were incubated in MCA assay buffer (50 mM Tris-HCl buffer, pH 7.2, 150 mM NaCl, 
10 mM CaCl2, 5 mM DTT) before the addition of 0 to 30 µM of various fluorogenic peptide 
substrates in triplicate and duplicate, respectively. The resultant fluorescence from the 
hydrolysis of the AMC fluorophore, over 60 min, was measured at Ex360nm and Em460nm. The 
kinetic parameters, Km and Vmax were determined using the Hyper32® software. 
Substrate (µM) 
TcoMCA5H147AC202G Native TcoMCA5 
Km (µM) 
kcat 
(1/s) 
kcat/Km 
(1/s.µM) 
Km (µM) 
kcat 
(1/s) 
kcat/Km 
(1/s.µM) 
Z-Gly-Gly-Arg-AMC 120 871 7.26 8.4 0.52 0.062 
H-Val-Gly-Arg-AMC 72.9 420 5.76 ND ND ND 
Z-Gly-Pro-Arg-AMC 171 808 4.73 ND ND ND 
Z-Pro-Arg-AMC 24.0 211 8.79 ND ND ND 
Z-Arg-Arg-AMC 13.2 175 13.3 ND ND ND 
Z-Arg-AMC 134 408 3.04 ND ND ND 
ND: not determined due to limited quantity of native TcoMCA5 enzyme available.  
The Boc-Val-Leu-Lys-AMC and H-Ala-Phe-Lys-AMC substrates had Km and Vmax values of less than 
0.02 µM, and were omitted from the table. 
 pH profile 
Using the Z-Gly-Gly-Arg-AMC substrate, along with the constant ionic strength AMT 
buffers, the pH profile of recombinant TcoMCA5H147AC202 was determined, using 
triplicate samples, in the absence and presence of calcium. Based on the results of the 
recombinant enzyme and limited amount of native enzyme, the pH profile of native 
TcoMCA5 was determined at six pH values instead of eleven, using duplicate samples, 
without the addition of calcium. 
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Recombinant TbbMCA2 has a pH optimum of 7.7 (Machado et al., 2013; Gilio et al., 
2017) due to the two ionising groups of the catalytic dyad with pKe1 = 6.7 (His) and 
pKe2 = 8.7 (Cys) (Machado et al., 2013). The addition (panel A) and omission of calcium 
(panel B) slightly affected the activity of recombinant TcoMCA5H147AC202G, but was 
shown to be most active between pH 7 and 9. Moderate activity was found between 
pH 6 and 7, with very little activity below pH 5.5 (Fig. 3.9). The omission of calcium 
(panel B) resulted in slightly increased velocities when compared to those obtained 
with the addition of calcium (panel A). As such, due to the limited amount of native 
TcoMCA5, the pH profile was determined without the addition of calcium. The pH 
profile for native TcoMCA5 (panel C) was very similar to that of recombinant 
TcoMCA5H147AC202G, with a broad pH optimum between 6.5 and 9, at a lower velocity, 
even after an extended period of measurements. This was expected following the low 
velocities observed in the range of 50 to 70 µM/s in Fig. 3.8, panel B. 
 
Figure 3.9: The pH profile of recombinant TcoMCA5H147AC202G and native 
TcoMCA5. Recombinant TcoMCA5H147AC202G (A and B; 0.5 µg/ml, in triplicate) and native 
TcoMCA5 (C; 7.5 µg/ml, in duplicate) were incubated in constant ionic strength AMT buffers 
(100 mM sodium acetate, 10 mM MES, 200 mM Tris-HCl, 5 mM EDTA, 5 mM DTT) varying in 
pH from 4 to 9 and containing Z-Gly-Gly-Arg-AMC (10 µM). In (A), the AMT buffer was 
supplemented with 10 mM CaCl2 whereas (B and C) was without. The resultant fluorescence 
from the hydrolysis of the AMC fluorophore by recombinant and native TcoMCA5 over 15 and 
60 min, respectively, was measured at Ex360nm and Em460nm. 
 
The estimated pI of the full length TbbMCA2 is 5.8 compared to 8.4 for TcoMCA5. A 
probable cause for the broad pH profile, and the deviation from the bell-shaped curve 
of TbbMCA2 may be due to the difference in amino acid composition of the N-terminal 
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domain and the longer C-terminal domain of MCA5 (Fig. 2.7 and Appendix A3) which 
remains attached to the main protein body after autoprocessing (McLuskey et al., 
2012). The pI-values of these domains differ between TbbMCA2 (N-terminal domain, 
6; C-terminal domain, 5), TcoMCA5 (N-terminal domain, 9.8; C-terminal domain, 8) 
and TviMCA5 (N-terminal domain, 10.2; C-terminal domain, 9).  
 Gelatin digestion 
In order to determine which of the proteins, purified using nickel- and immuno-affinity 
chromatography for recombinant TcoMCA5H147AC202 and immuno-affinity 
chromatography for native TcoMCA5, were active, zymography was employed. Activity 
is visualised by the digestion of the gelatin substrate, shown as clear areas in the amido 
black stained gelatin-containing non-reducing SDS-PAGE gel. As seen in Fig. 3.9, both 
recombinant TcoMCA5H147AC202G and native TcoMCA5 were active between pH 7 to 9, 
the three zymograms were therefore incubated at pH 7, 8, and 9. The recombinant 
catalytic domain (CD) of congopain, TcoCATL, which served as the positive control, 
showed activity at approximately 22 kDa. Activity of the MCA5 was observed at 
approximately 97, 63, 42 and 38 kDa with no discernible difference in activity observed 
between the three buffers (Fig. 3.10).  
Due to the addition of gelatin to the SDS-PAGE gels, the molecular weights are only 
approximations. Referring to Appendix B7, the two active protein bands of native 
TcoMCA5 correspond well to the 68 and 46 kDa protein bands detected after its 
immunoaffinity purification as detected using chicken anti-TcoMCA5 IgY (Fig. 3.7). 
Recombinant TcoMCA5H147AC202G was active as two protein bands which corresponds 
well to the 32 and 28 kDa protein bands seen in Fig. 3.5. Samples from the nickel- and 
immuno-affinity purifications of both recombinant WT and clones of the other mutants, 
were also electrophoresed on gelatin containing SDS-PAGE gels, with gelatin 
digestion only evident for the recombinant TcoCATL CD control (results not shown). 
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Figure 3.10: Gelatin containing SDS-PAGE to visualise the peptidolytic activity 
of native TcoMCA5 and recombinant TcoMCA5H147AC202G. A sample from each of the 
eluted fractions of purified native TcoMCA5, second eluted fraction of nickel purified 
recombinant TcoMCA5H147AC202G, together with recombinant TcoCATL CD (0.5 µg/ml), was 
electrophoresed on a non-reducing 12.5% SDS-PAGE containing 1% (w/v) porcine gelatin. 
After washing twice with 2.5% (w/v) Triton X-100 and incubation with AMT buffers pH 7, 8 and 
9, the gels were stained with Amido Black.  
 
 Inhibitors 
A panel of both reversible and irreversible inhibitors where incubated with recombinant 
TcoMCA5H147AC202G to determine which would have an effect on enzyme activity. As 
evident from Fig. 3.11, only the serine and cysteine specific inhibitors, leupeptin and 
antipain were able to reduce the enzyme activity of recombinant TcoMCA5H147AC202G by 
more than 20% at 10 µM. An increase in inhibitor concentration to 100 µM, did not 
increase the extent of inhibition. Both the general caspase inhibitor, Z-Val-Ala-Asp-
FMK, and negative control for caspase inhibitors, Z-Phe-Ala-FMK, showed no 
inhibition. Even the classical cysteine specific inhibitor, E-64 was unable to reduce 
activity (Appendix B8). The velocities and standard deviations of each inhibitor are 
given in Appendix B9. 
The inhibition constant, Ki, for antipain was 119.1 µM and 72.99 µM for leupeptin 
(Appendix B10), indicating that leupeptin was a better inhibitor than antipain. 
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Figure 3.11: Sensitivity of recombinant TcoMCA5H147AC202G to a variety of 
peptidase inhibitors. Recombinant TcoMCA5H147AC202G (0.5 µg/ml) was incubated in MCA 
assay buffer containing 10 µM Z-Gly-Gly-Arg-AMC, before the addition of 1, 10 and 100 µM of 
various peptidase inhibitors, in triplicate, diluted in assay buffer without substrate. The resultant 
fluorescence from the hydrolysis of the AMC fluorophore, over 60 min, was measured at Ex360nm 
and Em460nm. No inhibition was measured for calpain I, bestatin, AEBSF, 1,10 phenanthroline, 
Z-Phe-Ala-FMK, Z-Val-Ala-Asp-FMK and iodoacetic acid. Percentage inhibition was 
determined using 0 mM inhibitor as 0% inhibition. 
 
 Effect of divalent cations 
Some MCAs depend on calcium activation for peptidolytic activity (Bozhkov, 2005; 
Moss et al., 2007; He et al., 2008; Ojha et al., 2010; Meslin et al., 2011; Proto et al., 
2011; Laverrière et al., 2012; Wen et al., 2013) whilst others do not (Vercammen et al., 
2004; Gonzáles et al., 2007; Klemenčič et al., 2015). 
In the absence of calcium, recombinant TcoMCA5H147AC202G was active, however, the 
addition of 1 and 5 mM calcium, decreased its activity by 10%, but at 10 and 25 mM 
100% activity was observed (Fig. 3.12, panel A). Increasing the calcium concentration 
beyond 25 mM resulted in a steep drop in activity, where at 100 mM, half its activity 
had been lost. The decrease in velocity is given in Appendix B11. As such, the pH 
profile of native TcoMCA5 was tested without the addition of calcium in the MCA assay 
buffer.  
In an attempt to understand why extensive autoprocessing is evident in the second 
eluted fraction after nickel affinity purification of the solubilised recombinant MCA5s, 
the effect of other divalent cations was investigated. Nearly complete inhibition of Z-
Gly-Gly-Arg-AMC hydrolysis, was observed for 1 mM Cd2+ and Zn2+, 58% for Cu2+, 
54% for Fe2+ and 32% for Ni2+ when added to recombinant TcoMCA5H147AC202G 
(Fig. 3.12, panel B). When increased to 10 mM, all cations, with the exception of Mg2+, 
Mn2+ and Ca2+, decreased the activity of TcoMCA5H147AC202G by more than 90%. The 
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decrease in velocity is given in Appendix B12. This trend might be due to the size of 
the ions where Cd>Zn>Cu>Ni>Fe>Mn>Ca>Mg and the resultant percentage inhibition 
Cd=Zn=Cu>Fe> Ni>Mg=Mn=Ca are almost directly related. 
 
Figure 3.12: Effect of divalent cations on the enzymatic activity of recombinant 
TcoMCA5H147AC202G. Recombinant TcoMCA5H147AC202G (0.5 µg/ml) was incubated in MCA 
assay buffer containing 10 µM Z-Gly-Gly-Arg-AMC, before the addition of (A) 0 to 100 mM 
CaCl2 or (B) 1 and 10 mM of various divalent cations, in triplicate, diluted in assay buffer without 
substrate. The resultant fluorescence from the hydrolysis of the AMC fluorophore, over 60 min, 
was measured at Ex360nm and Em460nm. Percentage activity is determined using 0 mM CaCl2 as 
100% active and percentage inhibition using 0 mM inhibitor as 0% inhibition. 
 
3.4 Discussion 
Due to the structural similarities to the caspases and their absence in the metazoan 
kingdom, it was hypothesised that the MCAs may function in a similar manner, and 
have hence been described as virulence factors (Mottram et al., 2003). The MCAs’ 
involvement in both apoptotic (Proto et al., 2011; Zalila et al., 2011; Laverrière et al., 
2012) and non-apoptotic (Helms et al., 2006; Ambit et al., 2008; Lee et al., 2010) events 
have been demonstrated. Thus, targeting the MCA for the development of novel 
chemotherapies, may cause a disruption in the signalling pathways of the parasite, and 
be ideal for parasite control. As such, it is imperative to characterise the MCAs’ 
activation mechanisms and kinetic characteristics.  
Autoprocessing of MCAs generally functions to remove the N- and C-terminal domains 
from the catalytic domain. However, it has been suggested that the cleavage of the 
N-terminal domain is independent of the peptidase’s autoprocessing ability (Gonzáles 
et al., 2007). The MCAs do not necessarily require autoprocessing, nor dimerisation 
for activation of their peptidolytic activity (Moss et al., 2007), and are not all activated 
by calcium (Vercammen et al., 2004; Gonzáles et al., 2007). It has been demonstrated 
that recombinant TbbMCA2 undergoes autoprocessing, but this is not necessary for 
activity, whereas autoprocessing is key for activation of caspases (Moss et al., 2007). 
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No TbbMCA2 autoprocessing has been demonstrated in vitro, but it cannot be ruled 
out as its occurrence may be restricted to specific points of the cell cycle or under 
specific in vivo induction conditions (Moss et al., 2007; Ambit et al., 2008). It is a 
possibility that in vivo, autoprocessing plays a role in MCA targeting and/or protein 
interactions and thus, function in an indirect regulatory manner.  
The catalytic domain of LmjMCA, when expressed in yeast, was shown to be more 
active than the full length protein (Ambit et al., 2008). This is in line with the suggestion 
that processing is required for optimal enzymatic activity (Gonzáles et al., 2007). A 
similar result was obtained for PfMCA1 when expressed in E. coli (Meslin et al., 2007). 
Mutagenesis of the sites of autoprocessing in TbbMCA2 resulted in an active enzyme 
but not as active as when autoprocessing, to release the catalytic domain, had 
occurred (Gilio et al., 2017). This, however, was not the case for TcrMCA3 and -5 
where autoprocessing was not observed but the enzymes were still active (Kosec et 
al., 2006). Mutagenesis studies have been conducted to determine if the catalytic 
residues play a role in autoprocessing. The individual mutations of the catalytic His of 
the single yeast metacaspase, YCA1, and the residues of the catalytic dyad of 
LmjMCA, did not impair their ability to undergo autoprocessing (Gonzáles et al., 2007; 
Wong et al., 2012). In addition the Cys adjacent to the catalytic Cys, Cys201, of 
LmjMCA was shown not to be essential for peptidolysis but did have an influence on 
the catalytic Cys which was not discussed further (Gonzáles et al., 2007). The two Cys 
residues, Cys201 and Cys202, of TcoMCA5 and TviMCA5 do not interact directly with 
each other. Instead Cys201 and Cys202 form π-sulfur interactions with His200 and 
Tyr141, respectively, and is illustrated in Appendix B13. To date, there has been no 
record of a recombinant MCA clone in which both the catalytic His and Cys were 
mutated. 
Considering the conserved sequences between the MCAs of Leishmania spp., 
together with the preference of Arg at the P1 site of substrates, the domain assignment 
of the multiple bands seen in the expression samples of the recombinant WT and 
mutants of TcoMCA5 and TviMCA5 were based on that assigned for LmjMCA 
autoprocessing. Firstly, C-terminal cleavage at Arg298, followed by N-terminal 
cleavage at Arg63, Arg79 and Arg135, is required for the release of the active catalytic 
domain (Zalila et al., 2011). Upon the overexpression of TcoMCA5 and TviMCA5 in 
E. coli, several bands were detected, which included the full length protein, with and 
without the N-terminal 6xHis tag at 68 and 60 kDa, respectively. Through 
autoprocessing, the removal of the 23 kDa C-terminal domain from the 60 kDa protein 
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would produce the 38 kDa protein comprising the catalytic domain and the N-terminal 
domain. Removal of the N-terminal domain would result in the 31 kDa catalytic domain 
which is close to the expected size of TcoMCA5 and TviMCA5. To confirm the domains 
assigned to these proteins, and determine the sites of autoprocessing, N-terminal 
sequencing needs to be performed in future studies. 
No significant differences in the autoprocessing patterns were observed upon 
expression of the WT and the catalytic residue mutants. Significant differences were 
only observed in the elution profiles of the purifications of the soluble and insoluble 
expression fractions. In the case of the immunoaffinity purification of the soluble 
expression fraction, only TcoMCA5C202G possessed the full length protein. The nickel 
affinity purification of both the WT and mutant MCAs, from the solubilised expression 
fraction, resulted in nickel-induced over autoprocessing, as reported in Chapter 2, for 
the WT and each mutant with the exception of TcoMCA5H147AC202G. The nickel affinity 
purification of the TcoMCA5 in which both the catalytic dyad residues had been 
mutated, resulted in no nickel-induced over processing, but rather, only the full length 
68 and 35, 28 kDa proteins were eluted. The 35 kDa protein corresponds to the 
cleavage of the N-terminal 6xHis tag as well as the C-terminal domain. Removal of the 
N-terminal domain from this protein would result in the 28 kDa protein.  
Following the isolation of total protein content from T. congolense bloodstream 
trypomastigotes, native TcoMCA5 was immunoaffinity purified as a full length 68 kDa 
and a 45 kDa protein. The removal of the C-terminal domain from the full length protein 
is thought to produce the 45 kDa protein.  
When analysed on a zymogram, both the 68 and 45 kDa protein bands of native 
TcoMCA5, and the 35 and 28 kDa protein bands of TcoMCA5H147AC202G showed gelatin 
digestion. None of the other purified MCA WT and mutant clones showed any gelatin 
digestion, which correlates with the result of only the recombinant TcoMCA5H147AC202G 
and native TcoMCA5 showing any activity towards the Z-Gly-Gly-Arg-AMC substrate. 
The native TcoMCA5 had a low reaction velocity and affinity for the fluorogenic peptide 
substrate, which may have been caused by the small amount of active catalytic domain 
as well as the active full length protein which was visualised in the zymogram. To date, 
this is the first report of MCA, or caspase, digestion of gelatin. 
The existence of a secondary catalytic Cys has been suggested due to its close 
proximity to the catalytic Cys, and its conservation in all kinetoplastid species (Szallies 
et al., 2002; Belenghi et al., 2007). It is though that the secondary catalytic Cys may 
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be required for autoprocessing or for its peptidolytic activity (Szallies et al., 2002). The 
function of this secondary catalytic Cys has been shown to rescue AtMCA9 activity 
despite S-nitrosylation of the catalytic Cys when endogenous levels of nitric oxide are 
high (Belenghi et al., 2007). The fact that the only active recombinant MCA was the 
double catalytic mutant, provides more evidence towards the existence of a secondary 
catalytic Cys which supports that report that the ‘trypsin-like’ activity of LdnMCA is not 
completely dependent on the catalytic dyad residues (Lee et al., 2007). In the type II 
MCA from Triticum aestivum, TaeMCAII, it was shown, through mutagenesis studies 
of the catalytic Cys140 and secondary catalytic Cys23, that autoprocessing was 
dependent on catalytic Cys140 and that the secondary catalytic Cys23 was essential 
for catalytic activity (Piszczek et al., 2012). However, this does not rule out the role 
played by the Cys adjacent to the catalytic Cys in peptidolysis. 
To date, there is no suitable inhibitor of MCA that could be used for active site titration. 
However, Machado et al. (2013) for TbbMCA2, Laverrière et al. (2012) for TcrMCA3 
and TcrMCA5, as well as Vercammen et al. (2006) for AtMCA9, reported kcat values 
but failed to mention the active site titrant. Klemenčič et al. (2015) used the irreversible 
inhibitor Z-Phe-Arg-FMK as an active site titrant for the recombinant orthocaspase 1 
from Microcystis aeruginosa PCC 7806, whilst Watanabe and Lam (2011) showed that 
biotin-Phe-Pro-Arg-CMK was able to abolish the ability of recombinant AtMCA4 to 
cleave Z-Gly-Arg-Arg-AMC. However, they did not use this to determine the kcat. Thus, 
until it is shown that either Z-Phe-Arg-FMK or biotin-Phe-Pro-Arg-CMK are able to 
effectively inhibit TcoMCA5, we will assume that [E]t is equal to [E]0.  
In line with literature on AtMCA4 (Vercammen et al., 2004), AtMCA9 (Watanabe and 
Lam, 2005) and TbbMCA2 (Machado et al., 2013), it was demonstrated that 
recombinant TcoMCA5H147AC202G had a preference for Arg over Lys at the P1 site. The 
tripeptide fluorogenic substrates had greater reaction velocities than their dipeptide 
counterparts. The Z-Arg-AMC had the second highest substrate affinity, but hydrolysis 
occurred at a low velocity. At the P2 site, Pro was favoured over Gly, and at the P3 site, 
Gly was preferred over Val. These findings are in line with what was reported for 
recombinant TbbMCA2 where Val, Ala, Glu, Leu and Pro are preferred at the P3 site 
and Gly, Leu, Phe, Pro, Arg and Lys at the P2 site (Machado et al., 2013).  
Despite the lower affinity of recombinant TcoMCA5H147AC202G for Z-Gly-Gly-Arg-AMC, 
(119.6 μM) compared to 25.7 μM reported for recombinant TbbMCA2, hydrolysis 
occurred at a lower velocity of 435.6 μM/s for TcoMCA5H147AC202G compared to 
3372.5 µM/s of TbbMCA2, (McLuskey et al., 2012). Purified native TcoMCA5 
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possessed a higher substrate affinity of 8.384 μM for and slower hydrolysis 
(3.917 µM/s) of Z-Gly-Gly-Arg-AMC compared to recombinant TcoMCA5H147AC202G. 
This may be due to the incomplete autoprocessing to release the active catalytic 
domain of native TcoMCA5 as seen in the zymogram when compared to that of 
recombinant TcoMCA5H147AC202G.  
The pH optimum of MCA may give insight to its localisation, and hint at which functions 
it might be involved in. The different processed forms of LmjMCA are targeted to 
different subcellular compartments (Zalila et al., 2011; Castanys-Muῆoz et al., 2012). 
The optimal peptidolytic activity for MCAs has been reported to be between pH 7 and 
9 (Vercammen et al., 2004; Moss et al., 2007; Machado et al., 2013; Wen et al., 2013), 
with the exception of AtMCA9, which has a pH optimum of 5.5. In contrast to the 
bell-shaped curve demonstrated by most MCAs, native the LdnMCA1 was active over 
a broad pH range (Lee et al., 2007). This is similar to the pH profile of recombinant 
TcoMCA5H147AC202G and native TcoMCA5 showing activity from pH 6 to 9. This board 
pH range may be due to the difference in pI values of the N-and C-terminal domains 
between the single- and multicopy MCAs which stay attached to the main protein body 
after autoprocessing (McLuskey et al., 2012). The C-terminal domains of the single 
copy MCAs are longer than those of the multicopy MCAs and have a higher pI. In 
addition, the N-terminal domains of the single copy MCAs have a higher pI than those 
of the multicopy MCAs. It is, thus, hypothesised that the increased pI of both the N- 
and C-terminal domains may contribute to the observed activity across a broad range 
of pH values.  
The most successful inhibitors of recombinant TbbMCA2 (Moss et al., 2007), 
TbbMCA4S219C (Proto et al., 2011) and native LdnMCA (Lee et al., 2007) were found 
to be leupeptin, antipain, TLCK with 70 to 90% inhibition, AEBSF and chymostatin with 
30 to 45% inhibition. Only antipain, 119.1 μM, and leupeptin, 72.99 μM, had 
measurable inhibition kinetic constants for recombinant TcoMCA5H147AC202G, equating 
to a 20% inhibition by antipain and 21% by leupeptin. Each of the other inhibitors, 
specific for different peptidase classes and at different concentrations, which were 
tested, had no effect on the activity of recombinant TcoMCA5H147AC202G. Due to the 
limited supply of native TcoMCA5, inhibitor efficacy was not determined. 
Studies have shown that a number of MCAs have an absolute calcium requirement for 
activity (Bozhkov, 2005; Moss et al., 2007; He et al., 2008; Ojha et al., 2010; Meslin et 
al., 2011; Proto et al., 2011; Laverrière et al., 2012; Wen et al., 2013). The few MCA 
exceptions which do not require calcium for activity are LmjMCA (Gonzáles et al., 
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2007), AtMCA9 (Vercammen et al., 2004) and the orthocaspase, MaeOC1 (Klemenčič 
et al., 2015). Calcium has been shown to induce an allosteric conformational change 
which functions to stabilise substrate binding (McLuskey et al., 2012). As such, the 
calcium dependency of some MCAs is suggested to function as a mechanism for the 
control of peptidolysis (Moss et al., 2007). Autoprocessing of recombinant AtMCA4 
produces four protein bands which lack the N-terminal affinity tag (Watanabe and Lam, 
2011). After the addition of calcium to the expression sample, an increase in the 
number of AtMCA4 protein bands is observed with cleavage at both the N- and 
C-termini (Watanabe and Lam, 2011).  
The calcium-induced processing of AtMCA4 is similar to what was seen in the second 
eluted fraction in the present study’s nickel-affinity purification, hence the term, 
nickel-induced over autoprocessing. Various authors have used nickel-, and in some 
cases cobalt-, affinity chromatography to purify plant, yeast, leishmanial and 
trypanosomal recombinant MCAs (Vercammen et al., 2004; Kosec et al., 2006; 
Gonzáles et al., 2007; Lee et al., 2007; Moss et al., 2007; Proto et al., 2011; Laverrière 
et al., 2012; McLuskey et al., 2012; Piszczek et al., 2012; Wong et al., 2012; Wen et 
al., 2013). However, the SDS-PAGE gels showing the elution profiles were not reported 
in these studies. 
It was demonstrated that calcium was not required for the activity of recombinant 
TcoMCA5H147AC202G. In fact, activity decreased between 6 and 7% upon the addition of 
calcium up to 10 mM, while between 10 and 25 mM no reduction in activity was 
observed. Above 25 mM, a steep decrease in activity was observed with increasing 
calcium concentration, while at 100 mM, activity was reduced by 50%.  
In an attempt to understand why nickel-induced over autoprocessing occurred during 
nickel-affinity purification, the effect of different divalent cations was investigated. The 
addition of 1 mM Cd2+ and Zn2+ as well as 10 mM Cu2+, Fe2+ and Ni2+ resulted in the 
almost complete inhibition (>95%) of recombinant TcoMCA5H147AC202G. The addition of 
other divalent cations, Cu2+, Mg2+, Mn2+ and Zn2+ failed to affect the activity of 
recombinant TbbMCA2 (Moss et al., 2007). Addition of these cations to YCA1 and the 
MCA from Lycopersicon esculentum, LesMCA1 (Wen et al., 2013), showed no effect 
when visualised on a reducing SDS-PAGE gel (Wong et al., 2012). In the case of 
recombinant AtMCA2, the addition of Mg2+ and Mn2+ increased the activity slightly as 
determined by fluorescence (Watanabe and Lam, 2011). 
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The His-select® nickel affinity resin contains approximately 20 to 40 µmol divalent 
nickel ions per 1 ml of resin. At 1 mM Ni2+, a 30% reduction in activity was measured. 
Thus, the low concentration of nickel ions in the resin would be insufficient to 
significantly reduce the activity of the recombinant TcoMCA5H147AC202G. Bearing in mind 
that the recombinant TcoMCA5H147AC202G did not require calcium to be active, it is 
hypothesised that the binding of the 6xHis tagged recombinant enzyme to the nickel 
resin immobilises it and allows for the interaction of the MCA with itself, as reported for 
LmjMCA by Casanova et al. (2015), and other MCA molecules in its immediate 
surroundings. This is in line with what was suggested by Watanabe and Lam (2011), 
that recombinant MCA may exhibit minor catalytic activity which could initiate a 
cascade reaction of peptidolytic processes. Thus, when two proenzyme molecules are 
in close proximity, one slightly active proenzyme could cleave the second molecule 
(Watanabe and Lam, 2011). This suggests that TcoMCA5 requires autoprocessing to 
release the active catalytic domain. 
This may allow for the recombinant TcoMCA5 to over autoprocess at secondary 
cleavage sites or even non-specifically. Thus, upon elution, there is no intact active 
catalytic domain (35 and 28 kDa bands), left to hydrolyse the fluorogenic peptide 
substrate. This over autoprocessing was not evident in the immunoaffinity purification 
of the recombinant WT (Section 2.3.6) and, as such, must be attributed to the nickel 
ions in the resin.  
With this information about substrate and pH preferences, the modelling of these 
proteins including their catalytic residues, secondary catalytic Cys residues and the 
identification of other residues which may play a role in peptidolysis was performed. In 
addition, docking of an inhibitor library, which was designed for TbbMCA2 by Berg et 
al. (2012), was performed for both TbbMCA5 and TviMCA5 in an attempt to identify 
suitable pharmacophores for the development of effective anti-MCA inhibitors as 
described in Chapter 4. 
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CHAPTER 4 
DOCKING STUDIES OF MCA2 INHIBITORS WITH MCA2 FROM 
T. B. BRUCEI AND MCA5 FROM T. CONGOLENSE AND 
T. VIVAX  
4  
4.1 Introduction 
Trypanosomal parasites’ ability to evade the adaptive immune response of the host, 
by the process of antigenic variation, impedes the development of vaccines against 
both human and animal Africa trypanosomosis, HAT and AAT (Morrison et al., 2009). 
Thus, prevention through vector control and screening for infections, followed by the 
appropriate treatment are the only options for the control of AT. 
The currently used trypanocides have been in use for over 60 years (Barrett et al., 
2011), with the exception of the nifurtimox-eflornithine combination therapy for HAT 
(Priotto et al., 2009). None of the currently used chemotherapies are effective against 
both T. b. gambiense and T. b. rhodesiense, as well as both the initial and final disease 
stages. Side effects of HAT chemotherapies vary in severity, with the arsenical based 
melarsoprol causing reactive encephalopathy in 5 to10% of all treated patients. It is 
uncertain how the HAT chemotherapies, pentamidine, suramin and melarsoprol 
actually kill trypanosomes (Barrett et al., 2007). It has been shown previously that the 
HAT chemotherapies suramin (Morty et al., 1998) and pentamidine (Ashall, 1990; 
Morty et al., 1998) as well as the AAT chemotherapy, diminazene aceturate (Morty et 
al., 1998) were able to inhibit the activity of TbbOPB. However, it is probable that these 
drugs have several modes of action through the interaction with multiple targets within 
the parasite (Gilbert, 2013). Due to the indiscriminate use of AAT chemotherapies and 
the length of time that the same drugs have been in use, drug resistance has been 
reported (Giordani et al., 2016). Thus, it is imperative to develop novel chemotherapies 
to treat and control AT (Field et al., 2017).  
Drug discovery is predominately based on the identification of individual targets in the 
infectious organism which can be affected by small molecule ligands, which in turn can 
be modified to achieve better affinity for the target, resulting in a more potent inhibitor 
with drug-like characteristics (Brun et al., 2011; Lounnas et al., 2013). The most 
important feature of a target for drug discovery is that it must be essential to the 
parasite, i.e. be a virulence factor. Other important features to consider is the 
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availability of structural information of the target, the target’s ability to be inhibited by 
drug-like molecules and be selective for the parasite only (Frearson et al., 2007; Wyatt 
et al., 2011; Gilbert, 2013).  
Various methodologies are being pursued in the discovery of novel chemotherapies 
(Matthews, 2015; Field et al., 2017). The target-based methodology relies on the 
identification of a target, and along with its structural information (Sliwoski et al., 2013), 
structure-based drug design (SBDD) can be used for the identification of binding 
ligands, and the subsequent optimisation of ligand structure to increase binding affinity 
(Skinner-Adams et al., 2016). The SBDD methodology is one of the most promising 
methodologies to identify suitable ligands for target proteins (Bleicher et al., 2003; 
Foloppe et al., 2006; Klebe, 2006) and involves ligand docking, pharmacophore 
design, and ligand design methods (Sliwoski et al., 2013). Together with the three 
dimensional (3D) structure of the target, the interaction energies can be calculated for 
target specific ligands by molecular docking techniques (Kalyaanamoorthy and Chen, 
2011). A positive outcome of SBDD methodologies is the identification of the important 
residues involved in binding, which can inform modification of existing ligands to 
achieve a greater binding affinity for the target (Jain et al., 2011; Blaney, 2012).  
Knowledge of the target structure and the sites of interaction with specific ligands may 
assist in the deduction of the roles played by the target (Urwyler, 2011). Cellular 
peptidases (McKerrow et al., 2008) and multiple enzymes, involved in various 
biochemical pathways, have been validated as targets for the development of novel 
chemotherapies (Field et al., 2017), with some progress being made in the 
identification of chemical inhibitors. The MCAs have been identified as virulence factors 
and are attractive targets for drug discovery due to their absence in the animal kingdom 
and their potential involvement in parasite cellular processes. Trypanosoma b. brucei 
possesses five MCA genes, of which TbbMCA2 is well characterised. The single copy 
MCA5 differs from MCA2 by the presence of a Pro-, Glu-, Tyr-rich C-terminal domain, 
which is thought to be involved in protein-protein interactions (Kay et al., 2000). The 
MCA sequences of the human and animal infective Trypanosoma spp., T. cruzi and 
Leishmania spp. show a high level of conservation (Fig. 2.1 and Appendix A3). 
A library of ligand inhibitors was designed based on the P1 site specificity of TbbMCA2 
for basic Arg and Lys residues prior to the 3D structure being solved (Berg et al., 2012). 
The ligands were tested against the purified recombinant TbbMCA2 as well as in a 
phenotypic assay using in vitro cultured T. b. brucei, T. cruzi, L. infantum and 
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P. falciparum parasites, which achieved micromolar IC50 values, between 2.1 and 
50 µM. However, ligand optimisation was not pursued further. The 3D structure of 
TbbMCA2 has since been solved (McLuskey et al., 2012), but the binding site and 
affinity of the Berg ligands for the TbbMCA2 target has not been established.  
In the present study, the validation of ligand binding, from the previously designed Berg 
library, into the active site of the 3D structure of TbbMCA2 (solved by X-ray diffraction 
(McLuskey et al., 2012)) was performed using molecular docking software. This 
software evaluates the ligand conformation, when docked in the active site by specific 
scoring functions, and modifies the torsional, translational and rotational degrees of 
freedom of the ligands, until a minimum energy is achieved (Kapetanovic, 2008; Yuriev 
et al., 2009; Huang and Zou, 2010). In addition, the affinity of the Berg ligands for the 
MCA5s from animal infective T. congolense and T. vivax, is investigated. 
4.2 Materials and Methods 
 Materials 
Commercial library: The structures of the inhibitors and fluorogenic peptide 
substrates used in literature for the characterisation of various MCAs were obtained 
from the PubChem compound database (Kim et al., 2016) and can be found in 
Appendix C1. 
Berg library: The library was obtained from The Binding Database, 
(http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_pubmed.jsp?pubmed_submit
=Search&pubmed=20167486) (Gilson et al., 2016) and can be found in Appendix C2 
The IC50 values reported in the analyses are of the ligands tested against the 
recombinant TbbMCA2 as published by Berg et al. (2012).  
TbbMCA2 3D structures: The 3D structures, solved using X-ray diffraction, 
ofTbbMCA2 with the C213G mutant with, 4AF8 (1.4 Å), and without a Sm3+ ion, 4AFP 
(2.1 Å), and the C213A mutant with, 4AFV (1.5 Å), and without a calcium soak, 4AFR 
(1.6 Å), were obtained from the RCSB Protein Data Bank (www.rcsb.org)(Berman et 
al., 2000) as submitted by McLuskey et al. (2012). 
Discovery Studio docking software: The Centre for High Performance Computing 
(Cape Town, South Africa) is acknowledged for the provision of the computational 
resources necessary to conduct this work. 
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 Homology modelling 
The most reliable computational method for predicting protein structure from its 
sequence is homology modelling (Bordoli et al., 2008). This involves the identification 
of templates using a BLAST search, followed by the alignment and superimposing of 
the template to the query sequence using both structure and sequence alignment 
methods. The end result is a 3D model of the query protein.  
The SwissModel software (Biasini et al., 2014) was used to create 3D models for 
TcoMCA5 and TviMCA5. Together with multiple sequence alignment, the scoring 
functions, Qmean and GMQE (Global Model Quality Estimation), indicators of the 
reliability of the modelled protein, were reported (Benkert et al., 2009; Benkert et al., 
2011). 
The Ramachandran plots for TcoMCA5 and TviMCA5 were generated by Discovery 
Studio (Dassault Systèmes BIOVIA), and compared to those of TbbMCA2 reported in 
the Protein Data Bank by McLuskey et al. (2012). The quality of the generated models 
was verified using the ProSA-web protein structure analysis software whereby an 
overall quality score for a query structure is reported (https://prosa.services.came.sbg 
.ac.at/prosa.php) (Sippl, 1993; Wiederstein and Sippl, 2007). 
 Identification of residues involved in catalysis 
The residues which are involved in catalysis and calcium binding, in addition to the 
gatekeeper and latch residues, which function in the removal of the N-terminal domain 
from across the active site, were highlighted in Appendix A3 and listed in Table 4.1. 
The 3D structures, solved by X-ray diffraction, of TbbMCA2, 4AF8 and 4AFP had a 
catalytic Cys mutation at residue 213 to Gly, and in 4AFV and 4AFR to an Ala. This 
residue in each of the four TbbMCA2 models was changed back to Cys to best simulate 
the environment in the active site. 
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Table 4.1: Identification of residues in TbbMCA2, TcoMCA5 and TviMCA5 which 
are involved in catalysis. 
 TbbMCA2 TcoMCA5 and TviMCA5 
Gatekeeper Tyr31 Tyr19 
Latch/S1 binding Ser156 Ser145 
S1 binding Asp95, Asp211 Asp84, Asp200 
Calcium binding 
Asp173, Asp189, 
Asp190, Asp220 
Asp162, Asp178,  
Asp179, Asp209 
Secondary catalytic Cys Cys92 Cys81 
Catalytic dyad 
His158 His147 
Cys213 Cys202 
Adjacent Cys Cys212 Cys201 
 
 Protein and ligand preparation 
The TbbMCA2 models, 4AF8, 4AFP, 4AFV, 4AFR, and the homology modelled 
TcoMCA5 and TviMCA5, were prepared using the ‘Prepare Protein’ protocol from 
Discovery Studio (Dassault Systèmes BIOVIA). The protocol allowed for the 
optimisation of side chain conformation, the retention or removal of water molecules, 
the modeling of any missing loops and side chain atoms, and the protonation of the 
structure by the prediction of the site pKas at the optimum pH of TbbMCA2, 7.7, as 
determined by Machado et al. (2013). To assist in differentiation between the different 
protein models, the structures were coloured differently, 4AF8 (pink), 4AFP (white), 
4AFV (orange), 4AFR (blue), TcoMCA5 (purple) and TviMCA5 (turquoise). 
The structural water molecules are usually located in deep pockets of the protein 
‘receptor’ structure and mediate the formation of hydrogen bonds between the ligand 
and receptor binding site (Bissantz et al., 2010). Strongly bound water molecules are 
often conserved across multiple crystallographic structures (Ferreira et al., 2015) as is 
evident for TbbMCA2, where three conserved water molecules line the bottom of the 
active site in all four 3D structures (McLuskey et al., 2012). As such, each of the 
proteins were prepared in four ways. Firstly, with all the water molecules present; 
secondly, with all water molecules removed; thirdly, only the conserved water 
molecules present; and finally, from the prepared structure with all water molecules 
present, all but the conserved water molecules were removed. These preparations will 
be referred to as ‘all water’, ‘no water’, ‘conserved water, prepared’, and ‘conserved 
water without preparation’ for simplicity.  
The ligand inhibitors comprising the Berg library, as well as the substrates and 
inhibitors comprising the commercial library, were prepared using the ‘Prepare 
Ligands’ protocol from Discovery Studio (Dassault Systèmes BIOVIA). The protocol 
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allows for the generation of multiple tautomers and stereoisomers for each ligand 
molecule, the correction of valencies and formal charges associated with each 
functional group. Finally, the generated 3D conformation of each inhibitor, substrate 
and ligand was prepared for use in docking studies.  
 Binding site identification 
The binding sites were defined using the receptor cavity protocol using Discovery 
Studio (Dassault Systèmes BIOVIA). This method is based on an ‘eraser’ algorithm 
which functions to remove all points which are not in contact with the protein ‘receptor’ 
(Venkatachalam et al., 2003). The binding site which was identified within the active 
site cavity, comprising the catalytic dyad, secondary and adjacent Cys residues as well 
as the S1 binding residues, was selected for docking. 
Upon the addition of calcium, a conformational change occurs in TbbMCA2 which 
functions to remove the N-terminal domain from across the active site (McLuskey et 
al., 2012). This involves the S1 binding residue closest to the catalytic His residue, 
which functions as a latch, and the gatekeeper Tyr residue in the N-terminal domain 
(McLuskey et al., 2012). Taking this into consideration, some of the N-terminal domain 
was removed, residues 1 to 35 for TbbMCA2 and residues 1 to 25 for MCA5, the 
valence corrected, subjected to the ‘Prepare Protein’ protocol with each of the four 
different water preparations, followed by the re-evaluation of the binding sites. This 
final structure was used for all subsequent docking studies. 
 CDocker 
Protein ‘receptors’ and ligands are flexible and may occupy multiple conformations in 
solution. In addition, upon ligand binding, the protein ‘receptor’ may undergo a 
conformational change. Most docking algorithms function by the docking of flexible 
ligands into the rigid binding site of the protein ‘receptor’. Another method, which is 
more realistic but requires more CPU time, is flexible docking whereby various protein 
‘receptor’ conformations are used for docking with flexible ligand molecules. The 
CDocker algorithm was used in this study, which, through the use of random initial 
ligand placement and CHARMm forcefield, docks ligand molecules into the defined 
binding site of the protein ‘receptors’. Using the default settings in the CDocker protocol 
from Discovery Studio (Dassault Systèmes BIOVIA), the ligands from both the Berg 
and the commercial libraries where docked into the binding site of the 3D structures of 
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TbbMCA2 4AF8, 4AFP, 4AFV and 4AFR as well as the homology modelled structure 
of both TcoMCA5 and TviMCA5.  
 Common feature pharmacophore  
A pharmacophore is defined as the group of steric and electronic features which is 
required for the activation or inhibition of a receptor. A group of structurally diverse 
ligands are able to bind to a common site on a receptor should they share a common 
pharmacophore. Novel ligands targeting specific sites can be designed using these 
pharmacophore models. A common feature pharmacophore was generated using the 
same named protocol from Discovery Studio (Dassault Systèmes BIOVIA). This was 
achieved using the ligands which had the best CDocker interaction energies with 
corresponding low IC50 values and docked in a similar spatial position. 
4.3 Results 
 TbbMCA2 from the Protein Data Bank 
To date the only 3D structures of MCAs, solved by X-ray diffraction, are YCA1 from 
Saccharomyces cerevisiae, 4F6P and 4F6O (Wong et al., 2012), and TbbMCA2, 4AF8, 
4AFP, 4AFV and 4AFR (McLuskey et al., 2012). 
The TbbMCA2 peptidase is dependent on calcium for activation, and in 4AF8, 
samarium was used to define the calcium binding site (McLuskey et al., 2012). The 
Sm3+ ion coordinates four Asp residues and two water molecules (Fig. 4.1, panel A). 
Three structural water molecules were observed to be conserved between the four 3D 
structures, solved by X-ray diffraction, of TbbMCA2 and were found to line the bottom 
of the active site pocket (Fig. 4.1, panel B). These molecules interact with the catalytic 
His158, the S1 binding residue Asp211, the secondary catalytic Cys92 as well as with 
Gly157 and Gly159. The oxyanion hole of the caspases is formed by the backbone 
nitogen atoms of the catalytic Cys and the conserved Gly238, which is adjacent the 
catalytic His (Walker et al., 1994; Fuentes-Prior and Salvesen, 2004). The catalytic His 
of the MCAs is adjacent to a Gly residue which is conserved in all the kinetoplastid 
MCAs (Appendix A3). As such, Gly159 may form part of the oxyanion hole of 
TbbMCA2.  
Residues 269 to 275 form a disordered region which corresponds to the ‘280-loop’. 
Due to the disorder, this loop was not solved in the crystal structure (Fig. 4.1, panel C 
and D). Upon soaking TbbMCA2 4AFV crystals in calcium, a shift in position of the 
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‘280-loop’ was observed (Fig. 4.1, panels D and E). As a result, a 5.6 Å, 110° shift 
occurs at the Cα position of Gly280 caused by the change in direction at the Cα position 
of Ala279 (Fig. 4.1, panel F) as reported by McLuskey et al. (2012). 
 
Figure 4.1: Structural features of the 3D structures of TbbMCA2 for docking. (A) 
Water molecules and conserved Asp residues interacting with Sm3+ ion (teal) in TbbMCA2 
4AFP. (B) Interactions of the three conserved water molecules with the residues in the active 
site of TbbMCA2. Overlay of the 3D structures, solved by X-ray diffraction, of TbbMCA2 4AF8 
(pink), 4AFP (white), 4AFV (orange) and 4AFR (blue) (McLuskey et al., 2012) (C) with and (D) 
without all the water molecules. The C-terminal of the ‘280-loop’ is highlighted in (D) and the 
magnified view shown in E, F and G. Magnification of the ‘280-loop’ (E) ribbon structure, (F) 
atomic structure and (G) comparison change in direction of 4AFV and 4AFR due to calcium 
soaking. Structures were obtained from the Protein Data Bank (Berman et al., 2000), visualised 
and analysed using Discovery Studio (Dassault Systèmes BIOVIA). 
 
 Homology modelling 
The SwissModel alignment of TcoMCA5 and TviMCA5 resulted in a 48 to 49% 
sequence identity to the four 3D structures, solved by X-ray diffraction, of TbbMCA2. 
The results from the CDocker analysis of the four TbbMCA2 models, together with the 
four water preparations, with both the commercial and Berg libraries, indicated that 
4AF8 demonstrated the best ligand fitting (Section 4.3.5.1). As a result, both TcoMCA5 
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and TviMCA5 were modelled using TbbMCA2 4AF8 and superimposed onto the 
template (Fig. 4.2, panel A). The generated alignment from SwissModel is 
accompanied by Qmean scores which are represented in blue indicating a high-quality 
prediction, and in orange/red indicating a low-quality prediction (Fig. 4.2, panels B and 
C). The alignments are enlarged in Appendix C3. 
The final 3D structures of TcoMCA5 and TviMCA5 were validated using the protein 
structure analysis software, ProSA-web (Fig. 4.3) (Wiederstein and Sippl, 2007). The 
Z-score indicates the overall quality of the protein model and shows that the scores for 
the 3D structure, solved by X-ray diffraction, of TbbMCA2 (-7.93) and homology 
modelled TcoMCA5 (-9.12) and TviMCA5 (-9.12) are within the range of scores (-8 to 
-12) found for native proteins of a similar size as determined by X-ray diffraction.  
The Ramachandran plots for both TcoMCA5 and TviMCA5 are very similar to that of 
TbbMCA2 4AF8, whose structure was solved at a resolution of 1.4 Å using X-ray 
diffraction (Fig. 4.4). Considering all the data from Fig. 4.2 to 4.4, the homology models 
generated for TcoMCA5 and TviMCA5 were suitable for docking studies with the Berg 
and commercial libraries.  
 Protein preparation 
The N-terminal domain of TbbMCA2 is a well-ordered loop, consisting of 70 residues, 
which encircles the main body, forming 32 hydrogen bonds and eight salt bridges, and 
crosses over the active site cavity (McLuskey et al., 2012) (Fig. 4.5, panel A). The 
domain crosses over the active site cavity at Tyr31 (Fig. 4.5, panel B). A 
calcium-induced conformational change occurs in TbbMCA2 whereby it is suggested 
that the N-terminal domain is removed from the entrance of the active site using Tyr31 
as the gatekeeper, together with Ser156 as the latch (McLuskey et al., 2012). As such, 
residues 1 to 35 for TbbMCA2 and 1 to 25 for both TcoMCA5 and TviMCA5 were 
deleted to mimic the conformational change and allow access into the active site 
(Fig. 4.5, panel C). To validate the removal of the prodomain, binding site identification 
was carried out with and without the N-terminal domain. No binding site was identified 
at the active site while the N-terminal domain was present, but upon its removal, a 
binding site was identified in the same location of the active site.  
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Figure 4.2: Homology modelling of TcoMCA5 and TviMCA5. Using TbbMCA2 4AF8 
(pink) as the template, the 3D structures of TcoMCA5 (purple) and TviMCA5 (turquoise) were 
(A) modelled using SwissModel and superimposed. The alignment of the (B) TcoMCA5 and (C) 
TviMCA5 sequences to the TbbMCA2 4AF8 template is shown with the Qmean scores indicated 
in blue (high quality prediction) and orange/red (low quality prediction). (See Appendix C3 for 
enlarged versions of panels B and C). 
 
 
Figure 4.3: Z-score plot as an indication of model quality. The PDB files of the 
resulting (A) TbbMCA2 4AF8 and homology modelled (B) TcoMCA5 and (C) TviMCA5 
structures, were individually uploaded into the ProSA software for evaluation (Wiederstein and 
Sippl, 2007). 
 
 
Figure 4.4: Ramachandran plots of TbbMCA2 4AF8 and modelled TcoMCA5 and 
TviMCA5. The plots for (A) TbbMCA2 4AF8 was obtained from the PDB (Berman et al., 2000) 
(McLuskey et al., 2012) and those for homology modelled (B) TcoMCA5 and (C) TviMCA5 were 
generated using the Discovery Studio software (Dassault Systèmes BIOVIA). 
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Figure 4.5: Interactions of the N-terminal domain with the main body of TbbMCA2 
4AF8. (A) The N-terminal domain (yellow) encircles the main body of TbbMCA2 4AF8 (pink), 
(B) and blocks access to the active site using Tyr31. (C) After removal of residues 1 to 35, the 
active site is accessible to ligands, substrates and inhibitors. 
 
 Active site identification 
After the deletion of the N-terminal domain residues of TbbMCA2 (1 to 35) and MCA5 
(1 to 25), the binding sites were identified by the cavity method using the Discovery 
Studio protocol (Dassault Systèmes BIOVIA).  
The binding site used for docking studies needs to be located at the active site cavity 
which contains the catalytic dyad, S1 binding, adjacent and secondary catalytic Cys 
residues (Fig. 4.6, panel A) as well as the three conserved water molecules (Fig. 4.6, 
panel B). The spatial positions of these residues are similar and align well between 
TbbMCA2, TcoMCA5 and TviMCA5. 
The binding sites, which corresponded to the location of the active site in each of the 
four TbbMCA2 models, the homology modelled TcoMCA5 and TviMCA5, and in each 
of the four water preparations, were selected and detailed in Table 4.2. The surface of 
the active site of TbbMCA2 4AF8 in the four water preparations is depicted in Fig. 4.7. 
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Figure 4.6: Identification of the active site residues of TbbMCA2, TcoMCA5 and 
TviMCA5. (A) The residues involved in calcium binding, in substrate binding and catalysis are 
highlighted for TbbMCA2 4AF8 (pink), TcoMCA5 (purple) and TviMCA5 (turquoise). (B) 
Enlarged conserved water molecules lining the bottom of the active site. 
 
The ‘all water’ and ‘conserved water without preparation’ preparations of TbbMCA2 
4AF8 yielded the same structure (Fig. 4.8, panel A) with identical binding site positions 
(Table 4.2), hence the appearance of a single structure. A noticeable difference was 
observed between the ‘conserved water without preparation’ and ‘no water’ (panel B) 
as well as with ‘conserved water with preparation’ (panel C) where the location of the 
loop C-terminal to Cys213 varies. Hence, two different coloured structures are 
observed in panels B and C. The coordinates of the binding sites of the ‘no water’ and 
‘conserved water prepared’ preparations are different from the ‘all water’ and 
‘conserved water without preparation’. Similar structural features were obtained for 
both TcoMCA5 and TviMCA5. 
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Table 4.2: Binding site spheres, in which the catalytically important residues are found, to be used for docking studies. 
Protein (PDB ID) 
‘All water’ ‘No water’ ‘Conserved water, prepared’ ‘Conserved water without preparation’ 
Radius  
(Å) 
Coordinates (Å) Radius  
(Å) 
Coordinates (Å) Radius  
(Å) 
Coordinates (Å) Radius  
(Å) 
Coordinates (Å) 
X Y Z X Y Z X Y Z X Y Z 
TbbMCA2 (4AF8) 8 55.57 43.89 -5.72 6 60.1 43.67 -10.71 6 59.88 42.36 -8.63 8 58.57 43.89 -5.72 
TbbMCA2 (4AFP) 6 59.55 42.19 -7.04 6 60.13 43.19 -10.39 6 59.86 41.86 -8.47 6 59.55 42.19 -7.042 
TbbMCA2 (4AFV) 8 64.02 47.21 -12.14 10 57.78 43.41 -15.65 6 60.09 41.85 -8.40 8 64.02 47.21 -12.14 
TbbMCA2 (4AFR) 6 60.64 44.01 -8.48 10 57.52 43.33 -17.14 6 60.02 42.14 -8.76 6 60.64 44.01 -8.48 
TcoMCA5 8.6 58.74 43.88 -5.62 6 60.05 43.61 -10.34 6 60.01 43.23 -8.93 6 60.01 43.54 -9.33 
TviMCA5 9 57.59 43.32 5.64 6 60.04 43.60 -10.84 6 57.71 41.92 -8.50 6 59.80 42.02 -8.45 
 
 
Figure 4.7: Active site surface of TbbMCA2 4AF8 after deletion of residues 1 to 35 of the N-terminal domain. The surface of the 
active site cavity was determined in the various water preparations, (A) ‘all water’, (B) ‘no water’, (C) ‘conserved water, prepared’ and (D) ‘conserved 
water without preparation’. The atomic structures of the catalytic dyad (His158, Cys213), adjacent Cys (Cys212), secondary catalytic Cys (Cys92) and 
S1 binding residues (Asp95, Ser156 and Asp211) are represented in a stick configuration.
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Figure 4.8: Structural differences between the different water preparations of 
TbbMCA2 4AF8. Overlay of (A) ‘all water’ (light orange) and ‘conserved water without 
preparation’ (pink), (B) ‘no water’ (light green) and ‘conserved water without preparation’ (pink), 
and (C) ‘conserved water prepared’ (blue-grey) and ‘conserved water without preparation’ 
(pink). 
 
 CDocker analysis 
The substrates and inhibitors of the commercial library were shown in literature to be 
cleaved by MCAs and inhibit the MCAs, respectively. Together with the ligands in the 
Berg library, which were designed based on the P1 specificity of TbbMCA2, the 
substrates and inhibitors of the commercial library were docked into the active site of 
TbbMCA2 4AF8, 4AFP, 4AFV, 4AFR, TcoMCA5 and TviMCA5, in each of the four 
water preparations.  
The CDocker analysis predicts the interaction energy associated with each ligand 
conformation and which ligands are docked in the specified binding site (Kapetanovic, 
2008). Ligands with a high -CDocker interaction energy (kcal/mol) possess a higher 
binding affinity for the protein ‘receptor’ than those with lower energies. Multiple poses 
for each ligand are generated, with only the pose with the highest -CDocker interaction 
energy being reported. The IC50 values reported in the analyses are of the ligands 
tested against recombinant TbbMCA2 as published by Berg et al. (2012). The 
correlation of -CDocker interaction energies of the ligands, substrates and inhibitors 
docked into the active site of TbbMCA2, TcoMCA5 and TviMCA5 together with the IC50 
of the Berg ligands are given in Appendix C4. 
 TbbMCA2 
The -CDocker interaction energies for each ligand/inhibitor/substrate, which were 
successfully docked into the active site of TbbMCA2, from the commercial and Berg 
libraries are reported in Table 4.3 and 4.4, respectively. Since the substrates and 
inhibitors of the commercial library have been shown experimentally in literature to be 
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cleaved by MCAs, or inhibit the MCAs, these results were used to select the best water 
preparation for the analysis of the docking results using the Berg library. 
The 3D structure, solved by X-ray diffraction at a resolution of 1.4 Å, of TbbMCA2 4AF8 
had the best resolution compared to the other three TbbMCA2 structures, 1.6 and 
2.1 Å. Overall, more of the ligands from the commercial and Berg libraries were docked 
into the active site of 4AF8, with higher -CDocker interaction energies, than compared 
to those docked in the other TbbMCA2 structures. 
Out of the four water preparations of TbbMCA2 4AF8, only the ‘all water’ and 
‘conserved water without preparation’ preparations, docked all the ligands with higher 
-CDocker interaction energies than the other two water preparations. This may be a 
direct effect of the difference in structure as shown in Fig. 4.8. As such, only the results 
for the ‘all water’ preparation will be analysed. 
Antipain had the highest -CDocker interaction energy, 73 kcal/mol, of the four 
inhibitors, followed by chymostatin, 65 kcal/mol, and leupeptin, 53 kcal/mol. 
Low -CDocker interaction energies of 38 and 28 kcal/mol were obtained for TLCK and 
AEBSF, respectively. 
The fluorogenic peptide substrates which had the highest affinity for TbbMCA2 4AF8 
were Boc-Val-Pro-Arg-AMC, 3-Methoxysuccinyl (MeOSuc)-Ala-Phe-Lys-AMC and Z-
Gly-Gly-Arg-AMC with -CDocker interaction energies of 78, 71 and 69 kcal/mol, 
respectively. The remaining substrates had -CDocker interaction energies between 68 
and 61 kcal/mol. The substrates used as active site inhibitors, Phe-Arg-FMK 
(Klemenčič et al., 2015) and Phe-Pro-Arg-chloromethylketone (CMK) (Watanabe and 
Lam, 2011) had the lowest -CDocker interaction energies of 59 and 54 kcal/mol, clearly 
different from the fluorogenic peptide substrates. 
The Berg ligands with low IC50 values generally had higher -CDocker interaction 
energies than those with IC50 values above 100 µM. This was more evident for the 
‘conserved water without preparation’ when compared to the ‘all water’ preparation 
model. 
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Table 4.3: The -CDocker interaction energies for the inhibitors and substrates of the commercial library which were successfully 
docked into the active site, of the four water preparations, of TbbMCA2 4AF8. 
‘All water’ ‘No water’ 
‘Conserved water, 
prepared’ 
‘Conserved water without preparation’ 
Ligand 
Interact. 
energya 
Ligand 
Interact. 
energya 
Ligand 
Interact. 
energya 
Ligand 
Interact. 
energya 
Boc-Val-Pro-Arg-AMC 77.9998 TLCK 46.1507 TLCK 39.3022 Antipain 73.4214 
Antipain 73.8336 AEBSF 37.7071 AEBSF 30.6874 MeOSuc-Ala-Phe-Lys-AMC 65.2483 
MeOSuc-Ala-Phe-Lys-AMC 71.4556 Phe-Pro-Arg-CMK 31.8880    Z-Gly-Gly-Arg-AMC 64.1411 
Z-Gly-Gly-Arg-AMC 69.4528       Val-Leu-Arg-AMC 63.8513 
Val-Leu-Lys-AMC 68.0078       Chymostatin 63.1609 
Val-Leu-Arg-AMC 66.7398       Boc-Val-Pro-Arg-AMC 62.8661 
Chymostatin 65.4091       Val-Leu-Lys-AMC 61.9325 
Phe-Arg-FMK 59.5988       Phe-Arg-FMK 54.6182 
Phe-Pro-Arg-CMK 54.1384       Phe-Pro-Arg-CMK 51.2296 
Leupeptin 53.6793       Leupeptin 50.5274 
TLCK 38.8368       TLCK 39.1133 
AEBSF 28.0329       AEBSF 29.0082 
aThe interaction energy is reported as kcal/mol. 
Substrates and inhibitors were individually colour-coded for ease of interpretation of data.  
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Table 4.4: The -CDocker interaction energies for the ligands of the Berg library which were successfully docked into the active 
site, of the four water preparations, of TbbMCA2 4AF8.  
‘All water’ ‘No water’ ‘Conserved water, prepared’ 
‘Conserved water without 
preparation’ 
Ligand 
name 
IC50 (µM)b 
Interact. 
energya 
Ligand IC50 (µM)b 
Interact. 
energya 
Ligand 
name 
IC50 (µM)b 
Interact. 
energya 
Ligand 
name 
IC50 (µM)b 
Interact. 
energya 
777 1.4 57.3327 297 1.6 49.4469 773 2.2 44.5092 777 1.4 55.1019 
778 1.1 56.6135 772 62.0 47.5740 297 1.6 41.9132 778 1.1 54.6875 
775 3.9 49.0600 773 2.2 46.6269 779 1.9 40.8882 774 38.4 45.0717 
772 62.0 48.7148 781 >100 46.1817 772 62.0 39.6582 775 3.9 44.8550 
776 4.0 48.6662 774 38.4 43.7821 771 0.6 35.9593 776 4.0 44.6914 
771 0.6 48.5409 776 4.0 42.7313 765 >100 35.1611 772 62.0 44.6729 
770 >100 48.5346 779 2 42.2552 781 >100 34.9746 771 0.6 44.4879 
774 38.4 48.2427 767 >100 41.7179 782 >100 33.2580 297 1.6 43.8606 
769 >100 46.8011 771 0.6 41.6451 780 >100 32.6337 770 >100 43.7727 
297 1.6 46.5066 782 >100 41.3783 767 >100 31.2158 773 2.2 42.3363 
773 2.2 42.8317 768 >100 40.9039 766 >100 30.4471 781 >100 40.2067 
767 100 39.9584 765 >100 40.7637    779 1.9 40.1646 
779 1.9 38.9667 766 >100 38.8653    769 >100 38.3082 
781 >100 38.3100 775 3.9 35.0394    768 >100 33.9735 
768 >100 37.5578 780 >100 34.7704    765 >100 33.4806 
766 >100 37.3704       767 >100 33.0304 
780 >100 36.3873       780 >100 32.5654 
765 >100 34.9376       766 >100 32.5549 
782 >100 32.5698       782 >100 28.7093 
aThe interaction energy is reported as kcal/mol. 
bThe IC50 values were obtained from Berg et al. (2012). 
Ligands were individually colour-coded for ease of interpretation of data. 
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The commercial inhibitor, antipain, had the highest -CDocker interaction energy and 
has been shown to inhibit recombinant TbbMCA2 (Moss et al., 2007) and recombinant 
TcoMCA5 in the results reported in the Chapter 3. The spatial position of the inhibitor, 
substrate and ligand with the highest -CDocker interaction energies in the active site 
of TbbMCA2 4AF8, with the ‘all water’ preparation, is shown in Fig. 4.9. The 2D views 
and residue interactions are reported in Appendix C5. Despite the Z-Gly-Gly-Arg-AMC 
substrate having the third highest -CDocker interaction energy, it is the most commonly 
used substrate for the characterisation of MCAs in the published literature, and was 
used in the work described in Chapter 3 for the characterisation of recombinant 
TcoMCA5. The docked position of Z-Gly-Gly-Arg-AMC and the Berg ligand 777, which 
has a low IC50 value (1.4 μM) is shown in Fig. 4.9. 
 
Figure 4.9: The commercial inhibitor, substrate and Berg ligand which had the 
highest binding affinity, at the active site, for TbbMCA2 4AF8, prepared with ‘all 
water.’ The 3D interactions of the (A) commercial inhibitor, antipain, (B) commercial substrate, 
Z-Gly-Aly-Arg-AMC and (C) Berg ligand, 777, docked in the active site of TbbMCA2 4AF8.  
 
 TcoMCA5 and TviMCA5 
The docking of the commercial and Berg libraries into the active sites of TcoMCA5 and 
TviMCA5, which had been modelled on TbbMCA2 4AF8, using all four water 
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preparations, showed a similar result to what was seen for TbbMCA2 4AF8. Thus, only 
the results from the ‘all water’ preparation of TcoMCA5 and TviMCA5 is reported here.  
The -CDocker interaction energies for both the docked commercial and Berg ligands 
were slightly lower than those of TbbMCA2 4AF8, but overall, were very similar. (Table 
4.5). Antipain was the best docked inhibitor, followed by chymostatin, with a 15 kcal/mol 
difference between antipain and leupeptin. Lower -CDocker interaction energy, 
between 40 to 23 kcal/mol was observed between TcoMCA5 and TviMCA5 with TLCK 
and AEBSF.  
Similar to TbbMCA2 4AF8, the best docked substrate onto TcoMCA5 was MeOSuc-
Ala-Phe-Lys-AMC and Boc-Val-Pro-Arg-AMC for TviMCA5. The Z-Gly-Gly-Arg-AMC 
substrate had the third best -CDocker interaction energy for TcoMCA5 and the fifth 
best for TviMCA5, with a 6 and 9 kcal/mol difference from that of the best docked 
substrate. The substrates reported in literature as active site inhibitors, Phe-Arg-FMK 
(Klemenčič et al., 2015) and Phe-Pro-Arg-CMK (Watanabe and Lam, 2011) docked 
onto TcoMCA5 and TviMCA5 and had almost the exact same -CDocker interaction 
energies to those docked onto TbbMCA2 4AF8 (Table 4.3).  
Based on the results for TbbMCA2 4AF8, the position of antipain, Z-Gly-Gly-Arg-AMC 
and Berg ligand 777, which docked with either the highest or second highest -CDocker 
interaction energies in the active site of TcoMCA5 and TviMCA5, with the ‘all water’ 
preparation, is shown in Fig. 4.10. The 2D views and residue interactions are reported 
in Appendix C6. 
Overall, similar -CDocker interaction energies were obtained for the ligands of the Berg 
library when docked into the active sites of TbbMCA2 4AF8, TcoMCA5 and TviMCA5 
with the ‘all water’ preparation. The ligands which had the highest -CDocker interaction 
energies were 777 and 778. The ligands with high IC50 values (>100 µM), 770 and 769, 
had higher -CDocker interaction energies than 779 which had a low IC50 value (1.9 µM) 
in the above three protein ‘receptor’ models. 
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Table 4.5: The -CDocker interaction energies for the inhibitors and substrates from the commercial library, and ligands from the 
Berg library, which were successfully docked into the active site, of the ‘all water’ preparation, of TcoMCA5 and TviMCA5. 
Commercial library Berg library 
TcoMCA5 TviMCA5 TcoMCA5 TviMCA5 
Ligand name 
Interact. 
energya 
Ligand name 
Interact. 
energya 
Ligand 
name 
IC50 
(µM)b 
Interact. 
energya 
Ligand 
name 
IC50 
(µM)b 
Interact. 
energya 
Antipain 69.3579 Boc-Val-Arg-Pro-Arg-AMC 69.0750 777 1.4 56.7501 777 1.4 58.0676 
MeOSuc-Ala-Phe-Lys-AMC 69.1403 Antipain 69.0354 778 1.1 56.5844 778 1.1 54.8880 
Chymostatin 68.7365 MeOSuc-Ala-Phe-Lys-AMC 68.1931 772 62.0 50.7902 775 3.9 50.0416 
Val-Leu-Arg-AMC 65.779 Val-Leu-Arg-AMC 66.5845 770 >100 50.7726 776 4.0 49.9786 
Z-Gly-Gly-Arg-AMC 63.9770 Chymostatin 66.3283 774 38.4 49.4546 770 >100 48.1789 
Boc-Val-Arg-Pro-Arg-AMC 61.7294 Val-Leu-Lys-AMC 62.1262 775 3.9 49.1105 772 62.0 47.8103 
Phe-Arg-FMK 59.6302 Z-Gly-Gly-Arg-AMC 60.4820 771 0.6 48.7838 774 38.4 47.6948 
Val-Leu-Lys-AMC 59.2276 Phe-Arg-FMK 57.5471 776 4.0 47.5925 771 0.6 46.8969 
Leupeptin 54.5873 Phe-Pro-Arg-CMK 54.9999 769 >100 46.1706 773 2.2 45.5624 
Phe-Pro-Arg-CMK 54.2661 Leupeptin 54.2910 297 1.6 46.0371 769 >100 43.6866 
TLCK 40.0068 TLCK 37.2190 773 2.2 45.9522 297 1.6 43.2771 
AEBSF 25.8711 AEBSF 23.9091 768 >100 43.6187 766 >100 39.1067 
    781 >100 41.7428 782 >100 38.2214 
    767 >100 40.1867 779 1.9 38.0768 
    766 >100 39.6047 780 >100 37.5859 
    779 1.9 39.3659 765 >100 37.5521 
    765 >100 38.0949 768 >100 37.1429 
    780 >100 35.7624 767 >100 36.6743 
    782 >100 34.9732 781 >100 36.2713 
aThe interaction energy is reported as kcal/mol. 
bThe IC50 values were obtained from Berg et al. (2012). 
Substrates, inhibitors and ligands were individually colour-coded for ease of interpretation of data.
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Figure 4.10: The inhibitor, substrate and Berg ligand which had the highest 
binding affinity at the active site for TcoMCA5 and TviMCA5, prepared with ‘all 
water’. The 3D and 2D interactions of the commercial inhibitor, antipain, commercial substrate, 
Z-Gly-Gly-Arg-AMC and Berg ligand, 777 docked in the active site of TcoMCA5 and TviMCA5. 
 
 Ligand interactions 
Overall, more interactions between the ligands and the MCA ‘receptor’ were formed 
between the inhibitors and substrates of the commercial library than what was formed 
with the ligands from the Berg library (Fig. 4.11). Prominent residues, with which the 
library ligands formed hydrogen bonds (panel A) with TbbMCA2 4AF8 (equivalent 
residues in TcoMCA5 and TviMCA5 in brackets) were Ser90 (Ser79), Asp95 (Asp84), 
Gly279 (Val268), Ala280 (Pro269), Gly281 (Gly270) and Lys314 (Lys304).  
Charge interactions (panel B) of the residues of TbbMCA2 4AF8 (equivalent residues 
in TcoMCA5 and TviMCA5 in brackets) were most prominently formed with Asp95 
(Asp84) with the commercial ligands. Fewer interactions were formed with Asp84 of 
TcoMCA5 and TviMCA5, but an increase in Lys303 and Tyr305 interactions was 
evident (Lys314 and Phe316 in TbbMCA2).  
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A noticeable difference in the number of hydrophobic interactions between the MCA 
‘receptors’ and the ligands were observed, with more interactions being formed with 
those of the commercial library than with those of the Berg library (panel C). Residues 
of the TcoMCA5 and TviMCA5 (equivalent residues in TbbMCA2 in brackets) involved 
were Leu89 (Leu78), secondary catalytic Cys81 (Cys92), catalytic Cys202 (Cys213), 
Val268, Pro269 (TcoMCA5 only) and Tyr305 (Phe316). 
Pi-alkyl and Pi-sulfur interactions were more prominent in TcoMCA5 and TviMCA5 than 
in TbbMCA2 4AF8 (equivalent residues in TbbMCA2 in brackets), with interactions 
occurring at the secondary catalytic Cys81 (Cys92), and the catalytic Cys202 (Cys213) 
(panel D).  
The interactions formed, type and frequency, between ligand and ‘receptor’ highlight 
key features to take into account when considering the design of novel inhibitors or 
adjustment of the current ligands to improve binding affinity when combined with a 
common feature pharmacophore. 
 
Figure 4.11: Interactions of inhibitors, substrates and ligands of the commercial 
and Berg libraries with TbbMCA2 4AF8, TcoMCA5 and TviMCA5. The interaction 
frequency between residues and ligands in terms of (A) hydrogen bond formation, (B) charged 
interactions, (C) hydrophobic interactions and (D) Pi-alkyl and Pi-sulfur. 
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 Common feature pharmacophore 
To facilitate the selection of inhibitors/substrates/ligands to use in the generation of a 
common feature pharmacophore, the -CDocker interaction energies as well as the 
adopted conformations of the ligands in the active site were considered. Since the 
inhibitors and substrates from the commercial library have been successfully used in 
literature for the characterisation of various MCAs, the best aligned substrates, with as 
high -CDocker interaction energies as possible, were used. The commercial inhibitors 
were not used for the generation of the pharmacophore as they adopted very different 
conformations in the active site, and as such, did not align reasonably well, when 
compared to the commercial substrates and Berg ligands (Fig. 4.12).  
The commercial substrates, MeOSuc-Ala-Phe-Lys-AMC, Boc-Val-Pro-Arg-AMC, Z-
Gly-Gly-Arg-AMC and Val-Leu-Arg-AMC, were docked in similar conformations 
compared to the remaining substrates which did not adopt similar conformations in the 
active site. These four substrates were used to generate a common feature 
pharmacophore for TbbMCA2 4AF8, TcoMCA5 and TviMCA5 (Fig. 4.13).  
The pharmacophore for TbbMCA2 4AF8 is characterised by one positive ionisation 
and three hydrophobic features, together with one hydrogen bond donor and two 
hydrogen bond acceptors. For TcoMCA5, the pharmacophore consists of one 
ionisation and three hydrophobic features, together with three hydrogen bond 
acceptors. Four hydrogen bond acceptors as well as one positive ionisation and three 
hydrophobic features, constitute the pharmacophore of TviMCA5.  
4.4 Discussion 
An important component of modern medicinal chemistry is the use of the 3D structure 
of protein targets in structure-based drug design (SBDD) methods (Salum et al., 2008). 
Lounnas et al. (2013) proposed that the combination of homology modelling, molecular 
docking and virtual screening could be used to accelerate drug discovery. Njogu et al. 
(2016) contended that predictions using molecular docking can be improved using the 
experimental data from phenotypic whole-cell assays toward drug discovery for 
malaria, tuberculosis, trypanosomosis, and leishmaniasis.  
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Figure 4.12: Overlay of docked commercial inhibitors and substrates along with Berg ligands into the active site of TbbMCA2 
4AF8, TcoMCA5 and TviMCA5, prepared with ‘all water’.
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Figure 4.13: Generation of a common feature pharmacophore for TbbMCA2 
4AF8, TcoMCA5 and TviMCA5. The features of the generated pharmacophore using the 
docked commercial substrates are coloured as follows: hydrogen bond acceptor (green), 
hydrogen bond donor (pink), positive ionisation (red) and hydrophobic (turquoise). 
 
Molecular docking can provide insight into the conformation adopted by small-molecule 
ligands within the binding site of a protein ‘receptor’ (Meng et al., 2011). Using the 
structural alignment of a set of docked small-molecule ligands, a pharmacophore can 
be created (Lounnas et al., 2013). The application of molecular docking studies have 
enabled investigations into ligand−‘receptor’ interactions as well as the elucidation of 
the mechanism of action (Njogu et al., 2016). Together with this information, SBDD can 
direct the choice or design of ligands possessing the required features to control the 
activity of the target ‘receptor’ (Mandal et al., 2009; Blaney, 2012).  
More recently, phenotypic screening against T. b. brucei, T. cruzi and L. donovani 
allowed for the assembly of three anti-kinetoplastid chemical boxes targeting 
T. b. brucei, T. cruzi and Leishmania donovani. (Peña et al., 2015). Inhibitors of 
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cruzipain, a cathepsin-L like peptidase of T. cruzi, were identified within the T. b. brucei 
HAT and T. cruzi Chagas boxes (Salas-Sarduy et al., 2017). Common scaffolds of the 
inhibitors were identified along with predicted conformations within the active site and 
the interactions of the inhibitor with the cruzipain ‘receptor’ (Salas-Sarduy et al., 2017). 
Trypanosomatid cysteine peptidases, such as cruzipain and rhodesian, the 
cathepsin-L-like peptidase from T. b. rhodesiense (Mendez-Lucio et al., 2012), have 
been validated as drug targets. Through the utilisation of structure-based screening, a 
number of promising compounds have been identified (Ferreira and Andricopulo, 
2017). In addition, glyceraldehyde-3-phosphate dehydrogenase (Bressi et al., 2001), 
trypanothione reductase (Maccari et al., 2011) and tubulin (Goodarzi et al., 2010) have 
been identified as drug targets using both structure- and ligand-based drug design 
methodologies. 
The MCA cysteine peptidases are virulence factors and have been implicated in cell 
death (Lee et al., 2007; Zalila et al., 2011) and cell cycle regulation (Ambit et al., 2008; 
Laverrière et al., 2012) in the kinetoplastid parasites. The 3D structure, solved by X-ray 
diffraction, of TbbMCA2 (McLuskey et al., 2012) was elucidated two months after the 
creation of the Berg library of ligands which was designed based on peptidomimetics 
(2012). Using molecular docking studies, the effectiveness of the Berg ligands against 
both TbbMCA2 and the MCA5 of T. congolense and T. vivax, was investigated in the 
present study. In addition to the Berg library, a commercial library was assembled 
based on the peptide substrates and inhibitors used to characterise MCAs as reported 
in literature. 
Homology models are reasonable docking templates, provided that that they are built 
from a template with which it shares a high sequence similarity (Schmidt et al., 2014). 
Homology modelling of α-glucosidase, and the subsequent docking of stilbene urea 
derivatives into the active site resulted in the identification of interactions required for 
high binding affinity (Lee et al., 2014). Due to the limited numbers of solved MCA 
structures and the 50% sequence identity between TbbMCA2 and the MCA5s of 
T. congolense and T. vivax, the homology models for TcoMCA5 and TviMCA5 were 
generated using TbbMCA2 4AF8 as the template.  
The MCA5 homology models lacked the Pro-, Gln-, Tyr-rich C-terminal domain, but 
due to the fact that only the catalytic domain is active, the model would suffice for 
docking studies. It was determined that autoprocessing of recombinant TbbMCA2 at 
Lys55 and Lys268 to release the catalytic domain, was not an absolute requirement 
for activity as mutants of these residues were still catalytically active (Gilio et al., 2017). 
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Another factor to be taken into consideration is the conformational change which 
results in the destabilisation of the first 15 residues of the N-terminal domain upon 
calcium activation as well as in the presence of a substrate (McLuskey et al., 2012). It 
has also been suggested that calcium has a structural effect on TbbMCA2 in the vicinity 
of the S2 binding pocket (Machado et al., 2013). It was shown in Chapter 3 that neither 
the recombinant TcoMCA5, with both the catalytic dyad residues mutated, nor the 
native TcoMCA5 required calcium for peptidolytic activity. Despite the differences 
between the structures of TbbMCA2 and the MCA5s, the high Qmean scores of the 
homology models, indicating a high-quality prediction, together with Z-scores similar to 
those found for native proteins of a similar size, the homology modelled TcoMCA5 and 
TviMCA5 structures were suitable for docking studies.  
Deeply buried structural water molecules, or those within the active site, are highly 
ordered and detected in 3D structures which have been solved by X-ray diffraction 
(Ross et al., 2012). Structural data from X-ray crystallography, at a resolution better 
than 2.0 Å, are able to reliably discern water molecules which are present (Sousa et 
al., 2013). The four 3D structures of TbbMCA2 were determined at a resolution of 
between 1.4 and 2.1 Å, and as such, the water molecules identified within the structure 
are reliable. 
Ligand binding to the protein ‘receptor’ requires rearrangement of the water molecules 
which surround both the ligand and the ‘receptor’ (Lounnas et al., 2013). In many 
cases, ligand binding is mediated by structural water molecules (Ross et al., 2012). 
These water molecules adopt a highly ordered structure within the protein and mediate 
the binding of ligands to the ‘receptor’ through the formation of hydrogen bonds 
(Bissantz et al., 2010; Ross et al., 2012). In the case of LmjOPB, two well-ordered 
water molecules were identified, one of which was found to coordinate with Glu621 
which is responsible for the P1 substrate specificity, and the other with Asp662 which 
coordinates the catalytic His697 (McLuskey et al., 2010).  
Strongly bound water molecules are often conserved across multiple crystallographic 
structures (Ferreira et al., 2015), which is observed for the three water molecules lining 
the bottom of the active site in all four TbbMCA2 structures (McLuskey et al., 2012). In 
the active site pocket, these conserved water molecules interact with the secondary 
catalytic Cys92, catalytic His158, S1 binding residues Asp211, Gly157 and Gly159. The 
catalytic His237 is followed by Gly238 (caspase-1 numbering) and, together with the 
catalytic Cys, the backbone nitrogens are involved in the formation of the oxyanion 
hole (Walker et al., 1994; Fuentes-Prior and Salvesen, 2004). This residue (Gly159 in 
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TbbMCA2) is conserved in each of the MCAs with the expection of TcrMCA3. In 
addition, there is a conserved Gly (Gly158 in TbbMCA2) preceding the catalytic His 
and may be involved in the formation of the oxyanion site. The Cys92, His158 and 
Asp211 were demonstrated to interact with the ligands in both the Berg and commercial 
libraries. This supports the notion that these conserved water molecules mediate ligand 
binding.  
It has been demonstrated that docking performance is improved by the inclusion of 
water molecules in both predicted structures and those solved by X-ray diffraction 
(Yang and Chen, 2004; de Graaf et al., 2005). A such, molecular docking studies were 
performed with four different water preparations. The ‘all water’ and ‘conserved water 
without preparation’ preparations resulted in more docked compounds with greater 
CDocker interaction energies than those docked in the ‘no water’ and conserved water 
with preparation’. The CDocker values obtained from the molecular docking of the Berg 
ligands into the active site of TbbMCA2, TcoMCA5 and TviMCA5, despite some 
outliers, followed the trend of the IC50 values obtained in the phenotypic screening 
(Berg et al., 2012).  
Reversible cruzipain inhibitors which possessed a nitrile warhead were characterised 
by IC50 values of 1 nM against the recombinant enzyme and between 5 and 10 μM in 
epimastigote and intracellular amastigote in vitro assays (Ndao et al., 2014). It was 
expected that the Berg ligands which possessed a nitrile warhead would have a high 
affinity for TbbMCA2 indicated by high CDocker interaction energies. This however, 
was not the case as shown by the IC50 values as well as by the low CDocker interaction 
energies. This may be due to the MCAs’ resistance to the E-64 inhibitor (Appendix B8). 
This deviance from the cysteine peptidase characteristic follows the result where the 
inhibitor of serine peptidases (ISP), and not the inhibitor of cysteine peptidases (ICP), 
was shown to bind and inhibit the peptidolytic activity of the single MCA from 
L. amazonensis (Peña et al., 2017). In addition, LdnMCA activity was reported to be 
‘trypsin-like’ (Lee et al., 2007), which is a trait of serine peptidases rather than that of 
cysteine peptidases.  
The substrates and inhibitors of the commercial library were successfully docked into 
the active site of TbbMCA2, TcoMCA5 and TviMCA5, but the serine inhibitors had 
higher interaction energies than those of the cysteine inhibitors. The docking results 
suggest that whilst antipain has been shown as the most effective inhibitor of 
recombinant TbbMCA2 (Moss et al., 2007), chymostatin was predicted to be more 
effective than leupeptin and TLCK which is contradictory to what is reported in literature 
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(Moss et al., 2007). In the case of the MCA5s, the only effective inhibitors, were 
antipain and leupeptin, which only reduced the peptidolytic activity of recombinant 
TcoMCA5H147AC202G activity by 20% (Chapter 3). Docking studies suggest that inhibition 
should have been observed with chymostatin as well as TLCK. Despite the differences, 
the ligands of the commercial library bound in a similar spatial position within the active 
site of TbbMCA2, TcoMCA5 and TviMCA5 which correlates to the spatially conserved 
active site residues (Appendix B5). 
The poses are ranked according to their CDocker interaction energies where ligands 
with a lower associated energy possessed a higher affinity for the protein receptor. 
However, the calculation of docking scores and prediction of binding poses is not 100% 
accurate (Lounnas et al., 2013). This study did not take into account the flexibility of 
the protein receptor upon ligand binding which affects the accuracy of the docking 
scores. This can be corrected using molecular dynamics, whereby protein receptor 
flexibility is taken into consideration during docking, which is beyond the scope of this 
research. 
Docking of libraries containing diverse compounds are characterised by reduced 
reliability of scoring functions and inaccurate docking poses, thus making analysis 
difficult (Kitchen et al., 2004). Docking scores obtained using large sets of ligands, with 
the same scaffold, on a series of protein kinases indicated that the correct binding 
mode within the top set of docked poses was obtained compared to docking 100 poses 
generated from a single ligand (Chema et al., 2004). The Berg library and the 
commercial library contained compounds which were structurally similar. As such, the 
CDocker scores and poses should be reasonably accurate.  
Without prior knowledge or a strong hypothesis of bound conformations of ligands and 
spatial alignment, docking scores are unreliable (Spitzer and Jain, 2012). If the 
preferred binding mode of a series of chemically related compounds can be inferred, 
docking can provide correct ligand conformation and accurate structural alignment that 
is required to build predictive quantitative structure–activity relationship models 
(Kulkarni et al., 2007). Given the P1 specificity for Arg and the favourable alignment of 
the docked commercial substrates and inhibitors, which have been used in previously 
reported MCA characterisation, the docked poses of both the Berg and commercial 
library can be considered to be reasonably accurate.  
Due to the conservation of the caspase-hemoglobinase fold between the MCAs, the 
information from one structure can be transferred to others as is the case with protein 
kinases (Lounnas et al., 2013). Together with the structural similarity of the active site 
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of TbbMCA2 with that of TcoMCA5 and TviMCA5 suggests that the docking results can 
be compared across these three proteins. 
Interactions between the ligands and the protein ‘receptor’ were determined using the 
results of the docking studies. This can be optimised when used in combination with 
molecular dynamic studies, whereby different conformational changes of the protein 
‘receptor’ when binding to a ligand are modelled, as was reported for the identification 
of the interactions between the clathrin ‘receptor’ and its natural product inhibitor, 
bolinaquinone (Abdel-Hamid and McCluskey, 2014). A comparison of the number of 
interactions between the residues of the active site and the various substrates, 
inhibitors and ligands indicated that the commercial library substrates and inhibitors 
formed more interactions with the MCA ‘receptor’ than those of the Berg library ligands. 
For further optimisation of the Berg ligands and improvement of the IC50 values, the 
results of the commercial ligands need be taken into consideration. Both the Berg and 
commercial ligands displayed Pi-sulfur interactions with the secondary catalytic Cys 
and catalytic Cys in both TbbMCA2 (Cys92 and Cys213) and the MCA5s (Cys81 and 
Cys202) which gives credibility to the possibility of a secondary catalytic Cys. This 
could explain why when both the catalytic dyad residues of TcoMCA5 were mutated, 
activity was still evident (Chapter 3). The Cys adjacent to the catalytic Cys (TbbMCA2: 
Cys212, MCA5: Cys201) did not seem to interact with any residues of the various 
ligands.  
The generation of a pharmacophore summarises the steric and electronic features 
required for optimal interaction of a ligand with a protein ‘receptor’ (Sliwoski et al., 
2013). Using the spatial positions of the commercial and Berg ligands which had the 
highest CDocker interaction energies, pharmacophore models were produced, with 
hydrogen bond acceptors and hydrophobic interactions being the main features of the 
interactions with the MCAs followed by ionisation and hydrogen bond donors. These 
features can be utilised for virtual screening of compound libraries for the identification 
of novel ligands with high binding affinities for the MCA ‘receptor’ (Sliwoski et al., 2013). 
The use of molecular docking allowed for the selection of compounds which possessed 
higher binding affinities for cyclooxygenase-2 (COX-2) than the classical inhibitor, 
celecoxib (Puratchikody et al., 2016). In addition, pharmacophore models can be used 
to guide the design of new ligands for the optimisation of the IC50 values (Yang, 2010; 
Sliwoski et al., 2013).  
Various kinetoplastid MCAs have been shown to play a role in the cell cycle (Helms et 
al., 2006; Ambit et al., 2008; Proto et al., 2011; Laverrière et al., 2012). As such, 
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inhibitors against these peptidases are valuable contributions towards a drug which 
targets the MCAs. The successful molecular docking of the Berg ligands in the active 
site of the 3D structure of TbbMCA2 and homology modelled TcoMCA5 and TviMCA5 
suggest that the phenotypic assay results (Berg et al., 2012) were a reflection of the 
inhibition of MCAs. Together with that of the Berg library, the molecular docking of the 
commercial library provided insight into the interactions between the ligands and the 
protein ‘receptor’. Combined with this information and the pharmacophore model, 
ligand optimisation and virtual screening can be implemented to identify a ligand with 
a high binding affinity for the MCAs. Since the inhibitors, substrates and ligands bound 
to both the single- (MCA5) and multicopy (MCA2) MCAs, and in different species, 
T. b. brucei, T. congolense and T. vivax, it is possible that these ligands are pan 
specific. 
In the next chapter, work is presented on the application of phage display technology 
for the production of recombinant antibodies against OPB as a model antigen. This 
paves the way for applying this technology for the production of MCA specific 
antibodies for use in diagnostics as well as for parasite imaging in cellular research.  
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CHAPTER 5 
PHAGE DISPLAY AND ANTIGEN DETECTION ELISA OF 
OLIGOPEPTIDASE B FROM T. CONGOLENSE AND T. VIVAX 
5  
5.1 Introduction 
Due to the location of animal African trypanosomosis (AAT) infections in resource-poor, 
rural settings together with the waves of parasitaemia caused by antigenic variation, 
the development of an accurate, cost effective and easy to use diagnostic assay is 
imperative to the control of the spread of infections through the identification and 
treatment of infected individuals (Aksoy et al., 2017; Diall et al., 2017). One such 
diagnostic method is the immunochromatographic dipstick test, also known as a rapid 
diagnostic test (RDT), which has been successfully used for the detection of 
T. congolense and T. vivax (Boulangé et al., 2017), T. cruzi (Luquetti et al., 2003; 
Cardinal et al., 2006) and Leishmania infantum (Reithinger et al., 2002) infections.  
An attractive antigen to be incorporated into an RDT is one which is released by the 
parasites into the host circulatory system and is stable. As anti-trypanosomal 
antibodies persist long after successful treatment (Paquet et al., 1992; Yadav et al., 
2012), an antigen detection format would be able to differentiate between current and 
past infections. As such, parasite proteins which are present within the bloodstream of 
the infected host are attractive diagnostic antigens (Eyford et al., 2013). An antigen 
detection ELISA was developed using species-specific monoclonal antibodies against 
the antigens released from the lysis of in vitro cultured T. congolense parasites 
(Nantulya et al., 1987). This test was shown to be more than four times more sensitive 
than microhematocrit centrifugation technique in monitoring experimental 
T. congolense infections in goats and cattle (Masake and Nantulya, 1991). 
One such potential diagnostic antigen is the serine peptidase, oligopeptidase B (OPB) 
that was used as a model antigen in the present study. It has been demonstrated that 
TbbOPB (Morty et al., 2005b), TcoOPB (Pinto Dias, 2006) and TevOPB (Morty et al., 
2005a) are released from lysed, dead or dying parasites into the bloodstream, where 
they remain active (Morty et al., 2005a; Munday et al., 2011). The action of OPB has 
been implicated in the disruption of the hormone levels of the infected host (Morty et 
al., 1999; Morty et al., 2001; Morty et al., 2005a) through the cleavage of peptide 
hormones in the blood of T. b. brucei infected rats (Tetaert et al., 1993) and the reduced 
levels of regulatory peptides such as atrial natriuretic factor. This renders OPB a 
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desirable target for antigen detection. Anti-OPB antibodies were identified in sera from 
humans infected with T. cruzi and L. infantum, and T. cruzi experimentally infected 
rabbits using an antibody detection ELISA in an indirect format (Fernandes et al., 
2005). However, a previous study to detect anti-OPB antibodies in sera from 
T. congolense infected and non-infected cattle, in an antibody detection ELISA, was 
unsuccessful (Eyssen, 2013).  
Thus, in order to develop an antigen detection ELISA assay, antigen specific antibodies 
are required. The established method of the production of polyclonal antibodies is by 
animal immunisation (Schirrmann et al., 2011). Antibodies against the full length 
TcoOPB and TviOPB and peptides of TcoOPB have been produced in chickens and 
rabbits previously (Huson, 2006; Kangethe, 2011). However, TviOPB was poorly 
immunogenic in chickens, resulting in low chicken anti-TviOPB IgY titres (Eyssen, 
2013). As such, the production of alternative antibodies was investigated. Monoclonal 
antibodies created by hybridoma technology (Köhler and Milstein, 1975), at a high cost, 
have limited application in the generation of human therapeutic antibodies and 
antibodies against toxic or highly conserved antigens (Winter and Milstein, 1991). In 
vitro technologies have an advantage over animal immunisation in that it is completely 
independent of the immune system and it comprises an unlimited source of binders, of 
which the DNA sequence is known (Schirrmann et al., 2011). As a result, there would 
be no deviations between different batches as experienced with animal serum 
(Schirrmann et al., 2011). One such in vitro technology is that of phage display which 
expresses antibodies, derived from combinatorial libraries of immunoglobulin VH and 
VL genes, on phage particles (Pini and Bracci, 2000). 
Using a camelid library comprised of the variable heavy domain of camelid antibodies, 
VHH, panning against the variable surface glycoprotein (VSG) of T. b. brucei resulted 
in a VHH antibody which showed superior penetration within the spaces between VSG 
dimers, which is not accessible to the IgG and IgM antibodies produced during infection 
(Stijlemans et al., 2004). This demonstrates that the small antibody fragments are able 
to penetrate between the narrow cavities of immune-evasive antigens as demonstrated 
in the improved the pharmacokinetics of tissue penetration during antibody-based 
cancer therapy (Chowdhury et al., 1998; Deckert, 2009). 
The naïve, semi-synthetic and synthetic libraries, also known as ‘single pot’ libraries, 
are able to identify antibody fragments, which in theory, bind to every possible antigen 
(Hust and Dübel, 2004). These single pot libraries serve as the molecular repertoire for 
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the process of phage display (Sblattero and Bradbury, 2000). The naïve Nkuku® library 
is not confined to any specific target and, as a result, facilitates the generation of 
monovalent scFv antibodies against an almost unlimited range of antigens (van 
Wyngaardt et al., 2004). The scFv antibody (VL and VH) expressed using phage display, 
is able to retain the specific antigen binding affinity to that of the parent IgG. 
The Nkuku®  library was constructed from the rearranged immunoglobulin V genes from 
B cells (IgM) of non-immunised donor chickens (van Wyngaardt et al., 2004). These 
genes were then ligated into the pHEN1 phagemid plasmid and inserted into 
bacteriophages to produce a phagemid (Fig. 1.8, Step A). Those phagemids which 
possess complementary determining regions (CDRs) to that of the immobilised target 
antigen are retained (Step F), used to infect E. coli cells and are rescued by helper 
phages (Step D). The resulting phagemids are isolated and panned against the 
immobilised antigen to select for scFvs with a high binding affinity for the antigen. The 
resulting scFv antibodies are myc-tagged, and may be produced as a minor phage 
coat protein (pIII) fusion proteins, scFv::pIII, if expressed in amber suppressor E. coli 
cells (Appendix D1). The panning process is illustrated in Fig. 5.1 and numbered as 
detailed in Fig. 1.8, with each step detailed in the methods section. 
The production of phage displayed scFv antibodies against the OPB antigen from both 
T. congolense and T. vivax, and their application in an antigen detection ELISA towards 
the development of an AT diagnostic test is reported here. In addition, homology 
modelling of the scFv and its docking onto the OPB antigen is reported.  
5.2 Materials and methods 
 Materials 
Phage display library: The Nkuku® phage display library, M13KO7 helper phages and 
the amber suppressor TG1 {F' [traD36 proAB+ lacIq lacZΔM15]supE thi-1 Δ(lac-proAB) 
Δ(mcrB-hsdSM)5, (rK
-mK
-)} E. coli cells, were obtained from Wouter van Wyngaardt and 
Jeanni Fehrsen (Immunology section, Onderstepoort Veterinary Institute). 
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Figure 5.1: Selection of antigen specific scFv antibodies using panning. The 
image was adapted from Kuhn et al. (2016). The Nkuku® phagemid transfected E. coli cells, 
which display the scFv::pIII fusion protein are panned against the immobilised OPB antigen. 
The binders which are not OPB-specific, or bind weakly, are removed with stringent washing. 
The bound antibody phages are eluted, reinfected into the E. coli host, and coinfected with the 
M13KO7 helper phage. After amplification of the selected phagemid population, it is panned 
against the OPB antigen once more to facilitate the selection of highly specific antigen binders. 
This process was performed four times in total in this study. After the fourth round of panning, 
colonies of the reinfected E. coli cells containing the antibody phage specific to the OPB antigen, 
are expressed in 96-well culture plates. These clones are analysed by ELISA using antibodies 
against the phage coat protein (pIII) and the myc affinity tag for the identification of the scFv::pIII 
fusion proteins and soluble scFv proteins, respectively. The letters A-H correspond to those in 
Fig. 1.8 and each step is detailed in the methods section. 
 
Biopanning: Nunc-Maxisorp 4 ml immunotubes (Catalogue number: 444474) were 
obtained from Nunc Intermed (Roskilde, Denmark), ELITE skim milk powder, for 
panning, from Clover (SA), bovine serum albumin (Catalogue number: A7906) from 
Sigma (St. Louis, MO. USA.), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
(IPTG) from Fermentas (Vilnius, Lithuania), AluI and the 100 bp DNA ladder from New 
England Biolabs (Ipswich, MA, USA), ampicillin sodium salt from USB Corporation 
(Cleveland, OH, USA), kanamycin from Gibco, (Paisley, UK), and non-fat powdered 
milk for western blots and ELISAs, from Amresco (Solon, OH, USA). Bacteriological 
agar, tryptone and yeast extract were purchased from Merck Biolab (Darmstadt, 
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Germany). Buffer salts and other common chemicals were purchased from Merck 
(Germany) and Sigma (St. Louis, MO, USA) and were of the highest purity available.  
Purification and quantification of phage displayed scFv: As per Section 2.2.1 and 
3.2.1. The TcoOPB-Aminolink®, TviOPB-Aminolink® (Huson, 2006) and chicken 
anti-myc IgY hydrazide (Krause, 2016) resins were previously prepared. 
Antibodies: Mouse anti-M13 IgG was purchased from Pierce (Rockford, IL, USA), 
goat anti-mouse IgG HRPO conjugate from Jackson ImmunoResearch (PA, USA) and 
rabbit anti-chicken IgY HRPO conjugate from Sigma (St. Louis, MO. USA). The affinity 
purified chicken anti-myc IgY, raised against the EQKLISEEDL peptide, was produced 
previously by Rob Krause (2016). Both the rabbit anti-TcoOPB IgG and the affinity 
purified chicken anti-peptide 4 IgY were produced previously by Laura Huson (2006). 
The peptide 4 corresponds to the 282 to 299 amino acid residues of the TcoOPB 
protein, VRKREKNVRYEVEMHGT. 
3D structures of scFv antibodies: The 3D structures, solved by X-ray diffraction, of 
scFv complexed to human gankyrin (PDB: 4NIK, 2.5 Å) (Robin et al., 2014), cross 
reactive antibody which binds to respiratory syncytial virus and human 
metapneumovirus (5U68, 3.08 Å) (Wen et al., 2017), the scFv against prostate specific 
antigen (4P49, 1.4 Å) (Conroy et al., 2014), the scFv against cardiac troponin I (4P48, 
1.35 Å) (Conroy et al., 2014), the scFv against the major allergen from Blatella 
germanica (4OUO, 1.8 Å) (Mueller et al., 2014) and TbbOPB (4BP9, 2.8 Å) (Canning 
et al., 2013) were obtained from the RCSB Protein Data Bank (www.rcsb.org)(Berman 
et al., 2000). 
Discovery Studio docking software: The Centre for High Performance Computing 
(Cape Town, South Africa) is acknowledged for the provision of the computational 
resources necessary to conduct the prediction of the scFv interaction with the target 
TcoOPB antigen. 
Sera: Sera from infected and non-infected cattle were obtained from ClinVet 
International (PTY) LTD, Bloemfontein, South Africa. 
 Preparation of TG1 E. coli stock for log-phase culture 
Escherichia coli TG1 cells were streaked onto TYE plates [1% (w/v) tryptone, 0.5% 
yeast extract, 0.8% (w/v) NaCl, 1.5% (w/v) agar] without antibiotic, and grown at 37 °C 
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for 16 h. A single colony was inoculated into 2xYT (5 ml), without antibiotic, and grown 
at 37 °C for 16 h at 220 rpm. A 1:100 dilution of the overnight culture was performed in 
fresh 2xYT, without antibiotic, and incubated at 37 °C until the OD600 reached 0.5. This 
log-phase culture was stored at 4 °C for a maximum of 7 days. 
 Expression and titration of M13KO7 helper phages 
For the titre determination of the M13KO7 helper phages, a serial dilution of M13KO7 
in PBS (100 µl) were incubated with log-phase TG1 E. coli cells (100 µl) at RT for 5 min. 
To each dilution, pre-warmed 2xYT [containing 0.7% (w/v) agar] without antibiotic, at 
42 °C, was added and immediately plated onto 2xYT plates, without antibiotic and 
incubated at 37 °C for 16 h. 
A single kanamycin resistant (Kanr) M13KO7 plaque was incubated with log-phase 
TG1 E. coli cells (40 µl) in 2xYT (4 ml), without antibiotic, at 37 °C for 1 h at 100 rpm. 
Fresh 2xYT (800 ml), without antibiotic, was added and incubated for an additional 
hour. Thereafter, kanamycin (50 µg/ml) was added and incubated at 37 °C for 16 h at 
200 rpm. The cells were pelleted (10 800g, 5 min, 4 °C) and to the phage containing 
supernatant, 1/4 volume of 20% (w/v) PEG 6000 in 2.5 M NaCl added. The mixture 
was incubated on ice for 30 min before the phages were pelleted (10 800g, 15 min, 
4 °C). After resuspension in PBS (6 ml) and filtering through a 0.22 µM filter, the titre 
of the M13KO7 helper phages was determined as above. The M13KO7 helper phages 
were stored at a concentration of 1x1012 pfu/ml in 15% (v/v) glycerol at -80 °C. 
 Expression and titration of the Nkuku® phagemid library 
The Nkuku® phagemid library (Fig. 1.8, Step A) was provided in E. coli cells (step B). 
Following Step C, the ampicillin resistant (Ampr) Nkuku® library glycerol stock was 
added to 2xYT [containing 100 µg/ml ampicillin, 2% (w/v) glucose, 100 ml], until an 
initial OD600 of 0.05 was obtained. Incubation at 37 °C at 240 rpm was carried out until 
an OD600 of 0.5 was obtained. 
Following Steps D and E, to the Nkuku® culture (100 ml), 8x109 pfu/ml M13KO7 helper 
phages were added and incubated at 37 °C for 30 min without agitation, followed by a 
further 30 min at 100 rpm. The cells were pelleted (3 300g, 10 min, 4 °C), resuspended 
in 2xYT (containing 100 µg/ml ampicillin, 25 µg/ml kanamycin, 2 L), and incubated at 
30 °C for 16 h at 240 rpm. 
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The cells were pelleted (3 300g, 10 min, 4 °C), and to the phagemid containing 
supernatant,1/4 volume of 20% (w/v) PEG 6000 in 2.5 M NaCl added (250 ml). After 
1 h on ice, the phagemids were pelleted (3 300 g, 15 min, 4 °C), resuspended in PBS 
(20 ml), and pelleted once again (11 000 g, 2 min, 4 °C). The phagemids were filtered 
through a 0.22 µM filter and used for the first round of panning. 
 Panning of the Nkuku® library against oligopeptidase B 
from T. congolense and T. vivax 
Panning was performed as previously described by van Wyngaardt et al. (2004) as 
shown in Fig. 1.8 and Fig. 5.1, Step F. Briefly, immunotubes were coated with 100, 50, 
10 and 1 µg/ml antigen (3.5 ml) diluted in PBS, for pans 1, 2, 3 and 4, respectively, for 
16 h at 4 °C. The immunotubes were washed three times with PBS and blocked with 
either 2% skim milk powder-PBS (MP) or 3% (w/v) BSA-PBS (BP), two of the most 
commonly used blocking agents used in panning, at RT for 1 h. The immunotubes were 
then washed twice with 0.1% (v/v) Tween-20-PBS (PBS-T) followed by PBS. During 
the blocking of the immunotube, Nkuku® phagemid was diluted to 1012 pfu/ml in MP or 
BP [containing 0.1% (v/v) Tween-20, 3.5 ml] and incubated at 37 °C for 30 min. This 
blocking step assists in the reduction of binding to unrelated peptides (Thomas et al., 
2010; Vodnik et al., 2011). 
The MP and BP treated Nkuku® phagemid was added to the blocked immunotube after 
washing and incubated at RT for 30 min with gentle agitation followed by 1.5 h without 
agitation. The immunotube was washed twenty times with PBS-T and a further twenty 
times with PBS. Following Fig. 5.1, step G, freshly prepared 100 mM triethylamine 
(1 ml) was added to the immunotube and mixed with agitation using an end-over-end 
rotator at RT for 10 min. The eluted phage was neutralised by the addition of 1 M 
Tris-HCl buffer, pH 7.4 (0.5 ml). As per step H in Fig. 5.1, log-phase TG1 E. coli cells 
(5 ml) were transfected with the neutralised phages (1 ml) in a water bath at 37 °C for 
30 min. The cells were pelleted (3 300g, 10 min, 4 °C), resuspended in 2xYT (1 ml), 
without antibiotic, plated onto three TYE plates [containing 100 µg/ml ampicillin, 2% 
(w/v) glucose] and incubated at 30 °C for 16 h. To determine whether or not the TG1 
E. coli cells had been transfected previously, log-phase TG1 E. coli cells were also 
plated onto TYE plates [containing 100 µg/ml ampicillin, 2% (w/v) glucose]. 
Instead of using Nkuku® phagemid, all subsequent panning rounds will be screened 
using the resulting phagemids from the previous round of selection against OPB as per 
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step C in Fig. 5.1. The resulting colonies were resuspended in 2xYT (8 ml), without 
antibiotic, using a “hockey stick” and stored in 15% glycerol at -80 °C. This is the 
glycerol stock from the first round of panning. For amplification of the phages, the 
glycerol stock from the first panning round was added to 2xYT [containing 100 µg/ml 
ampicillin, 2% (w/v) glucose, 50 ml] to achieve an initial OD600 of 0.05. This was then 
incubated at 37 °C at 220 rpm until an OD600 of 0.5 was obtained. To this culture, 
8x109 pfu/ml M13KO7 helper phages were added and incubated at 37 °C for 30 min 
without agitation as per step D and E in Fig. 5.1. The cells were pelleted (3 300 g, 
10 min, 4 °C), resuspended in 2xYT [containing 100 µg/ml ampicillin, 25 µg/ml 
kanamycin, 25 ml], and incubated at 30°C for 16 h at 220 rpm. 
The cells were pelleted (3 300g, 10 min, 4 °C) and to the phage containing supernatant, 
1/4 volume of 20% (w/v) PEG 6000 in 2.5 M NaCl was added (5 ml). After 1.5 h at 4 °C, 
the phages were pelleted (3 300 g, 15 min, 4 °C), resuspended in PBS (1 ml), and 
pelleted once again (11 000 g, 2 min, 4 °C). The phages were filtered through a 
0.22 µM filter and used for the next round of panning as per step F in Fig. 5.1. This 
process was repeated for a total of 4 rounds with each immunotube being coated with 
decreasing concentrations of antigen, which functions to enrich for specific antigen 
binders.  
 Determination of enrichment of panned phages 
Purified recombinant OPB (Eyssen, 2013), diluted in PBS (1 µg/ml, 100 μl/well), was 
used to coat the wells of 96-well Nunc-Immuno™ Maxisorp ELISA plates for 16 h at 4 
°C. The coating solution was discarded, and the plates were blocked with blocking 
buffer (MP and BP, 200 μl/well) and incubated at 37 °C for 1 h. Phages from pans one 
to four, including the Nkuku® phagemid [1:10 in MP or BP, each containing 0.1% (v/v) 
Tween-20, 100 μl/well] were added and incubated at 37 °C for 2 h. The wells were 
washed three times with PBS-T using a BIOTEK® ELx50™ Microplate washer after 
which the mouse anti-M13 IgG [1:8 000 in MP or BP, each containing 0.1% (v/v) 
Tween-20, 100 μl/well], was added and incubated at 37 °C for 1 h. The wells were 
washed as before, followed by the addition of the goat anti-mouse IgG HRPO 
conjugate [1: 1 000 in MP or BP, each containing 0.1% (v/v) Tween-20, 100 μl/well], 
and incubated at 37 °C for 1 h. The wells were washed as before and the ABTS·H2O2 
chromogen substrate solution [0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in 0.15 M 
citrate-phosphate buffer, pH 5.0, 100 μl/well] added. The plate was incubated in the 
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dark prior to measuring the absorbance at 405 nm using a FLUORStar Optima 
spectrophotometer every 15 min for 1 h. 
 Selection of phage displayed scFv clones 
The glycerol stocks from the selected enriched pans were serially diluted on TYE plates 
[containing 100 µg/ml ampicillin, 2% (w/v) glucose] at 30 °C for 16 h, in order to obtain 
individual colonies (30 to 300). Forty eight individual colonies for each antigen were 
selected and inoculated into a 96-well plate containing 2xYT (100 µl/well), without 
antibiotic. After incubation at 37 °C for 16 h at 220 rpm, a final concentration of 20% 
(v/v) glycerol was added to each well and stored at -80 °C. This served as the master 
plate.  
In a new 96-well plate, an aliquot from each well of the master plate (5 µl) was used to 
inoculate 2xYT [containing 100 µg/ml ampicillin, 2% (w/v) glucose, 150 µl/well], and 
incubated at 37 °C for 2.5 h at 220 rpm. To each well, 2x109 pfu/ml M13KO7 was added 
and incubated for a further 30 min without agitation. The cells were pelleted (600g, 
10 min, 4 °C), resuspended in 2xYT (containing 100 µg/ml ampicillin, 25 µg/ml 
kanamycin, 150 µl/well) and incubated at 30 °C for 16 h at 220 rpm. The cells were 
pelleted and the phage containing supernatant (50 µl) was added to a blocked ELISA 
plate. 
The ELISA was performed as described in Section 5.2.6, with only MP being used as 
the blocking and the dilution agent. Instead of using the isolated phagemids, the phage 
containing expression supernatants (50 µl/well) were used and diluted in 2xMP 
[containing, 0.1% (v/v) Tween-20, 50 μl/well]. 
 Selection clones expressing soluble scFv 
In a 96-well plate, an aliquot from each well of the master plate (5 µl) was used to 
inoculate 2xYT [containing 100 µg/ml Amp, 2% (w/v) glucose, 150 µl/well] and 
incubated at 30 °C for 16 h at 220rpm. To the overnight culture (5 µl), 2xYT [containing 
100 µg/ml ampicillin, 0.1% (v/v) glucose, 100 µl/well] was added and incubated at 37 °C 
for 2.5 h at 220rpm. After the addition of 2xYT (containing 100 µg/ml ampicillin, 3 mM 
IPTG, 50 µl/well), the plate was incubated at 30 °C for 16 h at 220rpm. The cells were 
pelleted (600g, 10 min, 4 °C) and the phage containing supernatant (50 µl) was added 
to a blocked ELISA plate. 
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The ELISA was performed as described in Section 5.2.6, with only MP being used as 
the blocking and dilution agent, and the dilution of phage containing supernatants 
(50 µl/well) in 2xMP [containing, 0.1% (v/v) Tween-20, 50 μl/well]. The bound phages 
were detected using affinity purified chicken anti-myc IgY (0.5 µg/ml, 100 µl/well) 
followed by rabbit anti-chicken IgY HRPO conjugate (1:5 000, 100 µl/well). 
 Characterisation of OPB-specific scFv producing clones 
Clones which were identified as OPB-specific in both the phage displayed scFv 
(Section 5.2.7) and expressed, soluble scFv (Section 5.2.8) ELISAs, were selected and 
grown in 2xYT [containing 100 µg/ml Amp, 2% (w/v) glucose, 5 ml] at 37 °C for 16 h 
with agitation. The plasmid DNA of the recombinant colonies was isolated using the 
GeneJet™ Plasmid Miniprep Kit according to the manufacturer’s instructions. The 
isolated plasmid DNA was used for PCR amplification, DNA fingerprinting to determine 
the scFv insert diversity between the selected clones, and for sequencing. 
The final concentrations of the PCR master mix were: 0.25 μM of the OP52 forward 
(5' CCC TCA TAG TTA GCG TAA CG 3') and M13 reverse (5' CAG GAA ACA GCT 
ATG AC 3') primers, 1xFIREpol® Taq polymerase reaction buffer, 2.5 mM MgCl2, 1 U 
FIREpol® Taq polymerase and 0.25 mM dNTPs in a total reaction volume of 20 μl. The 
PCR amplification of the recombinant scFv gene, was performed with incubation at 
95 °C for 2 min as the initial DNA denaturation step, followed by 40 cycles of 95 °C for 
10 s, 45 °C for 15 s and 72°C for 1 min. A final elongation step was carried out at 72 °C 
for 7 min. The colony PCR products (10 μl) and samples of the plasmid DNA (5 μl) 
were electrophoresed on a 1.5% (w/v) agarose gel, containing ethidium bromide 
(0.5 μg/ml), in 1xTAE buffer. 
The high frequency endonuclease, AluI, was used to determine the diversity of the 
scFv between the individual clones. Due to its notable ability to differentiate between 
highly related antibody sequences, AluI was used instead BstOI (Hawlisch et al., 2000). 
Restriction digestion with 1 U of AluI was performed on plasmid DNA (5 µl) in 
10xcutsmart buffer at 37 °C for 15 min. Samples of the digestion (5 µl) were 
electrophoresed on a 3% (w/v) agarose gel, containing ethidium bromide (0.5 μg/ml), 
in 1xTAE buffer. 
The plasmid DNA of the various PCR clones were sequenced at the Central Analytical 
Facility, Stellenbosch University, South Africa, using the OP52 and M13 forward and 
reverse primers, respectively. 
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 3D modelling of TcoOPB and scFv and their interactions 
In a similar way as outlined in Section 4.2.2, suitable templates to model scFv and 
TcoOPB were obtained using SwissModel (Biasini et al., 2014).  
One of the computational prediction tools, EpiPred (Krawczyk et al., 2014), was 
accessed from the structural antibody prediction server (SAbPred) (Dunbar et al., 
2016) developed by the Oxford Protein Informatics Group (http://opig.stats.ox.ac.uk/ 
webapps/sabdab-sabpred/EpiPred.php). The generated epitope predictions can be 
used to improve the performance of antibody-antigen docking. Using the VH and VL 
sequences of the OPB-specific scFv, together with the homology modelled TcoOPB 
antigen, EpiPred was used for the prediction of the structural epitopes of TcoOPB 
specific to the scFv.  
Antibody-antigen docking was used to predict the interaction of the OPB-specific scFv 
onto TcoOPB using the ZDock protocol from Discovery Studio (Dassault Systèmes 
BIOVIA).  
 Expression and purification of the scFv antibodies 
Single colonies of the selected scFv clones were used to inoculate 2xYT (5 ml), without 
antibiotic, and incubated at 37 °C for 16 h at 220rpm. The overnight culture (1 ml) was 
diluted 1:100 in 2xYT [containing 100 µg/ml Amp, 2% (w/v) glucose], without antibiotic, 
and incubated at 37 °C at 220rpm until an OD600 of 0.9 was obtained. The cells were 
pelleted (3 000g, 10 min, 4 °C) and resuspended in terrific broth (containing 100 µg/ml 
ampicillin, 1 mM IPTG, 100 ml), and incubated at 30 °C for 16 h at 220 rpm. The cells 
were pelleted (4 000g, 10 min, 4 °C) and the supernatant retained. The cells were 
resuspended in 1/4 volume of ice cold sucrose buffer [50 mM Tris-HCl buffer, pH 7.4, 
1 mM EDTA, 20% (w/v) sucrose] and incubated on ice for 10 min with gentle agitation. 
After pelleting the cells (4 000g, 10 min, 4 °C), the periplasmic fraction was retained, 
and the cells were resuspended in 1/10 volume ice cold 5 mM MgCl2. Following 
incubation on ice for 10 min with gentle agitation, the cells were pelleted (8 000g, 
10 min, 4 °C) and the resulting osmotic shock fraction was retained. Samples of the 
periplasm (P) and osmotic shock (OS) fluid were analysed by a 12.5% reducing 
SDS-PAGE gel (Laemmli, 1970), transferred onto nitrocellulose, as per Section 2.2.4. 
The blot was probed with affinity purified chicken anti-myc IgY (0.5 µg/ml) followed by 
rabbit anti-chicken IgY HRPO conjugate (1:5 000).  
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 Affinity purification of expressed scFv 
Purification of scFv using the TcoOPB- and TviOPB-affinity matrices as well as the 
chicken anti-myc affinity matrix was performed as outlined in Section 2.2.7.2 using the 
scFv containing osmotic shock fraction (8 ml). Samples of each fraction were analysed 
by 12.5% reducing SDS-PAGE gels (Laemmli, 1970), stained with Coomassie Blue 
R-250 and transferred onto nitrocellulose, as detailed in Section 2.2.4. The blot was 
probed with affinity purified chicken anti-myc IgY (0.5 µg/ml) followed by rabbit 
anti-chicken IgY HRPO conjugate (1:5 000). 
 Antigen detection of recombinant and native 
oligopeptidase B by scFv  
The ability of the purified scFv to detect both the recombinant and the native TcoOPB 
present in the digitonin fractionated T. congolense parasites (Section 3.2.5) was 
determined using a dot blot. The primary antibodies used were rabbit anti-TcoOPB IgG 
(10µg/ml), affinity purified chicken anti-peptide 4 IgY (5 µg/ml), both made previously 
by Laura Huson (2006), chicken anti-TcoOPB IgY (10 µg/ml) (Eyssen, 2013) and 
purified scFv (1:25). The use of scFv required a bridging antibody of affinity purified 
chicken anti-myc IgY (0.5 µg/ml) before the addition of the secondary detection 
antibodies, rabbit anti-chicken IgY HRPO conjugate (1:5 000) and goat anti-rabbit IgG 
HRPO conjugate (1: 2500). Detection was achieved using the ECL western blotting 
substrate.  
An antigen detection ELISA was performed using the scFv as a capture antibody and 
either the chicken or rabbit anti-TcoOPB antibodies as the detection antibody. Purified 
scFv (1: 100) was used to coat the wells of 96-well Nunc-Immuno™ Maxisorp ELISA 
plates (100 μl/well) for 16 h at 4 °C. The coating solution was discarded, and the plates 
were blocked with blocking buffer [0.5% (w/v) BSA-PBS, 0.1% (v/v) Tween-20, 
200 μl/well] and incubated at 37 °C for 1 h. Sera from T. congolense infected and 
non-infected cattle diluted in blocking buffer (1:100, 100 µl/well) were added and 
incubated at 37 °C for 1 h. The wells were washed and either the rabbit anti-TcoOPB 
IgG or the chicken anti-TcoOPB IgY antibody, diluted in blocking buffer (1 µg/ml, 
100 µl/well), was added and incubated at 37 °C for 1 h. The wells were washed as 
before, and either the goat anti-rabbit IgG HRPO or the rabbit anti-chicken IgY HRPO 
conjugate, diluted in blocking buffer (1:15 000, 100 μl/well), was added and incubated 
at 37 °C for 1 h. The wells were washed and the ABTS·H2O2 chromogen substrate 
solution [0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in 0.15 M citrate-phosphate buffer, 
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pH 5.0, 100 μl/well] was added. The plate was incubated in the dark for 15 min prior to 
reading the absorbance at 405 nm using the FLUORStar Optima Spectrophotometer 
in 15 min intervals until absorbance values of above 1.0 were reached. 
5.3 Results 
 Enrichment of scFv specific for oligopeptidase B from 
T. congolense and T. vivax 
Using the Nkuku® library, scFv antibodies with complementary epitopes to OPB were 
selected for. Little to no enrichment was observed when using milk powder (MP) to 
block the immunotubes compared to that of BSA (BP) (Fig. 5.2). With the decrease in 
antigen coating concentration which was used as bait, together with stringent washing 
of non-specific binders during the four panning rounds, enrichment was observed. The 
Nkuku® phagemid as well as the BSA coating control displayed low absorbance values. 
Enrichment occurred at pan 3 and more so at pan 4 for TcoOPB. The only pan where 
enrichment was evident for TviOPB was at pan 4.  
 
Figure 5.2: Enrichment ELISA of the isolated phages from each round of panning 
with oligopeptidase B from T. congolense and T. vivax. ELISA plates were coated 
with TcoOPB, TviOPB or BSA (1 μg/ml in PBS, pH 7.2), blocked with 3% (w/v) BSA-PBS and 
incubated with isolated phages (1:10) from each round of panning using immunotubes blocked 
with either 3% (w/v) BSA-PBS (BP) or 2% (w/v) skim milk powder-PBS (MP). Mouse anti-M13 
IgG (1:8 000), followed by goat anti-mouse IgG HRPO (1:1 000) and ABTS∙H2O2 were used as 
the detection system. The absorbance readings at 405 nm represent the average of duplicate 
experiments at 60 min development. 
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Figure 5.3: Results of various methods to select the best clones from TcoOPB and TviOPB pans 3 and 4 in TG1 E. coli cells for 
the expression of scFv antibodies. Using the absorbance values from the phage binding ELISA (green) together with those of the soluble scFv 
ELISA (pink), the plasmid DNA of the selected clones were subjected to PCR amplification of the scFv sequence and the resulting product sizes are 
indicated in bp (orange). The plasmid DNA of the positive clones were sequenced (yellow), and those which were positive using all four selection 
methods, are highlighted in blue. 
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 Selection and characterisation of individual positive 
scFv clones 
For pans three and four of TcoOPB and pan four of TviOPB, in TG1 E. coli cells, 48 
single clones were randomly selected and tested in phage binding (Appendix D2) and 
soluble scFv ELISA formats (Appendix D3). In order to determine which of the clones 
were best for use in expression, the plasmid DNA of positive clones were subjected to 
colony PCR, to amplify the scFv gene, and DNA fingerprinting using AluI digestion 
(Appendix D4). The clones which had a high absorbance value in each of the ELISA 
formats and possessed a 1 000 bp amplified product were sequenced (Fig. 5.3). 
Absorbance cut-off values for the two ELISA formats had to be assigned for the 
evaluation of the best clones (Appendix D5). Those clones which possessed values 
above the cut-off values and had a 1 000 bp amplified PCR product, were sequenced. 
An ideal scFv would be positive in both the phage binding and soluble ELISA formats 
(Rakabe, 2008). As such, clones E4 and E5 from TcoOPB pan three, and C2 from 
TviOPB pan four, all in TG1 E. coli cells, were selected for scFv expression (Fig. 5.3). 
These three clones will be referred to at E4, E5 and C2, respectively. 
 scFv sequencing, 3D modelling, and interaction with 
TcoOPB 
 scFv sequencing 
Following the selection of positive clones, the sequences of the isolated plasmid DNA 
from both TcoOPB pans three and four, together with TviOPB at pan four, were 
determined and aligned with the immunoglobulin heavy (GenBank® BAE80128.1) and 
lambda (GenBank® BAB47352.1) chain sequences of Gallus gallus and referred to as 
the germline. Each of the sequenced clones possessed the exact same sequences in 
each of the complementary determining regions (CDRs) in both the VH and VL chains 
(Fig. 5.4). This may indicate a highly conserved region in OPB between the 
T. congolense and T. vivax species. 
 Homology modelling 
A 81.3% sequence identity is shared between TcoOPB and TbbOPB, the latter whose 
3D structure has been determined by X-ray diffraction (Canning et al., 2013). A 
homology model of TcoOPB was generated with a -Qmean of -0.83 using TbbOPB as 
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the template. Slight variations were evident at some loops, but overall, the homology 
modelled TcoOPB overlaid well with that of TbbOPB (Fig. 5.5). An enlarged image of 
the template and query sequence alignment is given in Appendix D6. 
 
Figure 5.4: Multiple sequence alignment of scFv clones panned against TcoOPB 
and TviOPB. The sequences of clones E5 and E4 selected from TcoOPB pan three (TCO3) 
and clone C2 selected from TviOPB pan four (TVO4) were aligned against the germline 
(GenBank® BAE80128.1 and BAB47352.1) using the BioEdit software (Hall, 1999). The VH 
CDR1, -2 and -3 regions are highlighted in green, blue and red, and the VL CDR1, -2 and -3 
regions in purple, pink and light orange, respectively.  
 
 
Figure 5.5: Homology modelling of TcoOPB. Using the 3D structure from the Protein 
Data Bank (Berman et al., 2000) of TbbOPB, 4BP9 (Canning et al., 2013), as the template 
(yellow), the 3D structure of TcoOPB (purple) was (A) modelled using SwissModel (Biasini et 
al., 2014) and superimposed. (B) The alignment of the OPB sequences is shown with the 
Qmean scores indicated in blue (high quality prediction) and red/orange (low quality prediction). 
(See Appendix D6 for an enlarged version of panel B). 
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To date, the 3D structures for only three chicken scFvs have been solved by X-ray 
diffraction, 4P48 (Conroy et al., 2014), 4P49 (Conroy et al., 2014) and 4OUO (Mueller 
et al., 2014), in addition to scFvs from other phage libraries, 4NIK (Robin et al., 2014) 
and 5U68 (Wen et al., 2017). Results from the SwissModel software indicated that of 
the five scFvs, 4NIK, 5U68 and 4P49 shared the highest identity with the E5 scFv, 
56.8, 58.3 and 54.3%, respectively. The E5 scFv was modelled using all three 
templates and are shown in Fig. 5.6. The lowest Qmean values were obtained with the 
4NIK model (panel A) indicating a better model, followed by 5U68 (panel B) and 4P49 
(panel C). Overall, the 4NIK and 5U68 models overlaid better on E5 scFv compared to 
that of 4P49, which only modelled the VH region of the E5 scFv. As such, the E5 scFv 
model, built using the 4NIK template, was selected for the docking interaction studies 
with the homology modelled TcoOPB.  
 
Figure 5.6: Homology modelling of scFv clone E5, from TcoOPB pan 3, using 
different scFv templates. The E5 anti-TcoOPB scFv antibody (white with coloured CDR 
regions) was modelled using and superimposed onto (A) 4NIK, scFv complexed to human 
gankyrin (Robin et al., 2014), (B) 5U68, cross reactive antibody which binds to respiratory 
syncytial virus and human metapneumovirus (Wen et al., 2017), and (C) 4P49, scFv against 
prostate specific antigen using the chicken anti-prostate specific antigen (Conroy et al., 2014), 
all of which were coloured beige. The structures were obtained from the Protein Data Bank 
(Berman et al., 2000). The E5 scFv VH CDR1, -2 and -3 are highlighted in green, blue, red, and 
those of the VL in purple, pink and light orange, respectively. The linker region is highlighted in 
yellow. The alignment of the scFv sequences is shown together with the Qmean scores 
indicated in blue (high quality prediction) and red/orange (low quality prediction). 
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The validation of the generated homology modelled structures of both TcoOPB and E5 
scFv, using the ProSA software and Ramachandran plots, are reported in 
Appendix D7.  
 scFv and TcoOPB interactions predictions 
Using Predict7, an epitope prediction program (Cármenes et al., 1989), seven 
immunogenic epitopes were identified in TcoOPB and anti-peptide antibodies 
produced in chickens (Huson, 2006). They corresponded to amino acids 20-37 (light 
green), 60-76 (red), 124-142 (purple), 282-299 (orange), 418-436 (pink), 658-671 
(blue) and 686-698 (dark green) and were numbered 1 to 7, respectively (Fig. 5.7, 
panel A).  
The EpiPred epitope predictions can be used to improve the performance of 
antibody-antigen docking. The hinge region is comprised of two polypeptide strands, 
residues 87-95 and 433-440 (Canning et al., 2013), the first of which was not identified 
as an epitope by Predict 7 and the latter forming part of epitope 5. The first prediction 
(Fig. 5.7, panel B1) showed three contacts within epitope 3, 11 in epitope 5 as well as 
five contacts in one of the polypeptide chains, 87-95. The second EpiPred prediction 
(Fig. 5.7, panel B2) showed four contacts within epitope 4 (282-299).  
The ZDock protocol yields coloured prediction clusters at the most probably positions 
where the scFv molecule will interact with the antigen. The higher ranked poses are 
shown in red and change to blue as interaction probability decreases. There were more 
clusters evident around epitopes 4 and 5 (Fig. 5.7, panels C2 and C3) than for the 
remaining five epitopes. Since epitope 3 was predicted by EpiPred, these results will 
be included for completeness (panel C1). The results reported by Huson (2006) were 
used to select the most probable binding epitope on TcoOPB. The affinity purified 
anti-peptide antibodies raised against epitopes 3, 4 and 5 were all able to detect 
recombinant TcoOPB and TviOPB. Epitope 5 was poorly immunogenic as low titres of 
antibodies were produced throughout the immunisation period. The anti-peptide 
antibodies against both epitopes 3 and 4 were highly immunogenic and high antibody 
titres were produced. Taken together with the results from the EpiPred (panel B) and 
ZDock predictions (panel C), scFv interaction at epitope 4 is the most probable 
scenario. 
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Figure 5.7: Predicted immunogenic and structural epitopes together with the possible scFv interactions with TcoOPB. (A) The 
predicted immunogenic epitopes as predicted by Predict 7 (Cármenes et al., 1989) and reported previously by Huson (2006). Epitopes are coloured in 
light green (epitope 1), red (2), purple (3), orange (4), pink (5), blue (6) and dark green (7). (B1 and 2) The two structural epitope predictions (highlighted 
in yellow) after entering the E5 scFv VH and VL protein sequences together with the 3D structure of TcoOPB into the EpiPred predictor (Krawczyk et al., 
2014). The amino acid residues of epitopes 3, 4 and 5 are represented in a stick configuration. The ZDock cluster results of the antigen-antibody of E5 
scFv and TcoOPB around (C1, purple) epitope 3, (C2, orange) epitope 4 and (C3, pink) epitope 5. 
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 Docking of scFv onto TcoOPB 
The modelled structures of TcoOPB (Fig. 5.8, panel A), E5 scFv (panel B) were used 
in the ZDock antibody-antigen interaction protocol using the Discovery Studio software 
(Dassault Systèmes BIOVIA). The resulting position in which the E5 scFv has been 
docked onto TcoOPB is shown in panel C. As shown in panel D, eight of the 12 VH 
CDR3 residues interacted with those of epitope 4. In addition, four residues from each 
VH CDR1 and CDR2 and VL CDR2 interacted with residues from both the catalytic and 
propeller domain. 
 Expression of scFv clones 
The scFv clones E4, E5 and C2 were all expressed in TG1 E. coli cells, which should 
result in an myc-tagged scFv::pIII fusion protein which is approximately 74 kDa in size 
(Appendix D1).  
A protein band at approximately 35 kDa was identified in the osmotic shock (OS) 
fraction, more intensely than in the periplasmic (P) fraction, using the affinity purified 
chicken anti-myc IgY antibody (Fig. 5.9). This protein was present in both the periplasm 
and osmotic shock fractions for clones E5 and C2, yet only in the osmotic shock fraction 
for clone E4. This protein may correspond to the myc-tagged scFv without the pIII coat 
protein, which has an expected size of 31 kDa (Appendix D1). Detection of the 74 kDa 
pIII fusion protein using the anti-M13 (phage coat protein) antibody was unsuccessful 
(not shown).  
There were no myc-tagged proteins evident in the TG1 E. coli cell control. A faint 
protein band at approximately 21.5 kDa in the osmotic shock fraction was visible for 
C2 which is smaller than the expected size of myc-tagged scFv without the pIII coat 
protein.  
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Figure 5.8: Docked scFv onto epitope 4 of TcoOPB. (A) Structural features of TcoOPB include the catalytic domain (light purple), the propeller domain 
(light blue), the hinge region of two polypeptide chains (dark blue and dark purple), epitope 4 (orange) and the catalytic triad Ser563, Asp648 and His683 within 
the catalytic domain. (B) The structural features of E5 scFv include the VH CDR1, -2 and -3 (green, blue, red), the VL CDR1, -2 and -3 (purple, pink, light orange) 
and the linker region (bright yellow). (C) Solvent accessible surface of docked E5 scFv onto TcoOPB using ZDock protocol in the Discovery Studio software 
(Dassault Systèmes BIOVIA). (D) Residues of the E5 scFv CDRs which interact with TcoOPB are highlighted in bold.
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Figure 5.9: Expression of anti-TcoOPB and anti-TviOPB scFv antibodies. Samples 
of the periplasm (P) and osmotic shock (OS) fractions from the expression of scFv antibodies 
from TcoOPB pan 3 clones E4 and E5 and TviOPB pan 4 clone C2, all in TG1 E. coli cells, were 
electrophoresed on a 12.5% reducing SDS-PAGE. After transfer onto nitrocellulose, and 
blocking with 5% (w/v) milk-TBS, the blot was incubated with affinity purified anti-myc IgY 
[0.5 µg/ml in 0.5% (w/v) BSA-PBS]. Rabbit anti-chicken IgY HRPO conjugate [1:5 000 in 0.5% 
(w/v) BSA-PBS] and 4-chloro-1-naphthol∙H2O2 were used as the detection system. 
 
 Affinity purification of scFv 
Anti-TcoOPB scFv (E5 scFv) and anti-TviOPB scFv (C2 scFv), were purified using the 
Aminolink® resin, to which purified TcoOPB and TviOPB had been previously coupled. 
Application of the osmotic shock fraction onto the resin resulted in the purification of a 
protein, approximately 70 kDa in size, as can be seen by the Coomassie stained gel 
(Fig. 5.10, panel A). This protein band was also detected by the affinity purified chicken 
anti-myc IgY antibody (panel B) and corresponds favourably to the predicted molecular 
weight of the myc-tagged scFv::pIII fusion. Detection of the scFv::pIII fusion protein 
using the anti-M13 antibody was unsuccessful (not shown). 
The fact that the anti-TcoOPB E5 scFv and anti-TviOPB C2 scFv, from the osmotic 
shock fraction, were able to bind to their respective OPB antigens coupled Aminolink® 
resins, is direct evidence that the expressed scFvs are specific for TcoOPB and 
TviOPB. The eluted fractions from the purification of E5 scFv were pooled and used in 
subsequent experiments.  
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Figure 5.10: Affinity purified scFv using TcoOPB-aminolink and TviOPB-
aminolink resins. Samples of the eluted fractions from the purification of E5 anti-TcoOPB 
and C2 anti-TviOPB scFv from the osmotic shock fraction, using their respective aminolink 
resins, were electrophoresed on two 12.5% reducing SDS-PAGE gels with one (A) stained with 
Coomassie Blue R-250 and the other transferred onto nitrocellulose, blocked with 5% (w/v) 
milk-TBS and incubated with (B) affinity purified chicken anti-myc IgY [0.5 µg/ml in 0.5% (w/v) 
BSA-PBS]. Rabbit anti-chicken IgY HRPO conjugate [1:5 000 in 0.5% (w/v) BSA-PBS] and 
4-chloro-1-naphthol∙H2O2 were used as the detection system. 
 
 Antigen detection  
Since it had been demonstrated that the E5 scFv was able to bind to recombinant 
TcoOPB during purification, the ability of the E5 scFv to detect native TcoOPB in the 
subcellular fractions of T. congolense parasites (Section 3.2.5) was tested and 
compared to the detection by antibodies raised in rabbits and chickens against the 
recombinant TcoOPB and raised in chickens against peptide 4 (Fig. 5.11).  
Recombinant TcoOPB was detected by each of the four anti-TcoOPB antibodies. 
Native TcoOPB is located in the cytosol (Burleigh et al., 1997; Morty et al., 2005a; Rea 
and Fülöp, 2006), and as such, was detected in both the total parasite proteins and 
cytosolic fraction, but not in the mitochondrial fraction by each of the four anti-TcoOPB 
antibodies. 
Detection of the native TcoOPB which was secreted into the culture medium was 
achieved by three out of the four anti-TcoOPB antibodies, each with varying degrees 
of success. Both the rabbit and chicken anti-TcoOPB antibodies detected native 
TcoOPB with a good intensity. However, E5 scFv detection of native TcoOPB was very 
faint, requiring a fair amount of contrast to see the spots. No detection was achieved 
using the affinity purified chicken anti-peptide 4 IgY antibody.  
143 
 
 
Figure 5.11: Detection of native and recombinant TcoOPB. Samples of each 
T. congolense subcellular fraction, together with the precipitated culture medium and 
recombinant TcoOPB, were dotted onto nitrocellulose. After blocking with 5% (w/v) non-fat 
milk-TBS, the nitrocellulose strips were probed with rabbit anti-TcoOPB IgG (10 µg/ml), chicken 
anti-TcoOPB IgY (10 µg/ml), affinity purified chicken anti-peptide 4 IgY (5 µg/ml) and purified 
scFv (1:25), which were all diluted in 0.5% (w/v) BSA-PBS. Before the addition of the detection 
antibody, the nitrocellulose strip which had been incubated with the purified E5 scFv, was 
incubated with affinity purified chicken anti-myc IgY [0.5 µg/ml in 0.5% (w/v) BSA-PBS]. The 
rabbit anti-chicken IgG HRPO conjugate and the goat anti-rabbit IgG HRPO conjugate, together 
with the ECL western blotting substrate, were used as the detection system. The panel detected 
using purified E5 scFv was subject to extensive contrast to better visualise the ECL signal. 
 
As it has been demonstrated that E5 scFv was able to detect native TcoOPB, ELISA 
optimisations were carried out to minimise the amount of scFv used and to increase 
the detection of TcoOPB. Comparison of the ability of the crude E5 scFv, periplasmic 
and osmotic shock fractions together with the purified scFv, to detect recombinant 
TcoOPB, indicated that the purified E5 scFv was superior (Fig. 5.12, panel A). A 1:100 
dilution of the purified E5 scFv yielded in absorbance values of over 1 at TcoOPB 
concentrations as low as 5 µg/ml. At 1 µg/ml, an absorbance of 0.4 was attained.  
Absorbance values between 0.210 and 0.356 were obtained when using the 
periplasmic fraction, even at 10 µg/ml of coated recombinant TcoOPB. However, a 
1:10 dilution of the osmotic shock fraction produced absorbance values of 0.663 and 
0.535 at 10 and 5 µg/ml coated recombinant TcoOPB, respectively (Fig. 5.12, panel 
A). Optimisation of the dilution of the osmotic shock fraction was characterised by 
absorbance values between 0.222 and 0.263 for the controls in the absence of coated 
TcoOPB, with a 1:2.5 dilution of the osmotic shock fluid having the highest absorbance 
values at each of the coated recombinant TcoOPB concentrations (Fig. 5.12, panel B). 
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Regrettably, the higher the coated concentration of recombinant TcoOPB, the higher 
the absorbance values of the ‘no linking antibody control’ (affinity purified chicken 
anti-myc IgY) and the ‘no detection antibody control’ (rabbit anti-chicken IgY HRPO 
conjugate). Despite this, the absorbance values of the osmotic shock fractions were 
still higher than those of the controls. Several attempts to lower the absorbance values 
of the controls, through the use of various blocking buffers, and even the use of rabbit 
anti-myc IgG, were unsuccessful. 
 
Figure 5.12: Checkerboard ELISA of crude and purified scFv against 
recombinant TcoOPB. ELISA plates were coated with TcoOPB (10, 5 and 1 µg/ml in PBS, 
pH 7.2), blocked with 0.5% (w/v) BSA-PBS and incubated with (A) crude scFv, from the 
periplasm and osmotic shock fractions, and purified scFv (1:10 and 1:100 dilutions) and (B) 
crude scFv from the osmotic shock fraction (1:10, 1:7.5, 1:5 and 1:2.5 dilutions). The bridging 
antibody used was affinity purified chicken anti-myc IgY (0.5 µg/ml). The rabbit anti-chicken IgY 
HRPO conjugate (1:5 000) and ABTS∙H2O2 were used as the detection system. The 
absorbance readings at 405 nm represent the average of (A) duplicate and (B) triplicate 
experiments after 45 min development. 
 
The purified E5 scFv was used to detect native TcoOPB in the sera of experimentally 
T. congolense infected cattle using an indirect antigen detection ELISA format. If the 
rabbit anti-TcoOPB antibody was used as the capture antibody, a linking antibody 
would be required between the scFv and the HRPO conjugate antibody, in the form of 
the affinity purified chicken anti-myc IgY antibody (Fig. 5.13). This would require a 
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rabbit anti-chicken HRPO conjugate which may cross-react with the capture antibody. 
As such, the scFv was used as the capture antibody. 
 
 
Figure 5.13: Comparison of the choice of capture and detection antibody in the 
indirect antigen detection ELISA. 
 
Sera from three individual cows, from three separate studies, were selected, based on 
the reactivity of the sera as tested in previous studies against other possible diagnostic 
antigens in an antibody detection ELISA format (Eyssen, 2013). A series of serum 
samples taken from each of these cows, at different times during the infection process, 
were selected. The values in brackets denote the days prior to and after infection, the 
T- values denote the days after treatment (Fig. 5.14). Parasitaemia, which was only 
measured for certain samples by the tecnicians at ClinVet (Bloemfontein), is denoted 
by black dots. Where parasitaemia was not measured, no value was assigned. Each 
of the three cows was infected with a different T. congolense isolate and treatment was 
administered after different time periods post infection. 
Since OPB is released from dead and dying parasites (Morty et al., 2001), serum 
samples taken prior to infection should be characterised by low absorbance values in 
the antigen detection ELISA. During infection, OPB levels should fluctuate together 
with the characteristic waves of parasitaemia. After successful treatment with 
trypanocides, dead parasites would release OPB, and result in increased absorbance 
values in the antigen detection ELISA.  
Serum prior to infection had higher absorbance values than that of the recombinant 
TcoOPB and the no serum control, which could suggest that there are factors in the 
serum samples which may be reacting with the capture and detection antibodies. 
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Figure 5.14: Indirect antigen capture ELISA of TcoOPB in sera of infected cattle. ELISA plates were coated with the purified scFv (1:100 in PBS, 
pH 7.2) as the capture antibody, blocked with 0.5% (w/v) BSA-PBS, incubated with sera from infected and non-infected cattle (1:100 dilution), and detected with 
rabbit anti-TcoOPB IgG (1 µg/ml). Goat anti-rabbit IgG HRPO conjugate (1:2 500) and ABTS∙H2O2 were used as the detection system. The absorbance readings 
at 405 nm represent the average of triplicate experiments after 30 min development. Parasitaemia is denoted by black dots.
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For cow 200, an increase in parasitaemia and absorbance values was evident until day 
7 post infection. A steady decrease in absorbance values was observed after 
treatment, which could indicate that treatment was not effective at killing the parasites, 
since more OPB would be present in the serum, released by dead parasites, resulting 
in increased absorbance values. Unfortunately, the parasitaemia was not quantified, 
but was observed, showing a sustained infection until day 90, 72 days after treatment, 
before the animal had to be euthanised. This could indicate that due to the ineffective 
treatment the parasites were not killed, evidenced by the positive confirmation of 
parasitaemia. 
For cow 81, parasitaemia was observed and quantified until day 35, thereafter, it was 
not evaluated. The ELISA absorbance values increased until day 14, and decreased 
slightly at day 35. The sharp increase in absorbance values was evident from day 28 
to day 48, after 14 days of treatment, which may indicate effective parasite killing where 
OPB was released into the serum. The next three tested samples had similar 
absorbance values to that seen at day 35, which could indicate that the treatment was 
no longer effective. 
Similar absorbance values were evident for the sample taken prior to infection and 7 
days after, despite an increase in parasitaemia in cow 167. From day 14 to 47, 
absorbance values fluctuated, together with those of parasitaemia values. After day 
49, 14 days post treatment, the absorbance values fluctuate again, peaking at day 112, 
77 days post treatment. The overall fluctuation of absorbance values may be linked to 
that of the fluctuating parasitaemia values, indicating that treatment was not successful 
as parasites were still evident in the serum and varying levels of OPB was detected 
throughout the post treatment period.  
5.4 Discussion 
The serine peptidase of trypanosomal parasites, oligopeptidase B (OPB), was detected 
in the serum of T. b. rhodesiense infected individuals (Eyford et al., 2013). 
Furthermore, analysis of the secretome of T. b. gambiense (Geiger et al., 2010), 
T. congolense (Eyford et al., 2011), T. cruzi (Bayer-Santos et al., 2012) and 
L. donovani (Silverman et al., 2008) indicated that OPB from these species are 
released by the dying parasites. It may therefore be inferred that OPB is an attractive 
diagnostic antigen. Another antigen shown to be secreted into the host bloodstream is 
TbbMCA4 (Proto et al., 2011) confirming the detection of TbgMCA4, with which it 
shares a 100% sequence similarity, in the T. b. gambiense secretome (Geiger et al., 
2010). The MCAs produced as described in Chapters 2 and 3 showed extensive 
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autoprocessing with only the double catalytic dyad mutants (TcoMCA5H147AC202G) 
showing minimal processing. However, an insufficient amount of protein could be 
purified to use to pan the Nkuku® phagemid libraries to isolate anti-MCA scFv 
antibodies. Here the use of phage display to produce recombinant antibodies against 
OPB as a model antigen for diagnostic application is reported.  
Antibodies produced with phage display have been used in a number of applications 
such as immunoblotting (Renart et al., 1979; Rakabe, 2008), ELISA (Engvall and 
Perlmann, 1971), immunofluorescence (Coons et al., 1941), flow cytometry (Bonner et 
al., 1972), affinity chromatography (Porter and Press, 1962) and microarrays (Silzel et 
al., 1998; Stoevesandt et al., 2009). Phage display has been able to successfully 
identify antibody fragments using the immunoglobulin genes from camels in a VHH 
format (Ghahroudi et al., 1997), from cattle in a Fab format (O'Brien et al., 1999), and 
from chickens (Davies et al., 1995), rabbits (Ridder et al., 1995) and sheep in an scFv 
format (Li et al., 2000). Since antibodies are generated from the immunoglobin genes 
of specific animal hosts, the resulting recombinant antibodies are suitable for veterinary 
applications. The Nkuku® phage display library is based on the immunoglobulin genes 
from B-cells isolated from the bursa of Fabricus of naïve white leghorn hens (van 
Wyngaardt et al., 2004). The PCR-amplified genes are incorporated into the pHEN1 
phagemid plasmid, the Nkuku® library phagemid, which results in the expression of a 
myc-tagged scFv::pIII fusion protein. When using in the E. coli TG1 suppressor strain, 
the scFv is expressed as the 74 kDa fusion protein.  
Panning of the Nkuku® library was performed to select TcoOPB- and TviOPB-specific 
scFv antibodies. The panning process was repeated four times, using the Nkuku® 
library phagemid as the starting material. It was demonstrated by the binding of the 
anti-M13 (phage coat protein) antibody that enrichment occurred at pans three and 
four for TcoOPB and pan four for TviOPB. The numerous individual clones selected 
from each of these pans, were analysed using an ELISA for their ability to produce 
M13 positive phage binding- and soluble myc positive scFv antibodies. None of the 
absorbance signals were above 1 and the signals between the phage binding- and 
soluble ELISA were comparable, unlike the doubling of absorbance values in the 
soluble scFv ELISA from those of the phage binding ELISA as reported by Rakabe 
(2008). 
Selection of clones for scFv expression is commonly based on the results of the 
sequencing of the plasmid DNA which becomes costly due to the high number of 
clones that can be tested. In this study, we employed a selection protocol whereby only 
the clones which were positive for phage binding and soluble scFv, had complete 
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coding sequences using colony PCR and those with similar sequences using DNA 
fingerprinting. This allows for a minimum number of plasmids to be sequenced.  
Clones E4 and E5 from TcoOPB pan three, and C2 from TviOPB pan four, were 
positively identified as positive as complete scFvs and were found to encode for the 
same protein sequence which may indicate a highly conserved epitope in OPB. The 
identification of the conserved epitope was achieved using molecular docking of the 
homology modelled E5 scFv onto TcoOPB. This approach has revealed the binding 
sites of phage displayed scFv on the HSP60 of the Strongyloides venezuelensis 
human infective parasite (Levenhagen et al., 2015). The VH CDR3 of E5 scFv 
interacted with TcoOPB at a previously identified epitope, VRKREKNVRYEVEMHGT 
(Huson, 2006). The VH CDR3 is the main source of antibody variation as it plays a key 
role in antibody binding (Marks et al., 1991; Nissim et al., 1994; Sheets et al., 1998; 
van Wyngaardt et al., 2004). As such, the interaction of this region with the target 
antigen verifies the application of the TcoOPB-specific scFv in diagnostics. In addition 
to the CDRs, the framework regions between the CDRs interacted with residues from 
both the catalytic and propeller domains of TcoOPB.  
The 3D structure of TbbOPB has been solved, using X-ray diffraction, in both a closed 
and open conformation, between which a domain rotation of 27.8° is evident (Canning 
et al., 2013). The process of domain opening disrupts the catalytic triad and results in 
the inactivation of OPB (Canning et al., 2013). Reactivation requires complete domain 
closure to restore the catalytic triad, which can only be achieved with peptide 
substrates which are shorter than 30 residues (Canning et al., 2013). The E5 scFv may 
not dock in the active site, but may hinder the OPB from adopting the open 
conformation which would allow substrate access. Due to the difficulties in purifying 
high concentrations of scFv, immuno-inhibition studies of both recombinant and native 
TcoOPB with E5 scFv could not be carried out for validation of the proposed docking 
model. 
The pelB leader sequence within the pHEN1 plasmid directs the scFv to the periplasm 
(Kipriyanov et al., 1997). Cold osmotic shock (Neu and Heppel, 1965) was used to 
obtain the periplasmic and osmotic shock fractions, in which 35 kDa myc-tagged scFv 
was detected using the anti-myc antibody as has been reported by Philibert et al. 
(2007). Since TG1 E. coli cells were used, a 70 kDa fusion protein was expected. Due 
to the peptidolytic degradation of the myc-tagged scFv::pIII fusion protein in the 
periplasm, only 20 to 30% of the fusion proteins are intact (McCafferty, 1996; Baek et 
al., 2002; Shi et al., 2007). When the scFv from the osmotic shock fraction was 
150 
concentrated by affinity purification using immobilised OPB, sufficient amounts of intact 
myc-tagged scFv::pIII fusion protein was available for the anti-myc antibody to detect 
the full length 70 kDa fusion protein.  
Various methods are implemented for the purification of scFv, most of which depend 
on the affinity tag incorporated onto the scFv by the phagemid plasmid. Both nickel- 
(Das et al., 2005; Finlay et al., 2005; Saerens et al., 2008; da Silva Ribeiro et al., 2013) 
and cobalt- (Dong et al., 2013) affinity chromatography has been successfully utilised 
for purification of 6xHis tagged scFv but the pHEN1 phagemid plasmid only encodes 
for a myc tag.  
The myc-affinity resin has been used to purify scFvs panned from the Nkuku® library 
(van Wyngaardt et al., 2004). However, due to the high cost and difficulties in importing 
the rabbit anti-myc antibody, two myc affinity resins were made inhouse using both 
chicken and rabbit anti-myc antibodies coupled to Hydrazide® resin. The 
myc-antibodies were successful in detecting the scFv in a western blot and ELISA 
format, but not for the immunoaffinity purification of the expressed scFvs. Purified 
TcoOPB and TviOPB immobilised on AminoLink® was used to purify the OPB-specific 
scFvs. The successful purification of the 70 kDa myc-tagged scFv::pIII fusion, indicated 
that the OPB-specific scFv was indeed able to detect OPB.  
Nanobodies (VHH) from a camelid library, raised against the paraflagellar rod protein 
in T. evansi, detecting the protein in T. b. brucei, T. congolense and T. vivax (Obishakin 
et al., 2014), and the T. congolense aldolase specific scFv, have both been shown 
have application in research imaging and diagnostics (Odongo et al., 2016). Despite 
the ability of scFv to detect recombinant TcoOPB, the polyclonal anti-TcoOPB 
antibodies produced in rabbits and chickens were superior in the detection of native 
TcoOPB secreted into the culture medium. This may indicate that the scFv has a lower 
limit of detection of OPB compared to that of the polyclonal antibodies.  
Both the purified and crude E5 scFv were able to detect OPB in a checkerboard ELISA 
but high background was observed. Cross reactivity was suspected using the 
polyclonal chicken anti-myc antibody to detect myc-tagged scFv, which is derived from 
chicken immunoglobulin genes. Rabbits were used to generate anti-myc antibodies but 
these antibodies did not react as well as those from chickens (results not shown). 
Blocking with various buffers along with the most commonly used 2% Milk-PBS and 
3% BSA-PBS as suggested in the Nkuku® library instructions did not reduce the 
background (results not shown).  
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The application of scFv antibodies has been successful in the diagnosis of bluetongue 
virus using an inhibition ELISA (Fehrsen et al., 2005) and human strongyloidiasis using 
a sandwich ELISA were the immune complexes were detected (Levenhagen et al., 
2015). An evaluation of the use of TcoOPB in an antibody detection ELISA showed 
that OPB was not suitable in this format (Eyssen, 2013). As such, neither the inhibition 
ELISA nor the detection of OPB-immune complexes was pursued.  
Using a sandwich ELISA, scFv have been used for the detection of African horse 
sickness virus, AHVS (van Wyngaardt et al., 2013), infectious bursal disease virus, 
IBDV (Sapats et al., 2003), Mycobacterium bovis (Wemmer et al., 2010), Neospora 
caninum (Dong et al., 2013) and T. congolense (Odongo et al., 2016). These ELISAs 
either made use of a homologous or heterologous scFv pair or a combination of a 
polyclonal antibody and scFv as the capture and detection antibodies. Modification of 
the scFv in the pair has been reported by Wemmer et al. (2010) were the detection 
scFv was conjugated to gold particles, and by Odongo et al. (2016) where the capture 
scFv was 6xHis tagged and the detection scFv was biotinylated.  
The binding of scFv to the antigen is confirmed using either anti-myc or anti-M13 
antibodies. The anti-M13 antibody did not detect the expressed nor the purified E5 
scFv in a western blot, and the absorbance values from the phage binding ELISA were 
similar to those of the soluble scFv ELISA. As such, the anti-myc antibody was used in 
the detection of the bound scFv when used as a capture antibody.  
Using scFv as the capture antibody and polyclonal rabbit anti-TcoOPB as the detection 
antibody, the absorbance values of the serum samples taken at different times during 
infection, fluctuated together with the parasitaemia values. Since OPB is released into 
the bloodstream upon parasite lysis, at peak parasitaemia, low levels of OPB is 
expected and vice versa. Similar to OPB, TcoAldolase is secreted by the parasite 
(Grébaut et al., 2009) into the bloodstream of the mammalian host by a mechanism 
which is still unknown. TcoAldolase-specific scFv antibodies used in a homologous 
sandwich ELISA detected aldolase even after the reduction of parasite numbers 
(Odongo et al., 2016). It was demonstrated that TcoAldolase-specific scFv was able to 
distinguish between cured and active infections (Odongo et al., 2016). It is, thus, 
possible that TcoOPB-specific scFv can be used as a diagnostic marker after further 
adjustments have been made to improve the ELISA performance. 
This study showed that using phage display, OPB-specific scFv antibodies were 
produced that were capable of detecting both recombinant and native TcoOPB. These 
antibodies have potential application in parasite imaging in cellular research and for 
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diagnostic development. The validation of the immuno-inhibition of OPB requires 
further investigation along with the generation of TcoMCA5-specific scFvs.  
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CHAPTER 6 
GENERAL DISCUSSION 
Human African trypanosomiasis (AT) is a neglected tropical disease caused by 
Trypanosoma spp. which can infect both humans, causing human AT (HAT), and 
animals, causing animal AT (AAT). These haemoprotozoa are transmitted by tsetse 
flies in sub-Saharan Africa. Human infections occur in 24 countries across the west 
and central regions of Africa (Simarro et al., 2012). Despite the major impact on 
livestock farming (Bouyer et al., 2014) and agricultural development in Africa (Alsan, 
2015), in contrast to HAT, AAT is not considered as a neglected tropical disease (Roger 
et al., 2017). In addition, human infective parasites can exist in both wild animals and 
domestic livestock (Anderson et al., 2011). As most trypanosome infections occur in 
predominantly rural areas where animal diseases have a direct impact on people’s 
livelihoods (source of food and income), AAT indirectly impacts human health and 
should be considered as a neglected tropical disease (Roger et al., 2017). 
The disability-adjusted life-years (DALYS) caused by HAT has decreased by 74.8% 
since 2005 (GBD et al., 2017) with fewer than 4 000 human infections reported in 2014 
(Franco et al., 2017). The reduction in reported cases is a direct result of active case 
finding, easier access to healthcare facilities, accurate diagnosis, and timeous 
treatment (Büscher et al., 2017). Despite their ability to screen and identify potential 
T. b. gambiense infections, the CATT and RDTs are not 100% specific (Jamonneau et 
al., 2015) and are less specific when disease prevalence is low. The prevalence of 
T. b. gambiense infections is well below 0.1% in most HAT endemic areas, and as a 
direct result, for a single true positive serological test, 99 false positive tests are 
reported (Büscher et al., 2017). 
The current HAT chemotherapies, which have been in use since the 1960s (Field et 
al., 2017), have adverse side effects and require lengthy administration at health clinics 
(Garcia-Salcedo et al., 2014). No new AAT chemotherapies have been introduced 
since 1961 (Giordani et al., 2016) and drug resistance has been reported in 17 African 
countries (Van den Bossche and Delespaux, 2011). Due to the immune-evasion 
mechanisms of African trypanosomes, the development of an effective vaccine is 
unlikely and as a result, new chemotherapies are required (Field et al., 2017). The 
identification of the infecting trypanosomal species as well as disease staging is crucial 
for the treatment of HAT infections. As such, positive serodiagnosis is followed by 
parasitological diagnosis to confirm infection (Wamboga et al., 2017). This is 
complicated by the waves of parasitaemia and the resistance of T. b. gambiense and 
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T. b. rhodesiense to the trypanosome lytic factor found in human serum (Vanhollebeke 
and Pays, 2010). Currently, HAT diagnosis is made using the card agglutination test 
(CATT), but is being replaced with the simpler BIOLINE HAT RDT in Uganda 
(Wamboga et al., 2017). This test is better-suited to the lack of cold chain and 
laboratory facilities in endemic regions. The CATT and RDT meet the ASSURED 
criteria as they are affordable, sensitive, specific, user friendly, rapid and robust, 
equipment free and are deliverable to the end user (Peeling et al., 2006). As a result, 
smaller health care facilities in rural areas are able to offer the BIOLINE RDT test which 
reduces the distance that the patients need to travel for diagnosis (Wamboga et al., 
2017). This allows for more people to be screened and cases to be detected and 
treated quickly.  
Parasitological methods are used for field diagnosis of AAT as well as other tropical 
diseases (OIE, 2013). Serological diagnosis of AAT includes the indirect fluorescent 
antibody test and ELISA, both of which do not meet the ASSURED criteria, and are 
used for disease surveillance (OIE, 2013). Recently, an RDT prototype for the detection 
of T. congolense, T. vivax as well as T. congolense and T. vivax mixed infections was 
reported using the recombinant cathepsin-B like peptidase and the tandem repeat 
protein associated with the flagellum (GM6) antigen (Boulangé et al., 2017). The 
prototype was characterised by a 92% sensitivity and 95% specificity for T. congolense 
and a 98.2% sensitivity and 95% specificity for T. vivax infections. 
Two relatively new compounds, fexinidazole and benzoxaborole SCYX-7158, which 
were identified using phenotypic screening, are in various stages of clinical trials as 
potential oral HAT chemotherapies (Jacobs et al., 2011; Tarral et al., 2014). Given that 
infected animals act as reservoirs for human infective trypanosomes (Anderson et al., 
2011), together with reports of drug resistance in the absence of new AAT drugs (Van 
den Bossche and Delespaux, 2011), emphasises the urgent need for new effective 
AAT chemotherapies. 
The development of a vaccine is improbable due to the evasion of the immune system 
by the parasite as well as elimination of B-cell memory following trypanosome infection 
(La Greca and Magez, 2011). An anti-disease approach entails targeting factors which 
are essential to the parasite’s survival within either the mammalian host or insect 
vector, to reduce disease symptoms, rather than killing the parasite per se (Antoine-
Moussiaux et al., 2009). The Kinetoplastid Target Database (http://rapid.lifesci. 
dundee.ac.uk/KTD/) lists potential proteins and peptidases which have been identified 
as targets for the development of novel chemotherapies against T. brucei spp., T. cruzi 
and Leishmania spp., the causative agents of African trypanosomiasis, Chagas 
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disease and Leishmaniasis, respectively. The peptidases studied here, i.e. the MCAs 
and OPB, are listed in this database as possible drug targets.  
The MCAs share the catalytic dyad residues and caspase-haemoglobinase fold 
(Aravind and Koonin, 2002) with the caspases but differ in numerous aspects, the most 
important being the MCAs’ preference for Arg or Lys at P1 over Asp. In the early years 
of MCA research, it was thought that the MCAs functioned in a similar manner to that 
of the caspases in cell death (Madeo et al., 2002). It has since been reported that the 
MCAs are sufficiently structurally and functionally diverse to be classed separately from 
the caspases (McLuskey and Mottram, 2015). Metacaspases have been implicated in 
cell death processes, but in an indirect manner. To date, the MCAs and caspases share 
two natural protein substrates: tudor staphylococcal nuclease and glyceraldehyde 3-
phosphate dehydrogenase. Both Picea abies MCA (Sundström et al., 2009), PfMCA2 
(Vandana et al., 2018) and caspase-3 (Sundström et al., 2009) could hydrolyse tudor 
staphylococcal nuclease, whilst YCA1 (Silva et al., 2011) and caspase-1 (Shao et al., 
2007) could hydrolyse glyceraldehyde 3-phosphate dehydrogenase. This indicates 
that although caspases and MCAs show distinct differences in their P1 residue 
requirements, similarities exist in their targeted molecular pathways (Sundström et al., 
2009; Bozhkov et al., 2010). Since the MCAs are found in all kingdoms except the 
metazoa (Uren et al., 2000), and are potentially involved in cell death processes, these 
peptidases are attractive drug targets.  
The hydrolysis of host peptide hormones by OPB, implicates this peptidase in the 
neurological disturbances of the final stage of AT infection (Morty et al., 1999; Morty et 
al., 2001). The peptidase is released by dead and dying parasites into the host 
bloodstream where it remains active (Morty et al., 2005a; Morty et al., 2005b; Munday 
et al., 2011). Despite being listed in the Kinetoplastid Target Database, it has been 
shown that OPB is not required for parasite infectivity (Moss et al., 2015) and as such, 
is not a target for the development of novel chemotherapies. The detection of the 
released OPB antigen in the mammalian host bloodstream is however, a viable option 
for the differentiation between cured and active infections. Hence OPB, is an attractive 
diagnostic antigen and its incorporation into a RDT would be ideal.  
The best studied MCAs are those from A. thaliana and S. cerevisiae. The only 
multicopy MCAs to be enzymatically characterised are those from T. b. brucei (Moss 
et al., 2007; Proto et al., 2011; Machado et al., 2013) and T. cruzi (Kosec et al., 2006), 
and the single copy MCAs from L. major (Gonzáles et al., 2007), L. donovani (Lee et 
al., 2007) and T. cruzi (Kosec et al., 2006). The single copy TbbMCA5 was shown to 
be expressed in both animal and insect infective forms (Helms et al., 2006). The 
156 
kinetoplastid single copy MCAs are syntenic orthologues suggesting that they are the 
possible progenitor of the multicopy MCAs (Ambit et al., 2008). Hence the 
characterisation of the single copy MCAs from the animal infective T. congolense and 
T. vivax could contribute to the understanding of the role played by the MCAs in cellular 
processes. 
In the present study, recombinant TbbMCA2, as well as the MCA5s from T. congolense 
and T. vivax, expressed in E. coli, were shown to undergo autoprocessing, similar to 
the caspases (Roy et al., 2014). In addition, immunoaffinity purified native TcoMCA 
showed slight autoprocessing in the current study and this has only been reported 
previously for native LmjMCA (Gonzáles et al., 2007). Autoprocessing has been 
observed following recombinant expression of the type I MCAs from A. thaliana 
(Watanabe and Lam, 2005), LmjMCA (Gonzáles et al., 2007), as well as TbbMCA2 
(Moss et al., 2007). It is thought that MCA autoprocessing allows for the cleavage of 
the N- and C-terminal domains, releasing the catalytic domain. Mutation of the residues 
in TbbMCA2 at which autoprocessing occurred, resulted in an unprocessed enzyme 
which could hydrolyse small peptide substrates but not large substrates, such as 
azocasein (Gilio et al., 2017). Comparison of the enzymatic activity of the recombinant 
full length and the catalytic domain of LmjMCA revealed that the catalytic domain was 
3.5 times more active than the full length enzyme (Gonzáles et al., 2007). This could 
explain the lower rate of Z-Gly-Gly-Arg-AMC hydrolysis by native TcoMCA5 than by 
TcoMCAH147AC202G reported in the current study. 
Similar to that of TbbMCA2 and TviMCA5, recombinant expression within insoluble 
inclusion bodies has been reported for both TcrMCA3 and -5 (Kosec et al., 2006) as 
well as TcoMCA5 (Eyssen, 2013). Nickel affinity chromatography has been used for 
the purification of MCAs from Trypanosoma spp. (Kosec et al., 2006; Moss et al., 2007; 
Proto et al., 2011), Leishmania spp. (Gonzáles et al., 2007; Lee et al., 2007; Peña et 
al., 2017), A. thaliana (Vercammen et al., 2004; Watanabe and Lam, 2011), 
S. cerevisiae (Wong et al., 2012) and Triticum aestivum (Piszczek et al., 2012) but the 
elution patterns obtained in these studies were not reported. In the present study, nickel 
purification of the sarkosyl solubilised MCAs in the present study resulted in more MCA 
fragments being eluted than what was loaded onto the resin. This phenomenon was 
not observed in the immunoaffinity purification of soluble recombinant MCA. This led 
to the hypothesis that MCA5, which had already undergone autoprocessing during 
expression, over autoprocessed in the presence of nickel ions. This process was 
termed nickel-induced over autoprocessing in the present study. The elution profile of 
the nickel purified MCA5 is similar to that of purified AtMCA4, which had already 
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undergone autoprocessing during expression, after the addition of calcium, resulting in 
the detection of more MCA fragments (Watanabe and Lam, 2011). It was shown that 
neither the recombinant nor the native TcoMCA5 required calcium for their peptidolytic 
activity. Most type I and -II MCAs are calcium regulated, requiring micromolar and 
millimolar concentrations of calcium, respectively (Madeo, 2002; Adams, 2003; Wong 
et al., 2012). Recombinant A. thaliana MCA-4, -5 and -8 (He et al., 2008) and Picea 
abies MCA (Bozhkov, 2005) have an absolute calcium requirement for enzymatic 
activity. It has been demonstrated that recombinant AtMCA9 (Vercammen et al., 2004), 
LmjMCA (Gonzáles et al., 2007) and TcoMCA5 (Chapter 3), all of which autoprocess, 
do not require calcium for enzymatic activity. Thus, it can be concluded, that different 
MCAs have different affinities for different divalent cations.  
It has been suggested that recombinant MCA may exhibit minor catalytic activity which 
could initiate a cascade of peptidolytic processes. Thus, when two proenzyme 
molecules are in close proximity, one slightly active proenzyme could cleave the 
second molecule (Watanabe and Lam, 2011). When 6xHis tagged recombinant 
TcoMCA5 and TviMCA5 bind to the nickel resin, each can interact with itself and those 
MCA molecules in its immediate surroundings, resulting in processing at secondary 
cleavage sites as well as Arg and Lys residues. This would result in cleavage within 
the catalytic domain rendering the peptidase enzymatically inactive. 
Mutagenesis of both the catalytic dyad residues of the MCA5s in the present study, 
resulted in little nickel-induced over autoprocessing, with only the MCA5H147AC202G 
mutant of T. congolense found to be enzymatically active. The activity of the double 
mutant may be explained by the presence of a secondary catalytic Cys, as reported for 
AtMCA9 by Belenghi et al. (2007) and the type II MCA from Triticum aestivum by 
Piszczek et al. (2012), where the catalytic Cys and secondary catalytic Cys are in close 
proximity. This hypothesis is strengthened by the conservation of this residue in all 
kinetoplastid MCAs as reported by Szallies et al. (2002) and shown in Appendix A3. In 
the current study it was demonstrated that the secondary catalytic Cys was hydrogen 
bonded to one of the conserved water molecules in the active site pocket and formed 
more Pi-alkyl interactions with the fluorogenic peptide substrates compared to that of 
the catalytic Cys as determined by docking studies. It has been reported that mutations 
of the catalytic dyad residues of recombinant LdnMCA were still peptidolytically active, 
albeit 2-fold less than the wild type peptidase, and were not essential to its ‘trypsin-like’ 
activity (Lee et al., 2007). It is, thus, hypothesised that the catalytic His and Cys 
residues are required for autoprocessing, as evidenced by the limited over 
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autoprocessing in the double mutant shown in the present study, and that the 
secondary catalytic Cys is responsible for the peptidolytic activity. 
The peptidolytic activity of TcoMCAH147AC202G was confirmed by the digestion of gelatin 
in the present study. It was also shown that the immunoaffinity purified native TcoMCA5 
was active. This is the first report of the digestion of gelatin by either a caspase or a 
MCA. The two lower molecular weight forms of TcoMCA5H147AC202G, which were thought 
to contain the catalytic domain, digested gelatin, but the full length protein did not. The 
full length native enzyme was more active than the single lower molecular weight form 
which confirms the reports that autoprocessing is not an absolute requirement for 
peptidolytic activity (Moss et al., 2007).  
Reported in this study, TcoMCAH147AC202G has a P1 specificity for Arg and Lys, with a 
preference for Arg over Lys. Similar to AtMCA4 (Vercammen et al., 2004) and AtMCA8 
(He et al., 2008), PaMCA (Bozhkov et al., 2005), TbbMCA2 (Machado et al., 2013) and 
LdnMCA (Lee et al., 2007) which are optimally active between pH 7 and 8.5, 
TcoMCA5H147AC202G was active over a broad pH range between 6 and 9. Inhibition of 
the enzymatic activity of TbbMCA2 (Moss et al., 2007), TbbMCA4S219C (Proto et al., 
2011), LdnMCA (Lee et al., 2007) by antipain and leupeptin was reported and 
corresponds to the inhibition of TcoMCAH147AC202G albeit less effectively, 20% compared 
to between 90 and 100% inhibition reported for each of the above mentioned MCAs. 
Inhibition by TLCK (70 to 100%) has been reported for the above mentioned MCAs but 
did not affect the activity of TcoMCAH147AC202G. The irreversible inhibitor Z-Phe-Arg-FMK 
was used as an active site titrant for the recombinant orthocaspase 1 from Microcystis 
aeruginosa PCC 7806 (Klemenčič et al., 2015), and biotin-Phe-Pro-Arg-CMK inhibited 
the enzymatic activity of recombinant AtMCA4 (Watanabe and Lam, 2011). Docking 
studies performed in the present work, showed that these reversible inhibitors had a 
lower affinity for TbbMCA2, TcoMCA5 and TviMCA5 than antipain and leupeptin. 
Experimental validation of the inhibition of TcoMCAH147AC202G is required to confirm this.  
The single MCA in S. cerevisiae, YCA1 (Madeo, 2002), and the type I MCAs from 
A. thaliana (Vercammen et al., 2004), possess a Gln and Asn-rich N-terminal domain. 
This domain was found to be responsible for the targeting of the MCA to insoluble 
protein aggregates as well as the stabilisation of the zymogen (Erhardt et al., 2010; 
Lee et al., 2010). The YCA1 and single copy kinetoplastid MCAs are phylogenetically 
more related compared to the multicopy MCAs. The single copy MCAs possess the 
Pro-, Gln-, Tyr-rich C-terminal extension, which is implicated in protein-protein 
interactions (Kay et al., 2000). This was demonstrated whereby the overexpression of 
TcrMCA5 without the C-terminal domain resulted in a drop in parasite cell number and 
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the presence of non-motile rounded cells resembling apoptotic cells (Laverrière et al., 
2012). It is, thus, thought that the C-terminal domain of TcrMCA5 may have pro-
apoptotic role, whereby it negatively regulates apoptotic-like cell death. Thus, one can 
hypothesise that the single copy MCA5s from T. congolense and T. vivax may function 
in a similar manner.  
Using RNA interference (RNAi), overexpression and gene knock-out studies, reported 
to date, it has shown that the kinetoplastid MCAs are involved in cell cycle and in the 
regulation of cell death processes. The RNAi of TbbMCA2, -3 and -5 resulted in the 
growth arrested parasites with multiple nuclei and kinetoplasts, almost four times more 
than the non-induced control, indicating an essential role in the cell cycle (Helms et al., 
2006). The loss of MCA2 and -3 can be compensated by MCA5 and vise versa as 
parasites were able to adapt to the successive gene knock-out of MCA2, -3 and -5 
(Helms et al., 2006). However, the rapid loss of all three MCA genes by RNAi was 
lethal to the parasite (Helms et al., 2006).  
When overexpressed in yeast, TbbMCA4 was shown to inhibit growth, disrupt 
mitochondrial function and ultimately resulted in cell death (Szallies et al., 2002). In 
T. b. brucei, MCA4 was found only in the bloodstream trypomastigotes, with RNAi 
resulting in rapid growth arrest, a decrease in the number of motile cells and the 
inability to execute cytokinesis (Proto et al., 2011). The deletion of TbbMCA4 prolonged 
mouse survival by 11 days when compared to that of the WT indicating that TbbMCA4 
plays a role in parasite virulence (Proto et al., 2011). 
Overexpression of TcrMCA3 in epimastigotes, but not where the catalytic Cys residue 
had been mutated, resulted in a reduction of parasite growth rate as well as cell division 
arrest at the G1/S phase (Laverrière et al., 2012. As such, cell division arrest was 
directly linked to the levels of active enzyme (Laverrière et al., 2012). Likewise, 
overexpression of TcrMCA3, but not where the catalytic Cys residue had been 
mutated, was shown to protect epimastigotes from death naturally occurring during the 
stationary phase and to promote cell differentiation to the metacyclic trypomastigote 
(Laverrière et al., 2012). Thus, strict regulation of TcrMCA3 is critical for the 
progression of the T. cruzi cell cycle. In addition to the pro-apoptotic role of the 
C-terminal domain of TcrMCA5, the transfection of T. cruzi epimastigotes with 
TcrMCA5 resulted in a decrease in the number of motile parasites when exposed to 
fresh human serum (Kosec et al., 2006).  
The induction of H2O2 cell death in amastigotes resulted in a 2.7-fold increase in 
LdnMCA activity as well as an increase in cells displaying DNA damage as measured 
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by TUNEL (Lee et al., 2007). As such, it was hypothesised that the LdnMCAs may act 
as effector molecules in cell death pathways (Lee et al., 2007). A gene knock-out study 
on LdnMCA1 showed arrested cell division at the S and G2/M phases, incomplete 
cytokinesis, and reduced cell growth (Raina and Kaur, 2012). Consequently, a role in 
the regulation of cell cycle and involvement in cell death was suggested for LdnMCA1.  
The overexpression of LmjMCA results in deficiencies in kinetoplast segregation, 
nuclear division and cytokinesis which could be independent of cell death (Ambit et al., 
2008). Higher levels of LmjMCA autoprocessing was observed in actively dividing log 
phase promastigotes than in stationary promastigotes (Ambit et al., 2008). During cell 
stress, cytoplasmic LmjMCA is translocated to the mitochondria due to a functional 
mitochondrial localisation sequence in the N-terminal domain (Zalila et al., 2011). In 
the mitochondrial matrix the full length LmjMCA is extensively processed into 
fragments containing the catalytic domain (Zalila et al., 2011). The activity of the 
catalytic domain enhanced the parasite’s sensitivity to H2O2 by impairing the 
mitochondrion (Zalila et al., 2011). This suggests that the catalytic activity of LmjMCA 
is required for cell death (Gonzáles et al., 2007; Zalila et al., 2011; Casanova et al., 
2015).  
Using phage display, panning of the recombinant MCA from L. amazonensis against a 
peptide library identified a peptide which shares a high sequence identity to the inhibitor 
of serine peptidase from L. major (Peña et al., 2017). The displayed 7-mer peptide 
expressed on the N-terminus of the minor phage coat protein (pIII) was shown to inhibit 
the peptidolytic activity of recombinant LamMCA (Peña et al., 2017). The inhibition of 
LamMCA by the inhibitor of serine peptidase rather than by the inhibitor of cysteine 
peptidase supports the finding in the present study that TcoMCA5H147AC202G activity is 
inhibited by serine rather than by cysteine inhibitors. Inhibition of LamMCA with the 
inhibitor of serine peptidase, shown to bind to MCA, decreased trypsin-like activity and 
cell death, suggesting that LamMCA is required for heat shock-induced cell death 
(Peña et al., 2017).  
Due to their phylogenetic relatedness and the presence of a Pro-, Gln-, Tyr-rich 
C-terminal domain, it can be hypothesised that the single copy MCA5s from 
T. congolense and T. vivax may function in a similar manner to that of the leishmanial 
MCAs. RNA interference of a cell cycle enzyme, TbbAurora kinase 1 (AUK1), 
demonstrated that the enzyme is essential for parasite virulence and was to be 
considered as a drug target (Jetton et al., 2009). Through the inhibition of TbbAUK1 
activity with a small-molecule inhibitor, VX-680, the functions of AUK1 were elucidated 
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and was found to be essential for cell cycle progression (Li et al., 2009). Thus, due to 
their involvement in the cell cycle, MCAs are desirable drug targets.  
A peptidomimetic library, designed based on the P1 specificity of TbbMCA2 for Arg and 
Lys residues, displayed micromolar IC50 values, between 2.1 and 50 µM, when tested 
in a phenotypic assay against T. b. brucei, T. cruzi, L. infantum and Plasmodium 
falciparum (Berg et al., 2012). The IC50 values associated with the inhibition of 
recombinant TbbMCA2 varied between 0.6 and 62 μM (Berg et al., 2012). The 3D 
structure of TbbMCA2 was solved by X-ray diffraction, two months after the publication 
of the Berg library (McLuskey et al., 2012). In the present study, the validation of the 
docking of the designed Berg ligands into the active site of the structure of TbbMCA2, 
solved by X-ray diffraction, will be performed using molecular docking. This will indicate 
as to whether or not the reported in vitro antiparasitic activity (Berg et al., 2012) is due 
to the inhibition of TbbMCA2 by the Berg ligands. In addition to the Berg ligands, a 
commercial library was created consisting of all the peptide substrates and inhibitors 
reported in the characterisation of other MCAs, and docked into the active site of 
TbbMCA2 as well as the homology modelled TcoMCA5 and TviMCA5. It was 
demonstrated that the Berg ligands had high affinity for TbbMCA2 as well as the 
MCA5s, and that the TbbMCA2 IC50 values correlated well to the docking score, 
indicating that the ligands were specific for the enzyme.  
The docking results of the current study highlighted the interactions which were 
essential for ligand binding. The Berg ligands formed fewer interactions with the 
residues in the active site than those of the commercial library, and thus, only the 
commercial ligands were used for the generation of a pharmacophore. This will allow 
for the screening for new compounds or the optimisation of the Berg ligands to produce 
a compound with a higher affinity for the MCA substrate in future studies. A similar 
methodology was employed for the identification of novel inhibitors against the 
cathepsin-L like peptidase of T. cruzi, cruzipain, which is an important virulence factor 
and drug target (Salas-Sarduy et al., 2017). The GlaxoSmithKline HAT and Chagas 
chemical boxes were assembled based on the results of phenotypic screening against 
T. b brucei and T. cruzi (Peña et al., 2015). Two scaffolds were identified after 
screening these chemical boxes and used to search the ChEMBL, a database 
containing information for a large number of drug-like bioactive compounds, to identify 
new possible ligands. The identified ligands were docked into the active site of 
cruzipain to determine the interactions between ligand and ‘receptor’ and the modes of 
binding (Salas-Sarduy et al., 2017). 
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Structural water molecules mediate ligand binding, in many cases, through the 
formation of hydrogen bonds (Ross et al., 2012). Three conserved water molecules, 
lining the bottom of the active site of TbbMCA2, were shown in the present study to 
interact with the secondary catalytic Cys92, catalytic His158 and S1 binding residue 
Asp211. The Cys92, His158 and Asp211 residues were demonstrated to interact with 
the ligands in both the Berg and commercial libraries. This supports the notion that 
these conserved water molecules mediate ligand binding. It has been demonstrated 
that docking performance is improved by the inclusion of water molecules in both 
predicted and X-ray diffraction solved structures (Yang and Chen, 2004; de Graaf et 
al., 2005). This was the case in the current study as more ligands were docked into the 
active site of the MCAs with higher interaction energies when all the water molecules 
were included than when they were absent. 
Parasite antigens released or secreted into the bloodstream of the mammalian host 
are ideal for the diagnosis of current infections as anti-trypanosomal antibodies persist 
after cure (Lejon et al., 2010). The TbbMCA4 is a pseudopeptidase as it possess a Ser 
in place of the catalytic Cys (Fig. 2.1), and is, thus, catalytically inactive (Proto et al., 
2011). This peptidase plays a role in the cell cycle and is also a virulence factor which 
is secreted into the bloodstream of the mammalian host (Proto et al., 2011). The 
presence of both OPB and MCA4 in the secretome of T. b. gambiense (Geiger et al., 
2010) makes OPB and TbbMCA4 attractive targets for AT diagnosis through antigen 
detection. An ELISA detecting circulating T. congolense antigens in goats and cattle, 
using monoclonal antibodies, was shown to be more sensitive than the microheamocrit 
centrifugation technique (Nantulya and Lindqvist, 1989; Masake and Nantulya, 1991). 
Attempts to develop an antigen detection test for AT have shown some success in the 
diagnosis of experimental infections (Liu et al., 1988; Nantulya and Lindqvist, 1989; 
Kashiwazaki et al., 1994) but fail when testing samples from natural AT infections 
(Büscher, 2014). This may be due to low levels of circulating antigens or the 
concealment of these antigens by immune complexes (Büscher, 2014).  
Nanobodies, which are derived from the heavy chain-only antibodies of camels and 
llamas, are comprised of the VHH domain, which possesses extended surface loops 
which are able to penetrate the narrow cavities on various pathogens’ surfaces (Nuttall 
et al., 2004; Streltsov et al., 2004). This was evident by the improved penetration of the 
nanobody between the variable surface glycoproteins on the surface of T. b. brucei 
compared to the Fab antibody fragment and the anti-VSG IgM antibody (Stijlemans et 
al., 2004). Nanobodies are characterised by nanomolar affinity for their targets 
(Skottrup et al., 2011) and the ability to detect both free and bound antigens due to 
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unique epitope recognition which is different from conventional antibodies (De Genst 
et al., 2006). Antigen binding antibody fragments can therefore be used to potentially 
improve antigen detection methods.  
The single chain variable fragment (scFv) antibodies, which consist of the VH and VL 
domains, have been successfully used in the development of ELISA immunodiagnostic 
tests against bluetongue virus (Fehrsen et al., 2005; Rakabe et al., 2011), African horse 
sickness virus (van Wyngaardt et al., 2004; van Wyngaardt et al., 2013), a 16 kDa 
antigen of Mycobacterium tuberculosis (Sixholo et al., 2011), and the 65 kDa HSP of 
Mycobacterium bovis (Wemmer et al., 2010). The detection of anti-OPB antibodies 
from sera from cattle experimentally infected with T. congolense, using chicken 
anti-OPB IgY antibodies in an inhibition ELISA format was unable to differentiate 
between infected and non-infected samples (Eyssen, 2013). As such, a smaller 
antibody fragment specific for OPB was thought have better chances of detecting OPB, 
which may be part of immune complexes, in an antigen detection ELISA. 
Since the MCAs were demonstrated to over autoprocess when purified using nickel 
chromatography, OPB was used as the model antigen to optimise the phage display 
protocol in the present study. The Nkuku® phage display library, which was designed 
using chicken immunoglobulin genes (van Wyngaardt et al., 2004), was used to this 
end. Panning of the library against both TcoOPB and TviOPB, resulted in the isolation 
of an OPB-specific scFv antibody. Sequencing of the phagemid plasmid indicated that 
both the anti-TcoOPB and anti-TviOPB scFv had the same DNA sequence suggesting 
that the OPB-specific scFv bound to a conserved OPB epitope. Due to the 
genotype:phenotype linkage, the genetic makeup of the scFv antibody is known and 
allows for the standardisation and accurate comparison of immunoassays (Schirrmann 
et al., 2011). 
The OPB-specific scFv antibody, purified using a TcoOPB affinity resin, was capable 
of detecting both recombinant and native TcoOPB in a western blot format in the 
current study. The OPB-specific scFv in combination with a polyclonal anti-TcoOPB 
antibody in a sandwich ELISA was utilised for the detection of TcoOPB in cattle 
experimentally infected with T. congolense. Despite high background values, which 
may be as a result of antibody cross reactivity, the absorbance values fluctuated 
together with the waves of parasitaemia. This indicates that upon parasite killing, low 
parasitaemia should result, causing higher levels of OPB due to parasite lysis. Prior to 
optimisation of the antigen detection ELISA in the future, the concentration of OPB in 
sera at each time point during infection needs to be measured to determine the limit of 
detection of OPB by scFv. This would confirm if OPB is a bona fida diagnostic 
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candidate and its application in an antigen detection ELISA using OPB-specific scFv. 
It has been reported that through the use of a nanobody library from an alpaca 
vaccinated with the soluble proteome of T. congolense, panning against the soluble 
proteome from four different T. congolense strains, an aldolase specific Nb474 was 
isolated (Odongo et al., 2016). Incorporation of 6xHis tagged and biotin labelled Nb474 
in an antigen detection ELISA showed a 87% sensitivity and 94% specificity and could 
successfully differentiate between active and cured experimental infections (Odongo 
et al., 2016).  
The 3D structure of LmjOPB, solved by X-ray diffraction, for both open and closed 
structures identified a hinge motion which links the α/β hydrolase catalytic domain from 
the β-propeller domain (Canning et al., 2013). Domain opening removes Glu172, found 
in the propeller domain, from the active site, freeing Arg650 which is critical for 
substrate binding (Canning et al., 2013). The molecular docking of the scFv antibody 
onto TcoOPB reported in the current study, predicted that the scFv bound to a 
previously identified epitope, residues 282 to 299 (VRKREKNVRYEVEMHGT) as well 
as residues in both the catalytic and propeller domains. If this is indeed the case, scFv 
binding would prevent the opening of TcoOPB to allow access of the substrate into the 
catalytic site. Antibody fragments have been reported to inhibit peptidase activity, with 
inhibition of cancer-associated membrane type serine peptidase (MT-SP) by an scFv 
(Sun et al., 2003). Panning of a naϊve, synthetic, human antibody library against the 
cancer-associated MT-SP as well as washing with ecotin, a bacterial homologue of the 
inhibitor of serine peptidase (McGrath et al., 1995), was employed to select for more 
potent peptidase inhibitors. Several scFv peptide antibodies were isolated of which the 
most potent had an inhibition kinetic constant of 50 pM against human MT-SP. The 
immunoinhibitory effect of OPB-specific scFv on the activity of TcoOPB requires further 
investigation.  
Since the phage display technology has been shown to produce antigen specific 
antibodies, it can be applied to the production of MCA-specific antibodies for use either 
in diagnostics (TbbMCA4), or cellular imaging in the laboratory for the detection of 
MCA5 and the elucidation of their role in cellular processes using RNAi, overexpression 
and gene knock-out studies. 
In conclusion, the MCA5s from T. congolense and T. vivax were found to autoprocess 
and over autoprocess when exposed to nickel ions in the affinity chromatography resin. 
Mutagenesis studies indicated that the catalytic dyad may be responsible for 
autoprocessing and that the secondary, putative, catalytic Cys may be responsible for 
enzymatic activity. Native TcoMCA5 was isolated using polyclonal anti-MCA IgY 
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antibodies and was enzymatically active. Here, we report the first digestion of gelatin 
by a MCA. The Berg ligands were demonstrated to be inhibitors of TbbMCA2, 
TcoMCA5 and TviMCA5 with suggested improvements in binding affinity provided by 
molecular docking of commercial substrates and inhibitors. Using OPB as a model 
antigen for the optimisation of the phage display technology, an OPB-specific scFv was 
isolated which could detect both recombinant and native OPB and has application 
towards the development of an antigen detection ELISA.  
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APPENDICES A 
Molecular weight marker calibrations 
Standard curves were constructed for the molecular weight markers separated on a 
1% (w/v) agarose gel (Appendix A1, panel A) and on a 12.5% reducing SDS-PAGE gel 
(panel B). These curves were constructed by the relation of the relative mobility of each 
of the marker proteins or DNA fragments to the log of its respective relative molecular 
mass (Mr) or number of base pairs (bp) respectively. 
 
Appendix A1: Standard curves of the molecular weight markers used in agarose 
and SDS-PAGE electrophoresis. (A) The commercial O’GeneRuler™ 1 kb DNA ladder 
was used for 1% (w/v) agarose electrophoresis. The equation of the trendline is given by y = -
0.449x + 2.102, with a correlation coefficient of 0.981. (B) The molecular weight marker used 
for reducing 12.5% SDS-PAGE electrophoresis consisted of phophorylase B (97.4 kDa), bovine 
serum albumin (BSA, 68 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa), soyabean 
trypsin inhibitor (SBTI, 21.5 kDa) and lysozyme (14 kDa). The equation of the trendline is given 
by y= -1.050x + 2.198, with a correlation coefficient of 0.977. 
 
Protein quantitation 
A water soluble, purple coloured complex is formed when cuprous ions are chelated 
by bicinchoninic acid (BCA). This complex is stable over a broad range of protein 
concentrations with a linear absorbance at 562 nm (Smith et al., 1985). When 
compared to bovine serum albumin standards, the protein concentration in samples 
can be determined through the direct correlation between the protein concentration 
and the production of cuprous ions (Walker, 1996). Protein quantitation using the 
bicinchoninate reagent is superior over other methods due to its high tolerance towards 
resistance to detergents and denaturing reagents (Bradford, 1976), high sensitivity and 
low protein-to-protein variation and its stability in alkaline conditions which allows for a 
simplified one-step reaction (Walker, 1996). A BSA standard curve using the BCA™ 
protein assay kit is shown in Appendix A2. 
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Appendix A2: Standard curve obtained using the BCA™ protein assay kit. Bovine 
serum albumin standards ranging from 25 to 2000 μg/ml were added to the BCA reagent and 
the resulting absorbance values measured at 595 nm after incubation at 37°C for 30 min. The 
equation of the trendline is given by y = 0.0005x + 0.016 with a correlation coefficient of 0.997. 
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Relatedness and conservation of the catalytic residues of the 
kinetoplastid MCAs 
The MCAs -1, -4 and -5 of T. b. brucei, T. b. gambiense and T. evansi share a 100% 
identity (Fig. 2.1). As such, only the analyses of the MCAs-1, -4 and -5 of T. b. brucei 
will be reported. The LmjMCA and LdnMCA2 share a 99% identity and as such, only 
LmjMCA will be reported. 
 
 
 
LmjMCA         -----------------------MTDLFDIWGIGAVASLIPMLANGLLLVDRPKRVDINA 
LdnMCA1        -----------------------MADLLDILGIGAVASLIPMLANGLLLVDRPKRVDINA 
LmxMCA         -----------------------MADFLDILGIGAVATLIPMLANGLLLVDRPKRVDINA 
TbbMCA5        -----------------------MDAALALLFGQVATAVLPYVVNSIGRVPRPKRVDVKK 
TcoMCA5        -----------------------MDLAVGLLLGQLASSALPYLVESIGKVKRPKRVDVKK 
TcrMCA5        -----------------------MDLLLGVLSSGILQNALPFVAG-VGRVKRPKRVKLEE 
TviMCA5        -----------------------MNILTDLFLGQVVPSIIPYLVNSIGTVQRPKRVDVRK 
TbbMCA3        MAVDPRCLLSLCS-TISKASSAKGTNDFVKIGMELWQTAQPYLVQALGLQPPPPKVDVDA 
TbgMCA3        MAVDPRCLLSLCS-TISKASSAKGTNDFVKIGMELWQTAQPYLVQALGLQPPPPKVDVDA 
TevMCA3        MAVDPRCLLSLCS-TISKASSAKGTNDFVKIGMELWQTAQPYLVQALGLQPPPPKVDVDA 
TbgMCA2        ----------MCS-LITQLCDAGQLADYVGLGWLNAVSSQPYLVQALGLQPPPRRVDVDA 
TevMCA2        ----------MCS-LITQLCDAGQLADYVGLGWLNAVSSQPYLVQALGLQPPPRRVDVDA 
TbbMCA2        ----------MCS-LITQLCDAGQLADYVGLGWLNAVSSQPYLVQALGLQPPPRRVDVDA 
TcrMCA3        MGFDFGCLLKLCS-TVLKRGGASGSINFMEIGLNLVKMAAPYVVQYLGPVQRPPRVDVEE 
TbbMCA4        -----MGGCVSTALKVGAETVAEGHIDLISFAINYFKNAVPYIVKYLGRQQRPKEVDMEA 
TbbMCA1        MSSEKVAGYVQCVVGIIFGVVTGGASIYVTIAMELLQVAVPYVLVTLGLQRRPPKGGVDK 
                                                       * :   :     * .      
 
 
 
 
 
LmjMCA          GRRLIHTVRPIIPYRAPVPYTGGRVRALFIGINYTGMRNALRGCVNDVSSMLGTLQQISF 
LdnMCA1         GRRLIHTVRPIIPYRAPVPYTGGRVRALFIGINYTGMRNALRGCVNDVSSMLGTLQQISF 
LmxMCA          GRRLIHTVRPIIPYRAPVPYTGGRVRALFIGINYTGTRNALRGCVNDVGSMLGTLQQITF 
TbbMCA5         AMGEAHQCRPVVPYRAPRPYTEGRVKALFIGINYTGSSAQLGGCVNDVMHMLQTLQRIEF 
TcoMCA5         AMSEAHTCRPVVPYHAPRPYTEGRVKALFIGINYTGRKGQLSGCINDVKQMLNTLQQIQF 
TcrMCA5         AFREAHLCRPVIPYRAPTPYTGGRVKALFVGINYTGTRNKLSGCVNDVRQMLGTLQRIQF 
TviMCA5         ELQRAHECRPSIPYRVPTLYTGGRVKALLIGINYTGKSGQLSGCVNDVRCMLSALHNISF 
TbbMCA3         AVANAGDAHGEQPWVAT-PLPGQTVRALFIGINYYGTSAALSGCCNDVKQMLATLQKKGL 
TbgMCA3         AVANAGDAHGEQPWVAT-PLPGQTVRALFIGINYYGTSAALSGCCNDVKQMLATLQKKGL 
TevMCA3         AVANAGDAHGEQPWVAT-PLPGQTVRALFIGINYYGTSAALSGCCNDVKQMLATLQKKGL 
TbgMCA2         AFRDAEGLHGHQPWVAT-PLPGRTVRALFIGINYYGTSAALSGCCNDVKQMLATLQKKGL 
TevMCA2         AFRDAEGLHGHQPWVAT-PLPGRTVRALFIGINYYGTSAALSGCCNDVKQMLATLQKKGL 
TbbMCA2         AFRDAKGLHGHQPWVAT-PLPGQTVRALFIGINYYGTSAALSGCCNDVKQMLATLQKKGL 
TcrMCA3         AFQQAEVTEGFKPWETT-THVSGTFRALFIGINYYGTSAELSGCCNDVKQIISTLQRKRI 
TbbMCA4         TLTEAKESKGFQPWKIS-CQPKGAVRGLFIGVNYGNTEAQLSGCCNDIMMMIGALQKRNF 
TbbMCA1         AMAEA-ESVEAEVMKKP-SKQQRSFRALFIGIDYKGTPAELRGCQADAVMMAGTMEKIGI 
                                .       .:.*::*::* .    * **  *   :  ::..  : 
  
Catalytic domain N-terminal domain 
N-terminal domain 
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LmjMCA          PISECCILVDDPSFPGFCGMPTRDNIIKHMLWLTGDVRPGDVLFFHFSGHGGQAKATRDS 
LdnMCA1         PISECCILVDDPSFPGFCGMPTRDNIIKHMLWLTGDVRPGDVLFFHFSGHGGQTKATRDS 
LmxMCA          PISECCILVDDPSFPGFSAMPTRENIIKHMLWLTGDVRPGDVLFFHFSGHGGQTKARRDT 
TbbMCA5         PISECCILVDDRRFPNFTAMPTRENIIKYMAWLVYDVRPGDVLFFHFSGHGAETKGGRDS 
TcoMCA5         PISSCCILVDDPRFPNYTAMPTRANIIKHMAWLVYDARPGDVLFFHYSGHGAETTGGRDS 
TcrMCA5         PISECCILVDDMRFPNFTALPTRENIIKHMAWLVHDVRPGDVLFFHYSGHGTETKAERDS 
TviMCA5         PITDCCILVDEEGFRGNTAEPTRANILKHMAWLVYDTRPGDVLFFHYSGHGTQTKSTKGS 
TbbMCA3         PINEAVILVDEDNFPGRTDQPTRDNIVRYMAWLVKDAKPGDVLFFHYSGHGTQCKSRGDS 
TbgMCA3         PINEAVILVDEDNFPGRTDQPTRDNIVRYMAWLVKDAKPGDVLFFHYSGHGTQCKSRGDS 
TevMCA3         PINEAVILVDEDNFPGRTDQPTRDNIVRYMAWLVKDAKPGDVLFFHYSGHGTQCKSRGDS 
TbgMCA2         PINEAVILVDEDNFPGRTDQPTRDNIVRYMAWLVKDAKPGDVLFFHYSGHGTQCKSRGDS 
TevMCA2         PINEAVILVDEDNFPGRTDQPTRDNIVRYMAWLVKDAKPGDVLFFHYSGHGTQCKSRGDS 
TbbMCA2         PINEAVILVDEDNFPGRTDQPTRDNIVRYMAWLVKDAKPGDVLFFHYSGHGTQCKSRGDS 
TcrMCA3         PIDEMSILVDERGFPGANGLPTRDNIVRYMAWLVRGAKPGDVLFMHYSGHCTQTRATSDT 
TbbMCA4         PLTEVVILADKEDVPGRTGEPTRANILRYLAWLAQDAQPNDVLFFHYSGHGTRANARDDD 
TbbMCA1         PITERCVLMDTDDPRFNAIKPTRANILQHMAWLVKDAKPGDALFLHYSGYGAQVRAEEDK 
                *: .  :* *          *** **:::: **. ..:*.*.**:*:**:  .  .  .  
 
 
 
 
 
LmjMCA           EEKYDQCLIPLDHVKNGSILDDDLFLMLVAPLPSGVRMTCVFDCCHSASMLDLPFSYVAP 
LdnMCA1          EEKYDQCLIPLDHVKNGSILDDDLFLMLVAPLPSGVRMTCVFDCCHSASMLDLPFSYVAP 
LmxMCA           EEKYDQCLIPLDHIENGSILDDDLFLMLVAPLPPGVRMTCVFDCCHSASMLDLPFSYVTP 
TbbMCA5          NEKMDQCLVPLDYDKAGAILDDDLFELMIKGLPAGVRMTAVFDCCHSASLLDLPFAFVAG 
TcoMCA5          EEENDQCLIPLDYEKEGSILDDDLFELMVKGLPAGVRMTAVFDCCHSASLLDLPFAFVAG 
TcrMCA5          EELYDQCLVPLDYQVQGAILDDDLFELLVKGLPAGVRMTAVFDCCHSASLLDLPFAFVGN 
TviMCA5          PEKYDQCLVPLDYDGEGAILDDDLFDLLVKHLPAGVRMTAVFDCCHSASLLDLPFSFVGN 
TbbMCA3          DEKYDQCIAPVDFQKSGCIVDDDIHKLLFSRLPEKVRLTAVFDCCHSGSIMDLPFTYVCS 
TbgMCA3          DEKYDQCIAPVDFQKSGCIVDDDIHKLLFSRLPEKVRLTAVFDCCHSGSIMDLPFTYVCS 
TevMCA3          DEKYDQCIAPVDFQKSGCIVDDDIHKLLFSRLPEKVRLTAVFDCCHSGYYGSS--FYLCL 
TbgMCA2          DEKYDQCIAPVDFQKSGCIVDDDIHKLLFSRLPEKVRLTAVFDCCHSGSIMDLPFTYVCS 
TevMCA2          DEKYDQCIAPVDFQKSGCIVDDDIHKLLFSRLPEKVRLTAVFDCCHSGSIMDLPFTYVCS 
TbbMCA2          DEKYDQCIAPVDFQKSGCIVDDDIHKLLFSRLPEKVRLTAVFDCCHSGSIMDLPFTYVCS 
TcrMCA3          EEKFDQCLAPVDFATKGCILDNDIFRILLPRLPQGVRLTVVFDCCHSGSMLDLPYTFVGS 
TbbMCA4          CEEYDQCIVPMDYVENGCIVDNEIHEILVSQLPKGVRLTAVFDCSHSGSMLDLPYAYVCD 
TbbMCA1          EEEFDQCIVPCDYEENGCILDNELHEIIS-TLPRGVRLTAVFDCSHAGTLLDLPFSLIC- 
                  *  ***: * *.   *.*:*:::. ::   **  **:* ****.*:.   .     :   
 
 
 
 
 
LmjMCA          RVGGGGACEYMQQVRRGNFSNGDVVMFSGCTDRGTSADVQNGG-------HANGAATLAF 
LdnMCA1         RVGGGGAREYMQQVRRGNFSNGDVVMFSGCTDSGTSADVQNGG-------HANGAATLAF 
LmxMCA          RVGGGGAREYMQQVRRGNFSNGDVVMFSGCTDSGTSADVQNGG-------HANGAATLAF 
TbbMCA5         RNVSSNQRHEMRMVRKDNYSRGDVVMFSGCEDSGTSADVTNTSSFGNGTVAAGGAATQAF 
TcoMCA5         RNALSSHRQEMRMVRKGNFSRADVVMFSGCEDSGTSADVQNTASFGNGTRVPGGAATQAL 
TcrMCA5         NNFYSGGRHEMRKVRANNFSMGDVVVFSGCDDSGTSADVSNVSSFGSGLVASGGAATQAL 
TviMCA5         NSALSSSRKEMRMVRQDNFSRGDVVMFSGCEDSGTSADVANTSSFGNGGRAAGGAATQAF 
TbbMCA3         GGEQASGTPHMKRIREGNDVLGDVMMISGCADEQTSADVKNTATFGTGSTGAGGAATQCI 
TbgMCA3         GGEQASGTPHMKRIREGNDVLGDVMMISGCADEQTSADVKNTATFGTGSTGAGGAATQCI 
TevMCA3         QWRQASGTPHMKRIREGNDVLGDVMMISGCADEQTSADVKNTATFGTGSTGAGGAATQCI 
TbgMCA2         GGEQASGTPHMKRIREGNDVLGDVMMISGCADEQTSADVKNTATFGTGSTGAGGAATQCI 
TevMCA2         GGEQASGTPHMKRIREGNDVLGDVMMISGCADEQTSADVKNTATFGTGSTGAGGAATQCI 
TbbMCA2         GGEQASGTPHMKRIREGNDVLGDVMMISGCADEQTSADVKNTATFGTGSTGAGGAATQCI 
TcrMCA3         RSLRSSVAGHMQRIRKGNDCAGDVLMISGCADEQTSADVSNAATFGTGASGAGGAATQCL 
TbbMCA4         SSKDGSGSCGMKRVREDNDVQADVLMISACADDEAALGVDNTQDFYESGKDSGGAATFCL 
TbbMCA1         SSNDCSAVGEMKRIRTGGDVNAHVLMFSACGDDEAAADLPNAGDFVEGASGSGGAATQCF 
                           *: :* ..   ..*:::*.* *  :: .: *          ..**** .: 
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LmjMCA          TWSLLNTHGLSYLNILLKTREELRKKGRVQVPQLTSSKPIDLYKPFSLFGMITVNASMMH 
LdnMCA1         TWSLLNTHGFSYLNILLKTREELRKKGRVQVPQLTSSKPIDLYKPFSLFGMITVNASMMH 
LmxMCA          TWSLLNTHGFSYLNILLKTREELRKKGRVQVPQLTSSKPIDLYKPFSLFGMITVNTSMMH 
TbbMCA5         TWALLNTTGYSYIDIFMKTREVLRQKGYKQVPQLSSSKPVDLYKQFSLFGPLTMNASLVQ 
TcoMCA5         TWALLNTSGYNYADIFMRMRDVLRNKGYRQVPQLSSSKPIDLYKPFSLFGTLTMNTNLIQ 
TcrMCA5         TWALVNTSQLSYADIFIRTREILRQKGYKQVPQLSSSKPVDLYKPFSLFGPITVNTSLIH 
TviMCA5         IWTLLNTHQLNYADIFLKTRDLLRKKKFKQVPQMSSSKPVDLYKPFSLFGPITVDNSVAQ 
TbbMCA3         TCMLMNNQSLSYGKLLIETRDMLKRKRFKQVPQLSASKAIDLDQTFSLTEMFSVDRSIQ- 
TbgMCA3         TCMLMNNQSLSYGKLLIETRDMLKRKGFKQVPQLSASKAIDLDQTFSLTEMFSVDRSVQ- 
TevMCA3         TCMLMNNQSLSYGKLLIETRDMLKRKRFKQAPQLSASKAIDLDQTFSLTEMFSVDRSVQ- 
TbgMCA2         TCMLMNNQSLSYGKLLIETRDMLKRKGFKQVPQLSASKAIDLDQTFSLTEMFSVDRSVQ- 
TevMCA2         TCMLMNNQSLSYGKLLIETRDMLKRKGFKQVPQLSASKAIDLDQTFSLTEMFSVDRSVQ- 
TbbMCA2         TCMLMNNQSLSYGKLLIETRDMLKRKGFKQVPQLSASKAIDLDQTFSLTEMFSVDRSIQ- 
TcrMCA3         TYTILKVSNLSYQDMLIATRDMLRRKRFTQVPQLSASKPINLQQEFSLMTTFEVDPAVAT 
TbbMCA4         TAMMMREEPLTFLDLLVHTREMLKSRGFTQVPHLSASKPINLMQRFSLEGLFPQER---T 
TbbMCA1         ISMLLNKTPGTIYSLLSTTRDKLREKGFKQSPQMSASRCLSLTEKFTLTELFSVAEPCPN 
                   ::.    .  .::   *: *: :   * *::::*: :.*   *:*   :         
 
 
 
 
 
LmjMCA          CVPQQYQQRPQSLPP---QVMPPATGYPVHVPP-------------PPQGYYPPPQSPGW 
LdnMCA1         CVPQQYQQRPQSLPP---QAMPPPAGYPVHVPP-------------PPQGYYPPPQRPGW 
LmxMCA          CVPQQYQQPPQSLPP---QAMPPPMGYPAYVPR-------------PPQSYYPPPQRRVW 
TbbMCA5         HLPQEYVQPWAPHP-----AY--QQPHEATLPA-------------SVSQPHSQPVM-GI 
TcoMCA5         NVPVEYTNAWNAQPPQ--HSYP-QLPQQQQVPV-------------PTPQ-NDGPVM-GI 
TcrMCA5         YVPQQYLQPWGPPQP----YYPPPQPQQPYYPP-------------PQPQQPYYPSS-QL 
TviMCA5         QYQHWLNASAQPPYPPQQHAYPQQQRHHAYPPQQHHAYPPQQQHAYPPQQQHAYPPQQQH 
TbbMCA3         ------------------------------------------------------------ 
TbgMCA3         ------------------------------------------------------------ 
TevMCA3         ------------------------------------------------------------ 
TbgMCA2         ------------------------------------------------------------ 
TevMCA2         ------------------------------------------------------------ 
TbbMCA2         ------------------------------------------------------------ 
TcrMCA3         ------------------------------------------------------------ 
TevMCA4         LL---------------------------------------------------------- 
TbbMCA4         LL---------------------------------------------------------- 
TbbMCA1         ILTGEPRWKTTPLGGK-------------------------------------------- 
                                                                             
 
 
 
 
 
LmjMCA          GLG-----YPVQGIPVQQATLGVSRCPPSQYLPAPPPAV--------------------- 
LdnMCA1         GLGYPAPGYPAQGIPVQQATLGVSRCPPSQYLPAPPPAL--------------------- 
LmxMCA          GSGYPAQEYLAQRIPVQQATPGVSGCPTSQYLPAPPSAP--------------------- 
TbbMCA5         PVASTSNGKSNPGVSDGGRASGEV-YPPTQYPSSHPAPQ-QQAYY-----QPPQQAYYQ- 
TcoMCA5         PISSSTNDQ-NSGNPPAAAAPTNV-VTPVQYPSQPPSHQPQQGYYSAPQQQPPQQGYYSA 
TcrMCA5         PTQYN-NLAPTAGIP--LMTSSSE-VPPGQYPQALSGDQ--------------------- 
TviMCA5         AYPPQQHHAYPPPQHHAYAPQQQHAYPPQQHHAYPPQQQHAYPPQQHHAYPPQQQHAYPQ 
TbbMCA3         ------------------------------------------------------------ 
TbgMCA3         ------------------------------------------------------------ 
TevMCA3         ------------------------------------------------------------ 
TbgMCA2         ------------------------------------------------------------ 
TevMCA2         ------------------------------------------------------------ 
TbbMCA2         ------------------------------------------------------------ 
TcrMCA3         ------------------------------------------------------------ 
TbbMCA4         ------------------------------------------------------------ 
TbbMCA1         ------------------------------------------------------------ 
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LmjMCA          ----------------------------------------------------YAPPPPGQ 
LdnMCA1         ----------------------------------------------------YAPPPPGQ 
LmxMCA          ----------------------------------------------------YAPPPPAQ 
TbbMCA5         ----PPQQAYYQ-----PPQQAYYQ-----PPQQAYYQPPQQAYYQPEPHHQPAPPP-PP 
TcoMCA5         PQQYPPQQGYYAAPQQYPPQQGYYSAPQQYPPQQGYYSAPQQ--YPPQQGYYSAPQQYPP 
TcrMCA5         --------------------------------------------------NGGVPPQYPS 
TviMCA5         QRQDAQGHSSAQGNIEQPAQLSAYAVG------------------SNGSTIRPSVLPPTQ 
TbbMCA3         ------------------------------------------------------------ 
TbgMCA3         ------------------------------------------------------------ 
TevMCA3         ------------------------------------------------------------ 
TbgMCA2         ------------------------------------------------------------ 
TevMCA2         ------------------------------------------------------------ 
TbbMCA2         ------------------------------------------------------------ 
TcrMCA3         ------------------------------------------------------------ 
TbbMCA4         ------------------------------------------------------------ 
TbbMCA1         ------------------------------------------------------------ 
                                                                             
 
 
 
 
 
LmjMCA          RGPPQPPPAQYTFS------PLPPG------------- 
LdnMCA1         HGPPQPPPAQYTFS------PLPPR------------- 
LmxMCA          YGPQQPPPAQYTFG------RLPPG------------- 
TbbMCA5         KKENKPARPGYPMSYCMKFSQGKPGRK----------- 
TcoMCA5         QQGYYSAPQQYPPQQSRPAQAQKPSRSGYPIDFLKGSK 
TcrMCA5         DQSTYYSSAQYLSG------VGKPL------------- 
TviMCA5         YKQSTKSSSSYPID----IYTKKDGHK----------- 
TbbMCA3         -------------------------------------- 
TbgMCA3         -------------------------------------- 
TevMCA3         -------------------------------------- 
TbgMCA2         -------------------------------------- 
TevMCA2         -------------------------------------- 
TbbMCA2         -------------------------------------- 
TcrMCA3         -------------------------------------- 
TbbMCA4         -------------------------------------- 
TbbMCA1         -------------------------------------- 
                                                  
Appendix A3: Multiple sequence alignment of the kinetoplastid MCAs. The protein 
sequences were obtained from the TriTrypDB (Aslett et al., 2010). TbbMCA from T. b. brucei 
(927), TbgMCA from T. b. gambiense (DAL972), TviMCA from T. vivax (Y486), TevMCA from 
T. evansi (STIB 805), TcoMCA from T. congolense (IL3000), TcrMCA from T. cruzi (Sylvio 
X10/1), LmjMCA from L. major (Friedlin), LmxMCA from L. mexicana (MHOM/GT/2001/U1103), 
LdnMCA from L. donovani (BPK282A1) and aligned using ClustalW (Larkin et al., 2007). 
Alignment characters are annotated as follows: conserved residues (*), strongly similar 
properties (:) and weakly similar properties (.). The amino acid residues involved in the S1 
binding pocket are highlighted in pink, those in the catalytic dyad in yellow, adjacent Cys to the 
catalytic Cys in turquoise, the secondary catalytic Cys in blue and the calcium binding sites in 
green. The gatekeeper residue is highlighted in grey and the sites of autoprocessing, reported 
in literature, in red. The residue predicted to be involved in the formation of the oxyanion hole 
is highlighted in teal. 
 
Cloning and expression plasmids used for TbbMCA2 and 
TviMCA5 
The plasmid maps of the cloning (panels A and B) and expression (panels C and D) 
plasmids used in the present study is given in Appendix A4. 
C-terminal domain 
C-terminal domain 
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Appendix A4: Sequence maps of the multiple cloning sites of the plasmids used of the cloning of TbbMCA2 and TviMCA5. T/A 
cloning plasmids (A) pTZ57R/t and (B) pGem®-T along with the (C) pET-28a and (D) pET-32a expression plasmids which both code for a N-terminal 
6xHis tagged recombinant protein.
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Chicken anti-TviMCA5 IgY production 
Chickens were immunised with TviMCA5 triturated with Freund’s complete adjuvant 
(FCA) at week 0 and thereafter with Freund’s incomplete adjuvant (FIA) at weeks 2, 4 
and 6. The pre-immune IgY is denoted by week 0 which had a low absorbance value. 
Antibody production fluctuated throughout the immunisation period (Appendix A5). In 
chicken 1, antibody production was above that of the pre-immune at weeks 4 to 6, 8 to 
11, and for chicken 2, weeks 1 to 4, 8 and 13. 
 
Appendix A5: ELISA of anti-TviMCA5 IgY antibodies isolated from the egg yolks 
of immunised chickens. ELISA plates were coated with TviMCA5 (1 μg/ml in PBS, pH 7.2), 
blocked with 0.5% (w/v) BSA-PBS, and incubated with anti-TviMCA5 IgY from chickens 1 and 
2, weeks 1 to 14 (100 μg/ml). Rabbit anti-chicken IgY HRPO conjugate (1:5 000) and 
ABTS∙H2O2 were used as the detection system. The absorbance readings at 405 nm represent 
the average of duplicate experiments at 60 min development. 
 
Mutation in the TbbMCA2 amplified gene 
Using the 3D structure of TbbMCA2 (PDB ID: 4AF8), solved by X-ray diffraction, the 
catalytic dyad residues, His158 and Cys213, which had been mutated to a Gly, were 
identified along with the gatekeeper reside Tyr31 which operates as a switch to allow 
access into the catalytic pocket (McLuskey et al., 2012). After sequencing the 
high-fidelity taq amplified TbbMCA2 gene from the DNA of T. b. brucei (927), that the 
Gln71 residue was found to be amplified as Arg71. This mutation was modelled on the 
protein structure to determine where in relation it was to the active site and if it could 
affect substrate binding (Appendix A6). 
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Appendix A6: The 3D structure of TbbMCA2 4AF8 showing the mutation which 
was introduced after PCR in relation to the catalytic dyad. The 3D structure of 
TbbMCA2C213G (4AF8), from diffraction data collected at 1.4 Å (McLuskey et al., 2012), was 
modelled using Discovery Studio software (Dassault Systèmes BIOVIA), and the mutated 
Gln71 residue along with the catalytic dyad, His158 and Gly213, and gate keeper (Tyr31) 
residues were shown in a stick configuration. 
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APPENDICES B 
Primers designed for mutagenesis 
The primers for the generation of the catalytic dyad mutants, H147A and C202G, along 
with the adjacent Cys, C201G, were designed using the Agilent QuikChange primer 
design software and detailed in Appendix B1. 
Appendix B1: Primer sequences to be used in the mutagenesis studies of 
TcoMCA5 and TviMCA5. 
Primer 5' - 3' 
TcoMCA5H147A 
forward 
TTC ACT ACT CTG GGG CCG GTG CGG AGA CGA C 
TcoMCA5H147A 
reverse 
GTC GTC TCC GCA CCG GCC CCA GAG TAG TGA A 
TcoMCA5C201G 
forward 
ATG ACG GCC GTC TTT GAT GGC TGC CAC TCT GCC 
TcoMCA5C201G 
reverse 
GGC AGA GTG GCA GCC ATC AAA GAC GGC CGT CAT 
TcoMCA5C202G 
forward 
GGC CGT CTT TGA TTG CGG CCA CTC TGC CTC TCT TC 
TcoMCA5C202G 
reverse 
GAA GAG AGG CAG AGT GGC CGC AAT CAA AGA CGG CC 
TviMCA5H147A 
forward 
CGT GTT GTT TTT TCA TTA TTC TGG AGC CGG CAC TCA 
AAC TAA AAG TAC 
TviMCA5H147A 
reverse 
GTA CTT TTA GTT TGA GTG CCG GCT CCA GAA TAA TGA 
AAA AAC AAC ACG 
TviMCA5C201G 
forward 
GTG CGT ATG ACA GCT GTT TTT GAT GGC TGT CAT TCA 
GCC TCT CTT TTG G 
TviMCA5C201G 
reverse 
CCA AAA GAG AGG CTG AAT GAC AGG CAT CAA AAA 
CAG CTG TCA TAC GCA C 
TviMCA5C202G 
forward 
GCG TAT GAC AGC TGT TTT TGA TTG TGG CCA TTC AGC 
CTC TCT TTT GG 
TviMCA5C202G 
reverse 
CCA AAA GAG AGG CTG AAT GGC CAC AAT CAA AAA 
CAG CTG TCA TAC GC 
Sequences in bold correspond to the point mutations. 
AMC standard curve  
To quantify the hydrolysis of fluorogenic peptide substrates by the purified recombinant 
and native MCAs, an AMC calibration curve was constructed. The AMC standards 
ranging from 5 to 15 000 nM (50 μl) were incubated with MCA assay buffer (50 mM 
Tris-HCl buffer, pH 7.2, 150 mM NaCl, 10 mM CaCl2, 5 mM DTT, 50 μl) at 37°C for 
10 min and the fluorescence (Ex360nm and Em460nm) measured using a FLUORStar 
Optima Spectrophotometer from BMG Labtech (Offenburg, Germany) (Appendix B2). 
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The slope of the calibration curve was used to determine the velocity of the enzymes 
when hydrolysing different substrates. 
 
Appendix B2: AMC standard curve to link the fluorescence from the hydrolysis 
of fluorogenic peptide substrates by the MCAs to their velocity. Dilutions of AMC, 
in triplicate, were incubated with MCA assay buffer at for 10 min at 37°C and the excitation and 
emission fluorescence measured at 360 and 460 nm respectively. The equation of the trendline 
is given by y = 3.6124x with a correlation coefficient of 0.9909. 
 
Analysis of the generated megaprimer after mutagenesis 
Using the primers shown in Appendix B1, along with the plasmid DNA templates of the 
WT TcoMCA5-pET28a and TviMCA5-pET32a, the point mutation within the plasmid 
was performed using the Q5 high-fidelity master mix. Successful mutagenesis resulted 
in bands at approximately 7 000 and 7 500 bp for TcoMCA5 and TviMCA5 
respectively. Only a few mutants are shown in Appendix B3.  
 
Appendix B3: High-fidelity amplification of TcoMCA5 and TviMCA5 mutants 
using the megaprimer method. Samples of the PCR amplification of point mutants were 
electrophoresed on a 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide. 
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Alignment of sequenced WT and mutant TcoMCA5 and 
TviMCA5 
To determine whether the resulting clones after transformation of the mutant plasmids, 
into competent NEB 5-alpha E. coli cells, possessed the desired mutations, the plasmid 
DNA was isolated and sequenced using the gene forward primer (Table 2.1). The 
results show that each of the selected clones were positive for the desired mutations 
(Appendix B4). 
 
Appendix B4: Sequence alignment of the mutant clones of TcoMCA5 and 
TviMCA5. The plasmid DNA of (A) TcoMCA5 and (B) TviMCA5 mutants was sequenced using 
the forward gene primer at the Central Analytical Facilities (CAF), Stellenbosch University, and 
the data analysed using the BioEdit software (Hall, 1999) and compared to that from GenBank®. 
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Secondary catalytic Cys of TbbMCA2, TcoMCA5 and TviMCA5 
 
Appendix B5: Visualisation of the proximity of the catalytically important 
residues in TbbMCA2, TcoMCA5 and TviMCA5. The residues comprising the catalytic 
dyad (His158 and Cys213; His147 and Cys202), Cys adjacent to the catalytic Cys (Cys212 and 
Cys201) and the secondary catalytic Cys (Cys92 and Cys81) of TbbMCA2 4AF8 (pink), 
TcoMCA5 (purple) and TviMCA5 (turquoise) were visualised using the Discovery Studio 
(Dassault Systèmes BIOVIA).  
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Lineweaver-Burke plots 
 
Appendix B6: Lineweaver-Burke plots of the hydrolysis of various fluorogenic peptide substrates by recombinant 
TcoMCA5H147AC202G and native TcoMCA5. Recombinant (A) TcoMCA5H147AC202G (0.5 µg/ml) and (B) native TcoMCA5 (7.5 µg/ml) were incubated 
in MCA assay buffer before the addition of 0 to 30µM of various fluorogenic peptide substrates in triplicate and duplicate respectively. The resultant 
fluorescence from the hydrolysis of the AMC fluorophore, over 60 min, was measured at Ex360nm and Em460nm. After the outliers were removed, the 
kinetic parameters, Km and Vmax were determined using the Hyper32® software.
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Molecular weight comparison between non-reducing 
zymograms and reducing SDS-PAGE gels  
 
Appendix B7: Molecular weight comparison of active MCA5 from a non-reducing 
zymogram with MCA5 on a reducing SDS-PAGE gel. (A) A direct comparison of gelatin 
containing non-reducing SDS-PAGE gel, also known as a zymogram, to reducing SDS-PAGE 
gels of (B) immunoaffinity purified native TcoMCA5 (green) detected in a western blot, and (C) 
nickel affinity purified recombinant TcoMCA5H147AC202G (pink). 
 
Clan CD peptidases resistance to classical E-64 inhibitor 
Appendix B8 is taken directly from Mottram et al. (2003). 
 
Appendix B8: Chemical structure of (a) the generic clan CA inhibitor E-64 and (b) 
aza-peptide epoxide inhibitors. The P2 binding sites are indicated in green, which is a 
leucine residue in the case of E-64. The P1 site of the aza-peptide epoxide inhibitors is indicated 
in blue. E-64 lacks a corresponding P1 residue, which accounts for the compound’s lack of 
activity towards clan CD peptidases. The active epoxide functional group, that covalently binds 
to the thiol of the active site Cys in cysteine peptidases, is shown in red. 
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Resultant velocity after inhibitor screening  
 
Appendix B9: Impact of varying concentrations of various inhibitors on the 
activity of recombinant TcoMCA5H147AC202G. Recombinant TcoMCA5H147AC202G 
(0.5 µg/ml) was incubated in MCA assay buffer containing 10 µM Z-Gly-Gly-Arg-AMC, before 
the addition of 1, 10 and 100 µM of various peptidase inhibitors, in triplicate, diluted in assay 
buffer without substrate. The resultant fluorescence from the hydrolysis of the AMC fluorophore, 
over 60 min, was measured at Ex360nm and Em460nm. No change in velocity was observed for 
calpain I, bestatin, AEBSF, 1,10 phenanthroline, Z-Phe-Ala-FMK, Z-Val-Ala-Asp-FMK, 
iodoacetic acid and iodoacetate. 
 
Determination of inhibition kinetic constant 
 
Appendix B10: Determination of the inhibition constants for antipain and 
leupeptin against recombinant TcoMCA5H147AC202G. Using equation [D] in Section 
3.2.6.5, the inhibition constant, Ki, for (A) antipain and (B) leupeptin was determined. The 
equation of the trendlines is given by (A) y = 0.0088x – 0. 01 with a correlation coefficient of 
0.9538 and (B) y = 0.0137x -0.0159 with a correlation coefficient of 0.8910.  
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Effect of calcium 
 
Appendix B11: The effect of varying concentrations of calcium on the velocity of 
recombinant TcoMCA5H147AC202G. Recombinant TcoMCA5H147AC202G (0.5 µg/ml) was 
incubated in MCA assay buffer containing 10 µM Z-Gly-Gly-Arg-AMC, before the addition of 
0 to 100 mM CaCl2, in triplicate, diluted in assay buffer without substrate. The resultant 
fluorescence from the hydrolysis of the AMC fluorophore, over 60 min, was measured at Ex360nm 
and Em460nm. 
 
Effect of various divalent cations 
 
Appendix B12: The effect of varying concentrations of various divalent cations 
on the velocity of recombinant TcoMCA5H147AC202G. Recombinant TcoMCA5H147AC202G 
(0.5 µg/ml) was incubated in MCA assay buffer containing 10 µM Z-Gly-Gly-Arg-AMC, before 
the addition of 1 and 10 mM of various divalent cations diluted in assay buffer without substrate. 
This was done in triplicate. The resultant fluorescence from the hydrolysis of the AMC 
fluorophore, over 60 min, was measured at Ex360nm and Em460nm. 
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Interactions of the catalytic and adjacent Cys residues 
 
Appendix B13: The interactions of the catalytic Cys202 and adjacent Cys201 in 
TcoMCA5. The 2D interaction map highlighting the Pi-sulfur interactions of the catalytic Cys 
with Tyr141 and Cys adjacent to the catalytic Cys, Cys201, with His200. The 2D interaction 
map for TviMCA5 is identical to that of TcoMCA5 and is thus omitted. 
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APPENDICES C 
Commercial library 
 
Appendix C1: Inhibitors and substrates used in literature for the characterisation of various MCAs. The chemical structures were 
obtained from the PubChem compound database (https://pubchem.ncbi.nlm.nih.gov/)(Kim et al., 2016). 
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Berg library 
 
Appendix C2: Inhibitors designed based on the P1 site preference of TbbMCA2 for Arg and Lys residues. The chemical structures 
of the Berg library (Berg et al., 2012) were obtained from the Binding Database (Gilson et al., 2016)(http://www.bindingdb.org). The given numbers are 
the last three numbers from the bindingDB monomer ID. The IC50 values against recombinant TbbMCA2 are indicated in brackets as per Berg et al. 
(2012). 
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Enlarged sequence alignment of the TbbMCA2 4AF8 template 
used for the homology modelling of TcoMCA5 and TviMCA5 
 
Appendix C3: Homology modelling of TcoMCA5 and TviMCA5. The alignment of the 
(A) TcoMCA5 and (B) TviMCA5 sequences to the TbbMCA2 4AF8 template is shown with the 
Qmean scores indicated in blue (high quality) and red/orange (low quality). 
 
 
221 
Correlation of the -CDocker interaction energies and the IC50 values of the Berg ligands 
A total of 31 compounds, consisting of seven substrates, four inhibitors and 19 Berg ligands were docked into the active site of 
TbbMCA2 4AF8, TcoMCA5 and TviMCA5, of which only the Berg ligands had an associated IC50 value. Of the Berg ligands, only ten 
possessed an IC50 value below 100 μM. 
 
Appendix C4: Correlation of experimental IC50 values of the Berg ligands and the -CDocker interaction energies of ligands docked into 
the active site of TbbMCA2, TcoMCA5 and TviMCA5. The alignment of the TbbMCA2 (pink), TcoMCA5 (purple) and TviMCA5 (turquoise) and the IC50 
values (black) as determined for the Berg ligands against TbbMCA2 (Berg et al., 2012). 
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2D interactions of ligands docked in the active site of TbbMCA2 
4AF8 
 
Appendix C5: The inhibitor, substrate and Berg ligand which had the highest 
binding affinity at the active site for TbbMCA2 4AF8, prepared with ‘all water’. 
The 2D interactions of the commercial inhibitor, antipain, commercial substrate, Z-Gly-Aly-Arg-
AMC and Berg ligand, 777 docked in the active site of TbbMCA2 4AF8.
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2D interactions of ligands docked in the active site of TcoMCA5 and TviMCA5 
 
Appendix C6.1: The commercial inhibitor which had the highest binding affinity at the active site for TcoMCA5 and TviMCA5 
prepared with ‘all water’. The 2D interactions of the commercial inhibitor, antipain, docked in the active site of TcoMCA5 and TviMCA5. 
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Appendix C6.2: The commercial substrate which had the highest binding affinity at the active site for TcoMCA5 and TviMCA5 
prepared with ‘all water’. The 2D interactions of the commercial substrate Z-Gly-Gly-Arg-AMC, docked in the active site of TcoMCA5 and TviMCA5. 
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Appendix C6.3: The Berg ligand which had the highest binding affinity at the active site for TcoMCA5 and TviMCA5 prepared 
with ‘all water’. The 2D interactions of the Berg ligand, 777, docked in the active site of TcoMCA5 and TviMCA5.  
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APPENDICES D 
pHEN1 phagemid plasmid used for scFv production 
The map of the phagemid plasmid used in the Nkuku® phage display library is provided 
in Appendix D1, with the different resulting scFv formats and expected molecular 
weights when using suppressor and non-suppressor E. coli cells.  
 
Appendix D1: Schematic diagram of the pHEN1 phagemid plasmid supplied in 
the Nkuku® phage display library. Adapted from Hoogenboom et al. (1991). 
 
Phage binding and soluble scFv ELISAs 
The phage binding ELISA format detects the pIII minor coat protein, which is fused to 
the myc-tagged scFv, when expressed in amber suppressor strains (Appendix D1). 
The soluble scFv ELISA format detected the myc tag using affinity purified chicken 
anti-myc IgY. This format is able to detect scFv from both amber suppressor and non-
suppressor E. coli cells. The clones which had high absorbance values in both the 
phage binding and soluble scFv ELISA formats (Appendix D2 and D3) were used to 
define absorbance cut-off values, and noted in the decision matrix (Appendix D5). 
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Appendix D2: Phage binding ELISA of TcoOPB and TviOPB panned phages. ELISA plates were coated with (A and B) TcoOPB and (C) 
TviOPB (1 µg/ml in PBS, pH 7.2), blocked with 3% BSA-PBS and incubated with equal volumes of expression supernatant of (A) TcoOPB pan 3, (B) 
TcoOPB pan 4 and (C) TviOPB pan 4 together with 6% (w/v) BSA-PBS. Thereafter, mouse anti-M13 (1:8000) was added. Goat anti-mouse IgG HRPO 
conjugate and ABTS∙H2O2 were used as the detection system. Absorbance values are the result after 60 min of development.  
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Appendix D3: Soluble scFv ELISA of TcoOPB and TviOPB panned phages. ELISA plates were coated with (A and B) TcoOPB and (C) 
TviOPB (1 µg/ml in PBS, pH 7.2), blocked with 3% BSA-PBS and incubated with equal volumes of expression supernatant (A) TcoOPB pan 3, (B) 
TcoOPB pan 4 and (C) TviOPB pan 4 together with 6% (w/v) BSA-PBS. Thereafter, affinity purified chicken anti-myc IgY (0.5 µg/ml) was added. Rabbit 
anti-chicken IgY HRPO conjugate and ABTS∙H2O2 were used as the detection system. Absorbance values are the result after 60 min of development.  
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Colony PCR and fingerprinting 
In order to narrow down the selection of clones which would be sequenced, the plasmid 
DNA from the positive clones, identified from the two ELISA formats (Appendix D2 and 
D3), was isolated and subjected to colony PCR and DNA fingerprinting using AluI 
(Appendix D4). The clones which resulted in a 1 000 bp amplified product (panel A), 
were digested using AluI resulting in the same pattern of DNA fragments (panel B).  
 
Appendix D4: Screening for full length scFv clones by PCR amplification and 
DNA fingerprinting. The isolated plasmid DNA from phage binding and soluble scFv ELISA 
positive clones were subjected to (A) PCR amplification of the scFv genes and (B) digestion 
with AluI. Samples were electrophoresed on 1.5% (w/v) and 3% (w/v) agarose gels respectively, 
both containing 0.5 µg/ml ethidium bromide. (A) M= O’GeneRuler™, (B) M= 100 bp ladder 
(NEB). 
 
Decision matrix for the selection of scFv clones for expression 
The results from the phage binding ELISA, soluble scFv ELISA and colony PCR, were 
used to generate a decision matrix to facilitate the selection of clones to be used for 
the expression of scFv (Appendix D5). 
Appendix D5: Positive clones resulting from the various techniques to determine 
the best clones for scFv expression. 
  cutoff % positive$ 
TcoOPB pan3 
Phage binding 0.4* 8 
Soluble scFv 0.5* 23 
colony PCR 1 000 bp# 100 
TcoOPB pan 4 
Phage binding 0.4* 19 
Soluble scFv 0.5* 8 
colony PCR 1 000 bp# 33 
TviOPB pan 4 
Phage binding 0.3* 8 
Soluble scFv 0.4* 12 
colony PCR 1 000 bp# 93 
* The absorbance value where the cut off was made for the selection of positive clones. 
# At 1 000 bp, a full length scFv was present. Anything below, would indicate a partial gene. 
$ percentage positive was calculated by the division of the number of positive clones by the total number 
of clones tested and multiplied by 100. 
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Homology modelling and structure validation of modelled 
TcoOPB and clone E5 from TcoOPB pan 3 
Enlarged sequence alignment of the TbbOPB template and TcoOPB query. 
 
Appendix D6: Homology modelling of TcoOPB. The alignment of the TcoOPB 
sequence to the TbbOPB 4BP9 template is shown with the Qmean scores indicated in blue 
(high quality prediction) and red/orange (low quality prediction). 
 
The validation of the generated structures, using the ProSA software (Wiederstein and 
Sippl, 2007) and the Ramachandran plots obtained from the Protein Data Bank 
(Berman et al., 2000) and the Discovery studio software (Dassault Systèmes BIOVIA), 
of TcoOPB (Fig. 5.6) and scFv clone E5 modelled (Fig. 5.7) is reported in Appendix 
D7. 
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Appendix D7: Z-score and Ramachandran plots as an indication of model quality. The resulting Z-score plots of the individually uploaded PDB 
files, TbbOPB (4BP9) and scFv (4NIK) along with the modelled TcoOPB and scFv clone E5 into the ProSA software (Wiederstein and Sippl, 2007). The 
Ramachandran plots for TbbOPB 4BP9 (Canning et al., 2013) and scFv 4NIK (Robin et al., 2014) was obtained from the PDB (Berman et al., 2000). Those for 
the TcoOPB and scFv clone E5 were generated using the Discovery Studio software (Dassault Systèmes BIOVIA). 
